Bcl-2 INHIBITOR
Compounds of formula (I) address the need for selective Bcl-2 inhibitors by offering improved potency and selectivity against both wild-type and mutant Bcl-2 proteins, enhancing treatment efficacy for diseases of unregulated apoptosis with reduced drug interaction risks.
Patent Information
- Application Number
- JP2024135320
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-09-21
- Filing Date
- 2024-08-14
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2039-04-29
AI Technical Summary
There is a need for new small molecules that selectively inhibit Bcl-2 protein to treat diseases of unregulated apoptosis such as cancer, autoimmune diseases, and prothrombotic diseases, with improved potency, selectivity, and lower risk of drug interactions, while also addressing resistance issues posed by mutations like Bcl-2G101V.
Development of compounds of formula (I) that inhibit Bcl-2 protein, exhibiting higher potency and selectivity, lower CYP2C9 inhibition, and efficacy against both wild-type and mutant forms, including Bcl-2G101V, with potential for reduced drug interactions and resistance.
The compounds of formula (I) demonstrate enhanced potency and selectivity in inhibiting Bcl-2, effectively targeting both wild-type and mutant forms, thereby providing a novel approach to treat diseases with reduced risk of drug interactions and resistance.
Smart Images

Figure 2024161475000907 
Figure 2024161475000908 
Figure 2024161475000909
Abstract
Description
[Technical Field]
[0001] This application claims the benefit of International Patent Application No. PCT / CN2018 / 085217, filed April 29, 2018, and PCT / CN2018 / 107134, filed September 21, 2018, the disclosures of which are incorporated herein by reference in their entireties for all purposes.
[0002] Disclosed herein are methods of using, and pharmaceutical compositions comprising, compounds of formula (I) for inhibiting Bcl-2 and treating diseases associated with unwanted bcl-2 activity (Bcl-2 associated diseases), neurodegenerative diseases, e.g., Alzheimer's disease; and proliferative diseases, e.g., diseases of dysregulated apoptosis, including cancer, autoimmune diseases, and prothrombotic diseases. [Background technology]
[0003] Programmed cell death, or apoptosis, occurs in multicellular organisms to eliminate damaged or unnecessary cells, which is important for normal tissue homeostasis (Br. J. Cancer 1972, 26, 239). However, defective apoptotic processes have been implicated in a variety of diseases. Excessive apoptosis leads to atrophy, while insufficient apoptosis leads to uncontrolled cell proliferation, such as cancer (Cell 2011, 144, 646). Resistance to apoptotic cell death is a hallmark of cancer and contributes to chemotherapy resistance (Nat Med. 2004, 10, 789-799). Several key pathways regulating apoptosis are commonly altered in cancer. Some factors, such as the Fas receptor and caspases, promote apoptosis, while several members of the B-cell lymphoma 2 (Bcl-2) family of proteins inhibit apoptosis. Negative regulation of apoptosis inhibits cell death signaling pathways, promoting tumor evasion of cell death and resulting in drug resistance.
[0004] There are two distinct apoptotic pathways, including the extrinsic pathway and the intrinsic pathway. The extrinsic pathway is activated in response to the binding of death-inducing ligands to cell surface death receptors (Nat. Rev. Drug Discov. 2017 16, 273-284). The B-cell lymphoma 2 (BCL-2) gene family, a group of proteins homologous to Bcl-2 proteins, encodes more than 20 proteins that regulate the intrinsic apoptotic pathway. Bcl-2 family proteins are characterized by containing at least one of four conserved Bcl-2 homology (BH) domains (BH1, BH2, BH3, and BH4) (Nat. Rev. Cancer 2008, 8, 121; Mol. Cell 2010, 37, 299; Nat. Rev. Mol. Cell Biol. 2014, 15, 49). The Bcl-2 family of proteins, consisting of pro- and anti-apoptotic molecules, can be classified into three subfamilies based on sequence homology within the four BH domains: (1) the anti-apoptotic subfamily, such as Bcl-2, Bcl-XL, and Bcl-w, shares sequence homology within all four BH domains; (2) the pro-apoptotic subfamily, such as Bax and Bak, shares sequence homology within BH1, BH2, and BH4; and (3) the pro-apoptotic subfamily, such as Bik, Bid, and HRK, shares sequence homology only within BH3. One unique feature of Bcl-2 family proteins is heterodimerization between anti- and pro-apoptotic proteins, which is thought to inhibit the biological activity of their partners. This heterodimerization is mediated by insertion of the BH3 region of the pro-apoptotic protein into a hydrophobic cleft composed of BH1, BH2, and BH3 from the anti-apoptotic protein. In addition to BH1 and BH2, the BH4 domain is required for anti-apoptotic activity. In contrast, the BH3 domain is important and is sufficient by itself for pro-apoptotic activity.
[0005] Similar to oncogene addiction, where tumor cells depend on a single dominant gene for survival, tumor cells can also become dependent on Bcl-2 for survival. Bcl-2 overexpression is commonly observed in acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), relapsed / refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), non-Hodgkin's lymphoma (NHL), and solid tumors such as pancreatic cancer, prostate cancer, breast cancer, and small cell and non-small cell lung cancer (Cancer 2001, 92, 1122-1129; Cancer Biol. 2003; 13:115-23; Curr. Cancer Drug Targets 2008, 8, 207-222; Cancers 2011, 3, 1527-1549). Dysregulated apoptotic pathways have also been implicated in the pathology of other serious diseases, such as neurodegenerative diseases (upregulated apoptosis), e.g., Alzheimer's disease; and proliferative diseases (downregulated apoptosis), e.g., cancer, autoimmune diseases, and prothrombotic diseases. Many small molecule BH3 mimetics targeting either Bcl-2 or Bcl-xL have been reported (Recent Patents on Anti-Cancer Drug Discovery, 2008, 3, 20-30; Bioorg. Med. Chem. Lett. 2016, 26, 2105-2114; Nature Reviews Drug Discovery 2017,16,273-284; International Publication No. 2002024636; International Publication No. 2005049593; International Publication No. 2006127364; International Publication No. 2006023778; International Publication No. 2007040650; International Publication No. 2008030836; International Publication No. 2009152082; International Publication No. 2009036051 International Publication No. 2010065824; International Publication No. 2010065865; International Publication No. 2010083441; International Publication No. 2010083442; International Publication No. 2010067067; International Publication No. 2011029842; International Publication No. 2011068561; International Publication No. 2011119345;International Publication No. 2011149492; International Publication No. 2011150016; International Publication No. 2012058392; International Publication No. 2012017251; International Publication No. 2012162365; International Publication No. 2012103059; International Publication No. 2013053045; International Publication No. 2013185202; International Publication No. 2013096060; International Publication No. 2013096059; International Publication No. 201309605 5; WO 2013096051; WO 2013096049; U.S. Patent Application Publication No. 2011312969; WO 2014158528; WO 2014113413; WO 2018027097; WO 2018041248; WO 2018009444; CN106749233; CN106565706). Several small molecule Bcl-2 inhibitors are currently in various stages of drug development: The Bcl-2 / Bcl-xL inhibitor ABT-263 (navitoclax, WO 2009155386) has shown promising clinical activity in lymphoid malignancies such as chronic lymphocytic leukemia. However, its efficacy in these settings is limited by platelet death and associated thrombocytopenia caused by Bcl-xL inhibition (Lancet Oncol. 2010, 11, 1149; J. Clin. Oncol. 2011, 29, 909; J. Clin. Oncol. 2012, 30, 488). A new generation of BCL-2 selective inhibitor, venetoclax (ABT-199 / GDC-0199), has been developed, which not only showed robust activity in these cancers but also spared spared platelets (Journal of Hematology & Oncology 2015,8,129;Clinical Advances in Hematology & Oncology 2017, 15, 210. S55746 (also known as BCL201), APG-101, and APG-1252 are currently being tested in clinical trials. Currently, venetoclax (formerly ABT-199) is the only Bcl-2 selective inhibitor approved by the FDA for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) with 17p deletion. However, a novel Gly101Val mutation in BCL2 was recently identified after patients were treated with the Bcl-2 inhibitor venetoclax (ABT-199) for 19 to 42 months (Cancer Discov. 2019, 9, 342-353). This mutation significantly reduced the binding affinity of Bcl-2 to venetoclax (ABT-199) by approximately 180-fold in cell-based assays. Summary of the Invention [Problem to be solved by the invention]
[0006] Therefore, there is a need for novel small molecules that selectively inhibit Bcl-2 protein for the treatment of diseases of dysregulated apoptosis, such as cancer, autoimmune diseases, and prothrombotic diseases. Unexpectedly, the inventors of the present application have found that several compounds disclosed herein exhibit not only much higher potency and selectivity, but also much lower CYP2C9 inhibition, indicating potentially better efficacy and a lower potential risk of drug-drug interactions (DDIs). Furthermore, the inventors of the present application have found that the compounds disclosed herein exhibit inhibitory activity against both wild-type and G101V mutant Bcl-2, suggesting a novel class of potential Bcl-2 inhibitors without resistance concerns. [Means for solving the problem]
[0007] Formula (I) [ka] (In the formula, L 1 , L 2 , L 3 and L 4 are each independently a direct bond, -(CR a R b ) t -, -(CR a R b ) t-1 -(CR c =CR d )-(CR a R b ) v-1 -, -(CR a R b ) t-1 -(C≡C)-(CR a R b ) v-1 -, -O-, -S-, -S(O)-, -SO2-, -C(O)-, C(O)O-, -OC(O)-, -NR a -, -C(O)NR a -, -NR a C(O)-, -NR a C(O)O-, -NR a C(O)NR b -,-SO2NR a -, -NR a SO2-, -NR a S(O)NR b -, -NR a S(O)NR b -, -C(O)NR a SO2-, -C(O)NR a SO- or -C(=NR a )NR b -, where t and v are independently a number from 1 to 7 at each occurrence, and -(CR a R b ) t -,-(CR a R b ) t-1 -(CR c =CR d )-(CR a R b ) v-1 -, -(CR a R b ) t-1 -(C≡C)-(CRa R b ) v-1 -One or two CRs a R b The moiety may be unsubstituted or may be selected from O, S, SO, SO2, C(O), and NR a substituted with one or more moieties selected from: Each ring A has 1 to 4 substituents R 2 cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclyl, or heteroaryl optionally substituted with; R 2 is independently hydrogen, halogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO2, -OR 2a , -SO2R 2a , -COR 2a , -CO2R 2a , -CONR 2a R 2b , -C(=NR 2a )NR 2b R 2c , -NR 2a R 2b , -NR 2a COR 2b , -NR 2a CONR 2b R 2c , -NR 2a CO2R 2b , -NR 2a SONR 2b R 2c , -NR 2a SO2NR 2b R 2c or -NR 2a SO2R 2b -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Each of alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is selected from the group consisting of halogen, hydroxy, -C 1~8optionally substituted with alkyloxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R 2a , R 2b and R 2c are each independently hydrogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Each of alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is selected from the group consisting of halogen, hydroxy, or -C 1~8 optionally substituted with alkyloxy; Each ring B has 1 to 4 substituents R 1 cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclyl, or heteroaryl optionally substituted with; R 1 is independently hydrogen, halogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO2, -OR 1a , -SO2R 1a , -COR 1a , -CO2R 1a , -CONR 1a R 1b , -C(=NR 1a )NR 1b R 1c , -NR 1a R 1b , -NR 1a COR 1b , -NR 1a CONR 1b R 1c , -NR 1a CO2R 1b , -NR 1a SONR 1b R 1c , -NR 1a SO2NR1b R 1c or -NR 1a SO2R 1b wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl each independently have 1 to 4 substituents R 1d optionally substituted with R 1a , R 1b and R 1c are each independently hydrogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Each of alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is selected from the group consisting of halogen, hydroxy, or -C 1~8 optionally substituted with alkyloxy; R 1d represents independently at each occurrence a halogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO2, -OR Ba , -SO2R Ba , -COR Ba , -CO2R Ba , -CONR Ba R Bb , -C(=NR Ba )NR Bb R Bc , -NR Ba R Bb , -NR Ba COR Bb , -NR Ba CONR Bb R Bc , -NR Ba CO2R Bb , -NR Ba SONRBb R Bc , -NR Ba SO2NR Bb R Bc or -NR Ba SO2R Bb wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl each independently have 1 to 4 substituents R Bd optionally replaced by; R Ba , R Bb and R Bc are each independently hydrogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Each of alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is selected from the group consisting of halogen, hydroxy, —NH2, or —N(C 1~6 alkyl)2, -C 1~8 optionally substituted with alkyloxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R Bd is independently hydrogen, halogen, oxo, -CN, -NO2, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Each of alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is selected from the group consisting of halogen, hydroxy, -C 1~8 optionally substituted with alkyloxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R 3 is hydrogen, halogen, C1~8 Alkyl, C 2~8 Alkenyl, C 2~8 alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Each of the alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl may be one to four substituents R 3a optionally replaced by; R 3a is independently a halogen, cyano, -NO2, -OR 3b , -SR 3b , -NR 3b R 3c , -COR 3b , -SO2R 3b , -C(=O)OR 3b , -C(=O)NR 3b R 3c , -C(=NR 3b )NR 3c R 3d , -N(R 3b )C(=O)R 3c , -N(R 3b )C(=O)OR 3c , -N(R 3b )C(O)NR 3c R 3d , -N(R 3b )S(O)NR 3c R 3d , -N(R 3b )S(O)NR 3c R 3d , -NR 3b SO2R 3c , -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 selected from alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; R 3b , R 3c and R 3d are independently hydrogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Each of alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is selected from the group consisting of halogen, hydroxy, or -C 1~8 optionally substituted with alkyloxy; R 4 is hydrogen, halogen, cyano, -NO2, -OR 4a , -SR 4a , -NR 4a R 4b , -COR 4a , -SO2R 4a , -C(=O)OR 4a , -C(=O)NR 4a R 4b , -C(=NR 4a )NR 4b R 4c , -N(R 4a )C(=O)R 4b , -N(R 4a )C(=O)OR 4b , -N(R 4a )C(O)NR 4b R 4c , -N(R 4a )S(O)NR 4b R 4c , -N(R 4a )S(O)NR 4b R 4c , -NR 4a SO2R 4b , -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, -cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Each of alkynyl, -cycloalkyl, heterocyclyl, aryl or heteroaryl may be selected from one or two substituents R 4d independently and optionally substituted with; R 4a , R 4b and R4c are independently hydrogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Each of alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is selected from the group consisting of halogen, hydroxy, or -C 1~8 optionally substituted with alkyloxy; R 4d is independently hydrogen, oxo, -CN, -NO2, halogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Each of alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is selected from the group consisting of halogen, hydroxy, or -C 1~8 optionally substituted with alkyloxy; m is an integer from 1 to 4; R 5 Ha-L 5 -CyC, where L 5 is a direct bond, -(CR a R b ) t -, -(CR a R b ) t-1 -(CR c =CR d )-(CR a R b ) v-1 -, -(CR a R b ) t-1 -(C≡C)-(CR a R b ) v-1 -, -O-, -S-, -S(O)-, -SO2-, -C(O)-, C(O)O-, -OC(O)-, -NRa -, -C(O)NR a -, -NR a C(O)-, -NR a C(O)O-, -NR a C(O)NR b -,-SO2NR a -, -NR a SO2-, -NR a S(O)NR b -, -NR a S(O)NR b -, -C(O)NR a SO2-, -C(O)NR a SO- or -C(=NR a )NR b -, where t and v are independently a number from 1 to 7 at each occurrence, and -(CR a R b ) t -, -(CR a R b ) t-1 -(CR c =CR d )-(CR a R b ) v-1 -,-(CR a R b ) t-1 -(C≡C)-(CR a R b ) v-1 -One or two CRs a R b The moiety may be unsubstituted or may be selected from O, S, SO, SO2, C(O), and NR a substituted with one or more moieties selected from: Each CyC has one or two substituents R 5a is a cycloalkyl, heterocyclyl, aryl, or heteroaryl optionally substituted with; R 5a is independently hydrogen, halogen, cyano, oxo, -NO2, -OR 5b , -SR 5b , -NR 5b R 5c , -COR 5b , -SO2R 5b , -C(=O)OR5b , -C(=O)NR 5b R 5c , -C(=NR 5b )NR 5c R 5d , -N(R 5b )C(=O)R 5c , -N(R 5b )C(=O)OR 5c , -N(R 5b )C(O)NR 5c R 5d , -N(R 5b )S(O)NR 5c R 5d , -N(R 5b )S(O)NR 5c R 5d , -NR 5b SO2R 5c , -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, -cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Each of alkynyl, -cycloalkyl, heterocyclyl, aryl or heteroaryl may be selected from one or two substituents R 5e optionally replaced by; where R 5b , R 5c and R 5d are each independently hydrogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, C 2~8 Each of alkynyl, -cycloalkyl, heterocyclyl, aryl or heteroaryl may be selected from one or two substituents R 5e optionally replaced by; R 5e is independently hydrogen, halogen, cyano, oxo, -NO2, -OR 5f , -SR5f , -NR 5f R 5g , -COR 5f , -SO2R 5f , -C(=O)OR 5f , -C(=O)NR 5f R 5g , -C(=NR 5f )NR 5g R 5h , -N(R 5f )C(=O)R 5g , -N(R 5f )C(=O)OR 5g , -N(R 5f )C(O)NR 5g R 5h , -N(R 5f )S(O)NR 5g R 5h , -N(R 5f )S(O)NR 5g R 5h , -NR 5f SO2R 5g , -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 selected from alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; R 5f , R 5g and R 5h are each independently hydrogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; or Two adjacent R on a phenyl ring 5 together with the phenyl ring form a benzo ring, said ring being free of halogen, oxo, cyano, -NO2, -OR 5i , -SR 5i , -NR 5i R 5j , -COR 5i , -SO2R 5i , -C(=O)OR 5i , -C(=O)NR 5i R 5j , -C(=NR 5i )NR5j R 5k , -N(R 5i )C(=O)R 5j , -N(R 5i )C(=O)OR 5j , -N(R 5i )C(O)NR 5j R 5k , -N(R 5i )S(O)NR 5j R 5k , -N(R 5i )S(O)NR 5j R 5k , -NR 5i SO2R 5k , -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 optionally substituted with alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R 5i , R 5j and R 5k are independently hydrogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Each of alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is selected from the group consisting of halogen, hydroxy, or -C 1~8 optionally substituted with alkyloxy; R a , R b , R c and R d are independently hydrogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8Alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently -CN, halogen, -NO2, -NR e R f , oxo, -OR e or -SR e is replaced by; where R e and R f are each independently hydrogen, C 1~8 Alkyl, C 1~8 Alkoxy-C 1~8 Alkyl-, C 2~8 Alkenyl, C 2~8 alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof is disclosed herein.
[0008] In one embodiment, R a , R b , R c and R d is independently at each occurrence hydrogen or C 1~6 Alkyl, preferably hydrogen or methyl.
[0009] In one embodiment, L 1 is a direct bond or -(CR a R b ) t -, where R a , R b and t are defined as in formula (I). In some embodiments, t is the number 1 or 2. In a preferred embodiment, L 1 is a direct bond or -(CR a R b )-, where R a and R b is hydrogen or C 1~6 In the most preferred embodiment, L 1 is a direct bond.
[0010] In one embodiment, L 2 is a direct bond, -(CRa R b ) t -,-(CR a R b ) t-1 -(CR c =CR d )-(CR a R b ) v-1 -,-(CR a R b ) t-1 -(C≡C)-(CR a R b ) v-1 -, -O-, or -NR a -, where R a , R b , R c , t, and v are defined as in formula (I). In one embodiment, t or v is a number from 1 to 4. In a preferred embodiment, L 2 is a direct bond, -(CR a R b ) 1~5 -,-(CR a R b ) 1~3 —(C≡C)—, —O—, or —NR a -, where R a , R b and R c is independently at each occurrence hydrogen or C 1~6 alkyl, -(CR a R b ) 1~5 -,-(CR a R b ) 1~3 -One or two CRs in (C≡C)- a R b The moieties are O, S, SO, SO2, C(O) and NR a In a further preferred embodiment, L 2 is a direct bond, -(CR a R b ) 1~5 -,-(CR a R b ) 1~3 -(C≡C)- or -NR a -, where Ra , R b and R c is independently at each occurrence hydrogen or C 1~6 alkyl, -(CR a R b ) 1~5 -,-(CR a R b )-(C≡C)- in which one or two CR a R b The moiety is O or NR a and is substituted with one or two heteroatoms from a is hydrogen or C 1~6 alkyl, preferably hydrogen or CH. In another embodiment, L 2 is a direct bond, -CH2-, -O-, -NH-, [ka] wherein: * 3 refers to the position attached to ring A, and ** 4 refers to the position attached to the phenyl ring. 2 is a direct bond.
[0011] In a preferred embodiment, L 1 and L 2 are both direct bonds, or L 1 is -CH2- or -CH2-CH2-, and L 2 is a direct bond.
[0012] In one embodiment, L 3 is a direct bond, -(CR a R b ) t -, -O-, -S-, -S(O)-, -SO2-, -C(O)-, C(O)O-, -OC(O)- or -NR a -, where R a , R b and t are defined as in formula (I). Preferably, R a and R b are independently hydrogen or C 1~6alkyl and t is 1 or 2. In a preferred embodiment, L 3 is -O-, -CH2-, a direct bond or -C(O)-. More preferably, L 3 is -O-.
[0013] In one embodiment, R 3 is one or two substituents R defined as in formula (I) 3a Preferably, R is heteroaryl optionally substituted with 3 is a halogen, -C 1~8 Alkyl or -NR 3b R 3c one or two substituents R selected from 3a heteroaryl optionally substituted with 3b and R 3c are independently hydrogen or -C 1~8 It is alkyl.
[0014] In one embodiment, R 3 is a halogen, -C 1~8 Alkyl or -NR 3b R 3c one or two substituents R selected from 3a is a 5-7 membered nitrogen-containing monocyclic heteroaryl optionally substituted with 3b and R 3c are independently hydrogen or -C 1~8 Preferably, R 3 are halogen and -C, respectively. 1~8 Alkyl or -NR 3b R 3c one or two substituents R selected from 3a tetrazolyl, trizolyl, pyrazolyl, pyrrolyl, pyridinyl, pyrimidinyl optionally substituted with 3b and R 3c are independently hydrogen or -C 1~8 It is alkyl.
[0015] In one embodiment, R 3is an 8-12 membered bicyclic heteroaryl containing 1, 2, or 3 nitrogen atoms. 3 are halogen and -C, respectively. 1~8 Alkyl or -NR 3b R 3c one or two substituents R selected from 3a indolyl, pyrrolopyridinyl, or pyrazolopyridinyl optionally substituted by 3b and R 3c are independently hydrogen or -C 1~8 More preferably, R 3 are indol-4-yl, pyrrolo[2,3-b]pyridin-5-yl, and pyrazolo[4,3-b]pyridin-1-yl.
[0016] In one embodiment, R 3 is a halogen, -C 1~8 Alkyl or -NR 3b R 3c one or two substituents R selected from 3a and an 11-14 membered tricyclic heteroaryl containing 1, or 2, or 3, or 4, or 5 nitrogen atoms optionally substituted with 3b and R 3c are independently hydrogen or -C 1~8 Preferably, R 3 is pyrazolo[4,3-b]pyrrolo[3,2-e]pyridin-1(5i)-yl.
[0017] In one embodiment, L 3 is -O- and R 3 is pyrrolo[2,3-b]pyridin-5-yl.
[0018] In one embodiment, L 4 is -C(O)NR a SO2-, where R a is hydrogen and C 1~6 is alkyl; preferably hydrogen. In a preferred embodiment, L 4 teeth, * -C(O)NRa SO2- ** where R a is hydrogen and C 1~6 alkyl; preferably hydrogen, where * indicates the position attached to ring C, and ** indicates the position attached to ring D.
[0019] In one embodiment, R 4 is -NO2, F, Cl, Br, cyano or -SO2R 4a where R 4a is defined as in formula (I). 4 is -NO2, F, Cl, Br, cyano or -SO2R 4a where R 4a is —C optionally substituted with halogen 1~8 alkyl, preferably -CF. In a preferred embodiment, R 4 is -NO2.
[0020] In one embodiment, each ring A contains 1 to 4 substituents R 2 Preferably, R is a cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or heteroaryl optionally substituted with 2 is hydrogen, halogen (e.g., F, Cl, or Br), or C optionally substituted with halogen (e.g., F, Cl, or Br). 1~6 It is alkyl (eg, methyl).
[0021] In a preferred embodiment, ring A is a phenyl ring which is 1,2-phenylene, 1,3-phenylene, or 1,4-phenylene.
[0022] In a preferred embodiment, ring A is C 3~8In a more preferred embodiment, ring A is selected from cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. In particular, ring A is 1,2-cyclobutylene, 1,3-cyclobutylene, 1,2-cyclopentylene, 1,3-cyclopentylene, 1,2-cyclohexylene, 1,3-cyclohexylene, 1,4-cyclohexylene, 1,2-cycloheptylene, 1,3-cycloheptylene, or 1,4-cycloheptylene.
[0023] In a preferred embodiment, ring A is C 3~8 Preferably, ring A is cyclohexenyl. More preferably, ring A is cyclohex-3-enyl or cyclohex-2-enyl.
[0024] In a preferred embodiment, ring A is heteroaryl. Preferably, ring A is a monocyclic 5- or 6-membered heteroaryl containing one, two, three, or four heteroatoms selected from nitrogen, oxygen, and sulfur. In particular, ring A is pyridine, pyrazole, thiophene, or pyrimidine. Preferably, ring A is an 8- to 12-membered bicyclic heteroaryl ring. In particular, ring A is a pyrazolopyrimidine (e.g., pyrazolo[1,5-a]pyrimidine), benzothiophene (benzo[b]thiophene), or pyrazolopyridine (e.g., pyrazolo[1,5-a]pyridine) group.
[0025] In a preferred embodiment, ring A is heterocyclyl. a) a monocyclic 4- to 9-membered heterocyclyl group containing, as ring members, one or two heteroatoms selected from nitrogen, oxygen, or sulfur; b) 5-12-membered spiroheterocyclyl containing, as ring members, one or two heteroatoms selected from nitrogen, sulfur and oxygen; c) a 5- to 12-membered fused heterocyclyl containing, as ring members, one or two heteroatoms selected from nitrogen, sulfur, and oxygen; and d) 5- to 12-membered bridged heterocyclyl containing one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members. is selected from.
[0026] In a more preferred embodiment, ring A is a 5- to 12-membered spiroheterocyclyl containing one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members. In particular, ring A is a 4-membered / 4-membered, 3-membered / 5-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 6-membered monospiroheterocyclyl containing one or two nitrogen or oxygen ring members. In particular, ring A is a 4-membered / 4-membered or 4-membered / 6-membered monospiroheterocyclyl containing one nitrogen ring member. More particularly, ring A is [ka] (7-azaspiro[3.5]nonane-2,7-diyl), [ka] (2-azaspiro[3.5]nonane-2,7-diyl), [ka] (3-azaspiro[5.5]undecane-3,9-diyl), [ka] (2-azaspiro[3.3]heptane-2,6-diyl), [ka] (8-azaspiro[4.5]decane-2,8-diyl), [ka] (2-azaspiro[4.5]decane-2,8-diyl).
[0027] In particular, ring A is a heterocyclic group selected from the group consisting of piperidine, pyrrolidine, and azetidine; 7-azaspiro[3.5]nonane, 2-azaspiro[3.5]nonane, 8-azabicyclo[3.2.1]octane; tetrahydrothienopyridine (e.g., 4,5,6,7-tetrahydrothieno[2,3-c]pyridine), tetrahydropyrrolopyrazine (e.g., 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine), tetrahydropyrrolopyrazine (e.g., 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine), hexahydroindolizine (e.g., 1,2,3,5,8,8a-hexahydroindolizine), dihydropyrrolothiazole (e.g., 5,6-dihydro-4H-pyrrolo[3,4-d]thiazole), and isoindoline.
[0028] In a further preferred embodiment, ring A is [ka] (7-azaspiro[3.5]nonane-2,7-diyl), [ka] (2-azaspiro[3.5]nonane-2,7-diyl), [ka] (8-azabicyclo[3.2.1]octane-3,8-diyl), [ka] (3-azaspiro[5.5]undecane-3,9-diyl), [ka] (2-azaspiro[3.3]heptane-2,6-diyl), [ka] (8-azaspiro[4.5]decane-2,8-diyl), [ka] (2-azaspiro[4.5]decane-2,8-diyl), [ka] wherein: * 1 is L 1 and ** 2 is L 2 It refers to the position where it is bonded to
[0029] In the most preferred embodiment, ring A is [ka] is.
[0030] In one embodiment, each ring B contains 1 to 4 substituents R 1 is a cycloalkyl, cycloalkenyl, aryl or heterocyclyl optionally substituted with; R 1 represents independently at each occurrence a halogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, aryl, heteroaryl, oxo, -CN or -OR 1a wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 The alkynyl, aryl, or heteroaryl each independently have 1 to 4 substituents R 1d optionally substituted with R 1a is hydrogen or -C 1~8 alkyl, and the -C 1~8 Alkyl is halogen, hydroxy or -C 1~8 optionally substituted with alkyloxy; R 1d represents independently at each occurrence a halogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8Alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -CN, -OR Ba , -SO2R Ba , -CONR Ba R Bb , -NR Ba R Bb , -NR Ba COR Bb or -NR Ba SO2R Bb wherein said -C 1~8 The alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl each independently have 1 to 4 substituents R Bd optionally replaced by; R Ba and R Bb are each independently hydrogen, -C 1~8 alkyl, cycloalkyl or aryl, 1~8 Each of alkyl, cycloalkyl, or aryl may be selected from halogen, hydroxy, -C 1~8 optionally substituted with alkyloxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R Bd is independently hydrogen, halogen, -CN, -C 1~8 Alkyl, -C 2~8 alkynyl, cycloalkyl or aryl, 1~8 Alkyl, -C 2~8 Each of the alkynyl or aryl groups may be selected from halogen, hydroxy, -C 1~8 Optionally substituted with alkyloxy, cycloalkyl, heterocyclyl, aryl or heteroaryl.
[0031] In one embodiment, cycloalkyl as ring B is a monocyclic C 3~8 Cycloalkyl, preferably R 1 In one embodiment, R is cyclopentyl or cyclohexyl substituted with 1 is a monocyclic C 3~8 R is cycloalkyl 1d is an aryl group (e.g., phenyl) optionally substituted with
[0032] In one embodiment, the cycloalkenyl as ring B is a monocyclic C 3~8 Cycloalkenyl, preferably one, two, or three R 1 In one embodiment, R is cyclopentenyl or cyclohexenyl substituted with 1 is a halogen R 1d C optionally substituted with 1~8 Alkyl (e.g., C 1~6 It is an alkyl group (preferably methyl) or an aryl group (for example, phenyl).
[0033] In one embodiment, the heterocyclyl as ring B is each selected from 1 to 4 substituents R 1 and R is a monocyclic 4- to 9-membered heterocyclyl, a 5- to 20-membered spiroheterocyclyl, a 5- to 20-membered fused heterocyclyl, or a 5- to 20-membered bridged heterocyclyl optionally substituted by
[0034] In one embodiment, the monocyclic heterocyclyl is a monocyclic 4-9 membered heterocyclyl containing, as ring members, one or more heteroatoms selected from the group consisting of NH, O, S, SO, or SO2 heteroatoms.
[0035] In one embodiment, the monocyclic heterocyclyl is a monocyclic 4- to 9-membered heterocyclyl containing one nitrogen atom as a ring member. In a preferred embodiment, the monocyclic 4- to 9-membered heterocyclyl containing one nitrogen atom as a ring member is C-bonded or N-bonded. In a further preferred embodiment, the monocyclic 4- to 9-membered heterocyclyl containing one nitrogen atom as a ring member is saturated. In particular, the saturated heterocyclyl is an N-bonded saturated heterocyclyl, including, but not limited to, aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, and azocan-1-yl, preferably pyrrolidin-1-yl. In particular, saturated heterocyclyl is a C-linked saturated heterocyclyl, including, but not limited to, aziridin-2-yl, azetidin-2-yl, azetidin-3-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, azepan-2-yl, azepan-3-yl, azepan-4-yl, azocan-2-yl, azocan-3-yl, azocan-4-yl, and azocan-5-yl. In another more preferred embodiment, the monocyclic 4- to 9-membered heterocyclyl containing one nitrogen atom as a ring member is unsaturated. In an even more preferred embodiment, the monocyclic 4- to 9-membered heterocyclyl containing one nitrogen atom as a ring member contains one carbon-carbon double bond. In particular, a monocyclic 4- to 9-membered heterocyclyl containing one nitrogen atom as a ring member is dihydropyrrolyl, such as 2,3-dihydro-1H-pyrrolyl and 2,5-dihydro-1H-pyrrolyl or tetrahydropyridinyl.
[0036] In another embodiment, the monocyclic heterocyclyl is a monocyclic 4- to 9-membered heterocyclyl containing, as ring members, one nitrogen atom and one additional heteroatom selected from the group consisting of NH, O, S, SO, or SO heteroatoms. In a preferred embodiment, the monocyclic 4- to 9-membered heterocyclyl containing, as ring members, one nitrogen atom and one additional heteroatom selected from the group consisting of NH, O, S, SO, or SO heteroatoms is C-bonded or N-bonded. In a further preferred embodiment, the monocyclic heterocyclyl is saturated. In an even more preferred embodiment, the saturated monocyclic heterocyclyl is N-bonded. In another even more preferred embodiment, the saturated monocyclic heterocyclyl is C-bonded.
[0037] In a preferred embodiment, ring B contains 1 to 4 substituents R 1 and pyrrolidin-1-yl substituted with
[0038] In one embodiment, R 1 is a phenyl group.
[0039] In a more preferred embodiment, ring B is aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, azepan-1-yl or azocan-1-yl, preferably substituted at the 2-position with a phenyl group and one, two or three substituents R 1 and said phenyl group at 2-position is R as defined in formula (I). 1d is optionally replaced by
[0040] In one aspect of this embodiment, R 1 represents independently at each occurrence a halogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, aryl, heteroaryl, oxo, -CN or -OR 1a wherein said -C1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, aryl or heteroaryl may be one to four substituents R 1d where R 1a is hydrogen or C 1~8 alkyl, preferably methyl, and R 1d is a halogen, -C 1~8 Alkyl or -OR Ba where R Ba is hydrogen or -C 1~8 In another embodiment, R 1 is heteroaryl, preferably furanyl, more preferably furan-3-yl. 1 is substituted at the 2-position of the monocyclic heterocyclyl.
[0041] In one aspect of this embodiment, R 1d is substituted on the phenyl group at the 2-position of ring B (including an aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, azepan-1-yl or azocan-1-yl, preferably a pyrrolidin-1-yl group), independently represents a halogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -CN, -OR Ba , -SO2R Ba , -CONR Ba R Bb , -NO2, -NR Ba R Bb , -NR Ba COR Bb or -NR Ba SO2R Bb wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl each independently represent one to four substituents R as defined in formula (I).Bd , preferably one or two substituents R as defined in formula (I) Bd In another embodiment, one R 1d is at the 2-position of the phenyl ring at the 2-position of ring B.
[0042] In one embodiment, R 1d -C as 1~8 Alkyl includes halogen, phenyl, cycloalkyl (e.g., C 3~8 cycloalkyl, preferably cyclopropyl), C 1~6 one to four substituents R which are heterocyclyl optionally substituted with alkyl (e.g., piperazinyl, piperidinyl); Bd In particular, R 1d is R Bd -C selected from methyl, ethyl, isopropyl, propyl, tert-butyl and isobutyl, optionally substituted with 1~8 In another embodiment, the two methyl groups are at the 2-position of the phenyl ring at the 2-position of ring B.
[0043] In one embodiment, R 1d Cycloalkyl as a group can be substituted with halogen, cyano, C 2~8 C optionally substituted with alkynyl (preferably ethynyl) or halogen 1~8 1 to 4 substituents R which are alkyl (preferably CF3) Bd In particular, R 1d is R Bd C selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted with 3~8 In another embodiment, one cyclopropyl is at the 2-position of the phenyl ring at the 2-position of ring B.
[0044] In one embodiment, R 1d -C as 2~8 Alkenyl is prop-1-en-2-yl.
[0045] In one embodiment, R 1d -C as 2~8 Alkynyl is ethynyl.
[0046] In one embodiment, R 1d as -OR Ba In the definition of R Ba is hydrogen, C 1~8 alkyl (selected from methyl, ethyl, propyl and isopropyl), C 3~8 cycloalkyl (preferably cyclopropyl or cyclohexyl), aryl (preferably phenyl), where C 1~8 Alkyl, C 3~8 Cycloalkyl and aryl are each independently halogen, heterocyclyl (preferably a monocyclic 4- to 9-membered heterocyclyl, more preferably morpholino), hydroxy or -C 1~8 It is substituted with alkoxyl (preferably methoxyl).
[0047] In one embodiment, R 1d is an aryl which is phenyl.
[0048] In one embodiment, R 1d is a heterocycle which is a monocyclic 4- to 9-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen, oxygen, or sulfur as ring members, preferably a monocyclic 4- to 6-membered heterocyclyl containing one oxygen atom as a ring member or a monocyclic 6-membered heterocyclyl containing one or two nitrogen atoms as ring members.
[0049] In one embodiment, R 1d is heteroaryl, preferably thiophenyl or furanyl.
[0050] In one embodiment, Ring B is pyrrolidin-1-yl substituted with a naphthyl group, preferably substituted at the 2-position with naphthyl.
[0051] In one embodiment, Ring B is pyrrolidin-1-yl substituted with a heteroaryl group, preferably substituted at the 2-position with a heteroaryl group. In one embodiment, the heteroaryl is a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur. Preferably, the heteroaryl is pyridinyl, furanyl, thiophenyl, or pyrazolyl. In another embodiment, the heteroaryl is a halogen or C 3~8 It is optionally substituted with cycloalkyl (preferably cyclopropyl).
[0052] In one embodiment, ring B is -C 1~8 Alkyl, -C 2~8 Alkenyl or -C 2~8 alkynyl-substituted, preferably at the 2-position -C 1~8 Alkyl, -C 2~8 Alkenyl or -C 2~8 pyrrolidin-1-yl substituted with alkynyl, 1~8 Alkyl, -C 2~8 Alkenyl or -C 2~8 Each alkynyl is unsubstituted or substituted with a phenyl group, said phenyl group being substituted with a halogen or C 3~8 It is optionally substituted with cycloalkyl (preferably cyclopropyl). In a preferred embodiment, Ring B is pyrrolidin-1-yl substituted with methyl, ethenyl, or ethynyl, each of which is optionally substituted with a phenyl group, optionally substituted as described above.
[0053] In a preferred embodiment, ring B contains 1 to 4 substituents R as defined in formula (I). 1 is pyrrolidin-1-yl optionally substituted with
[0054] In a preferred embodiment, [ka] teeth, [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] is selected from the group consisting of:
[0055] In one preferred embodiment, Ring B is a 2-substituted pyrrolidin-1-yl group, L is a direct bond, and L 2 is a direct bond, and ring A is a 1,4-phenylene ring or a 5- to 12-membered spiroheterocyclyl containing one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members, preferably a 5- to 12-membered spiroheterocyclyl containing one or two nitrogen atoms as ring members; more preferably a 4-membered / 4-membered, 3-membered / 5-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 5-membered ring containing one or two nitrogen or oxygen atoms as ring members. and most preferably, Ring A is 7-azaspiro[3.5]nonane-2,7-diyl, 2-azaspiro[3.5]nonane-2,7-diyl, 3-azaspiro[5.5]undecane-3,9-diyl, 2-azaspiro[3.3]heptane-2,6-diyl, 8-azaspiro[4.5]decane-2,8-diyl, or 2-azaspiro[4.5]decane-2,8-diyl. In a more preferred embodiment, Ring B is a 2-(substituted phenyl)pyrrolidin-1-yl group, L is a direct bond, and L 2is a direct bond, and ring A is a 1,4-phenylene ring or a 5- to 12-membered spiroheterocyclyl containing one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members, preferably a 5- to 12-membered spiroheterocyclyl containing one or two nitrogen atoms as ring members; more preferably a 4-membered / 4-membered, 3-membered / 5-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 5-membered ring containing one or two nitrogen or oxygen atoms as ring members. most preferably, ring A is 7-azaspiro[3.5]nonane-2,7-diyl, 2-azaspiro[3.5]nonane-2,7-diyl, 3-azaspiro[5.5]undecane-3,9-diyl, 2-azaspiro[3.3]heptane-2,6-diyl, 8-azaspiro[4.5]decane-2,8-diyl, or 2-azaspiro[4.5]decane-2,8-diyl. In an even more preferred embodiment, ring B is a 2-(2-substituted phenyl)pyrrolidin-1-yl group or a 2-(3-substituted phenyl)pyrrolidin-1-yl group, L is a direct bond, and L 2 is a direct bond, and ring A is a 1,4-phenylene ring or 7-azaspiro[3.5]nonane-2,7-diyl, 2-azaspiro[3.5]nonane-2,7-diyl, 3-azaspiro[5.5]undecane-3,9-diyl, 2-azaspiro[3.3]heptane-2,6-diyl, 8-azaspiro[4.5]decane-2,8-diyl, or 2-azaspiro[4.5]decane-2,8-diyl, wherein the phenyl group at the 2-position of the pyrrolidin-1-yl is selected from 1 to 4 substituents R defined in formula (I). 1dis replaced by In an alternative preferred embodiment, ring B is a 2-(2-substituted phenyl)pyrrolidin-1-yl group or a 2-(3-substituted phenyl)pyrrolidin-1-yl group, L is a direct bond, ring A is a 1,4-cyclohexylene ring or 1,4-cyclohex-3-enyl, or 1,4-cyclohex-2-enyl, or 1,4-cyclohex-1-enyl, or 7-azaspiro[3.5]nonane-2,7-diyl, 2-azaspiro[3.5]nonane-2,7-diyl, 3-azaspiro[5.5]undecane-3,9-diyl, 2-azaspiro[3.3]heptane-2,6-diyl, 8-azaspiro[4.5]decane-2,8-diyl, or 2-azaspiro[4.5]decane-2,8-diyl, and L 2 is a direct bond, wherein the phenyl group at the 2-position of the pyrrolidin-1-yl is substituted with one to four substituents R as defined in formula (I). 1d In one embodiment, one substituent R 1d is substituted at the 2-position of the phenyl group at the 2-position of the pyrrolidin-1-yl.
[0056] In one embodiment, m is 1.
[0057] In one embodiment, L 5 is a direct bond, -(CR a R b ) t -or-NR a -, where t is a number from 1 to 7, and -(CR a R b ) t -One or two CRs a R b The moiety is unsubstituted or is selected from O and NR a wherein R a and R b is defined as in formula (I).
[0058] In a preferred embodiment, L 5 is a direct bond, -(CR a R b )1~4 -, -O-(CR a R b ) 1~3 -, -NH-(CR a R b ) 1~3 or -NH-, where R a and R b is defined as in formula (I), whereby -L 5 The -CyC moiety is CyC, -(CR a R b ) 1~4 -CyC, -O-(CR a R b ) 1~3 -CyC, -NH-(CR a R b ) 1~3 -CyC or -NH-CyC. More preferably, L 5 is a direct bond, -(CH2) 1~4 -, -O-(CH2) 1~3 -, -NH-(CR a R b )-(CH2)2- or -NH-, where R a is hydrogen and R b is C optionally substituted with phenyl-S- 1~8 alkyl, whereby -L 5 The -CyC moieties are CyC and -(CH2), respectively. 1~4 -CyC, -O-(CH2) 1~3 -CyC, -NH-(CR a R b )-(CH2)2-CyC or -NH-CyC. More preferably, L 5 is a direct bond, -CH2-, -O-CH2-, -NH-CH2- or -NH-, whereby -L 5 The -CyC moiety is CyC, -CH2-CyC, -O-CH2-CyC, -NH-CH2-CyC, or -NH-CyC, respectively.
[0059] In one embodiment, CyC each contains one or two substituents R 5a is cycloalkyl or heterocyclyl optionally substituted with; R5a are independently hydrogen, halogen, cyano, oxo, -OR 5b , -NR 5b R 5c , -COR 5b , -SO2R 5b , -C 1~8 Alkyl, -C 2~8 alkynyl, -cycloalkyl, or heterocyclyl; 1~8 Each of alkyl and heterocyclyl is selected from hydrogen, halogen, cyano, -OR 5f , -C 1~8 one or two substituents R selected from alkyl, cycloalkyl or heterocyclyl; 5e optionally replaced by; where R 5b and R 5c are each independently hydrogen, -C 1~8 alkyl or heterocyclyl, 1~8 Alkyl is hydrogen, -NR 5f R 5g or one or two substituents R which are cycloalkyl 5e optionally replaced by; R 5f and R 5g are each independently hydrogen or -C 1~8 is alkyl; or Two adjacent R on a phenyl ring 5 together with the phenyl ring form a benzo ring, as described above.
[0060] In one embodiment, CyC each contains one or two substituents R 5a Monocyclic C optionally substituted with 3~8 Cycloalkyl or bridged cycloalkyl [ka] and preferably each CyC is selected from one or two substituents R 5a and cyclopentyl or cyclohexyl optionally substituted with
[0061] In one embodiment, CyC each has one or two R 5a optionally substituted with a) a monocyclic 4- to 9-membered heterocyclyl group containing one nitrogen, oxygen, or sulfur heteroatom as a ring member; b) a monocyclic 4- to 9-membered heterocyclyl group containing, as ring members, two heteroatoms selected from oxygen, sulfur, and nitrogen; and c) 5- to 20-membered spiroheterocyclyl containing one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members is a heterocyclyl selected from:
[0062] In a preferred embodiment, CyC is a monocyclic 4- to 6-membered heterocyclyl group containing one nitrogen, oxygen, or sulfur heteroatom as a ring member. More preferably, CyC is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, and piperidinyl. Even more preferably, CyC is selected from oxetan-2-yl, oxetan-3-yl, tetrahydrofuran-4-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, azetidin-3-yl, azetidin-2-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-4-yl, piperidin-2-yl, and piperidin-3-yl.
[0063] In a preferred embodiment, CyC is a monocyclic 6-membered heterocyclyl group containing, as ring members, two heteroatoms selected from oxygen and nitrogen. More preferably, CyC is dioxanyl, morpholino, morpholinyl, or piperidinyl, even more preferably 1,3-dioxan-2-yl, 1,3-dioxan-4-yl, 1,4-dioxan-2-yl, morpholin-1-yl, morpholin-2-yl, or morpholin-3-yl.
[0064] In preferred embodiments, CyC is a 4-membered / 4-membered, 3-membered / 5-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered or 5-membered / 6-membered monospiroheterocyclyl containing one or two nitrogen or oxygen ring members. [ka] (7-oxa-2-azaspiro[3.5]nonan-2-yl), or [ka] (2-oxaspiro[3.5]nonan-7-yl).
[0065] In a preferred embodiment, R 5a are independently hydrogen, halogen, cyano, oxo, -OR 5b , -NR 5b R 5c , -COR 5b , -SO2R 5b , -C 1~8 Alkyl, -C 2~8 Alkynyl, monocyclic C 3~8 cycloalkyl or a monocyclic 4- to 9-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen, oxygen, or sulfur heteroatoms as ring members, 1~8 Each of the alkyl and monocyclic 4- to 9-membered heterocyclyl groups may have one or two substituents R 5e Preferably, R 5a Cycloalkyl as C 3~6 Cycloalkyl; more preferably cyclopropyl. Preferably, R 5a The heterocyclyl as R is a 4- to 6-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen, oxygen, or sulfur heteroatoms as ring members. More preferably, R 5a Heterocyclyl as R is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl or morpholinyl. Even more preferably, R 5aHeterocyclyl as is oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydro-2H-pyran-4-yl or morpholin-4-yl.
[0066] In one embodiment, R 5e The heterocyclyl as R is a monocyclic 4- to 9-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen, oxygen, or sulfur heteroatoms as ring members. 5e Heterocyclyl as is tetrahydro-pyran-4-yl.
[0067] In one embodiment, R 5a is -NR 5b R 5c where R 5b is hydrogen and R 5c is heterocyclyl. In a more preferred embodiment, R 5a is -NR 5b R 5c where R 5b is hydrogen and R 5c is tetrahydro-pyran-4-yl. In one embodiment, R 5a is -NR 5b R 5c where R 5b and R 5c are each independently hydrogen or cycloalkyl-substituted -C 1~6 Alkyl, preferably monocyclic C 3~8 -C substituted with cycloalkyl 1~6 It is alkyl.
[0068] In one embodiment, R 5a -OR 5b or -SO2R 5b where R 5b is hydrogen or C 1~8 It is alkyl, preferably methyl.
[0069] In one embodiment, R 5a -COR 5b where R5b is hydrogen or -NR 5f R 5g C optionally substituted with 1~8 alkyl, where R 5f and R 5g are each independently hydrogen or C 1~8 It is alkyl, preferably methyl.
[0070] In one embodiment, two adjacent R on the phenyl ring 5 together with the phenyl ring forms an indazolyl substituted with tetrahydropyranyl.
[0071] In a preferred embodiment, -L 5 -CyC is [ka] [ka] [ka] is selected from the group consisting of:
[0072] Formula (II) [ka] (In the formula, Each ring A has 1 to 4 substituents R 2 a phenyl ring that is 1,4-phenylene optionally substituted with; or a 5- to 12-membered spiroheterocyclyl containing one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members; R 2 is independently at each occurrence hydrogen, halogen, or —C optionally substituted with halogen 1~8 selected from the group consisting of alkyl; Ring B is a monocyclic 4- to 9-membered heterocyclyl containing one nitrogen atom as a ring member or a monocyclic 4- to 9-membered heterocyclyl containing one nitrogen atom and one additional heteroatom selected from the group consisting of NH, O, S, SO, or SO heteroatoms as ring members, said ring being N-linked; R 1 , R 5 and m is defined in formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof is also disclosed herein.
[0073] The compound of formula (II) is a compound of formula (I) L 1 and L 2 are each independently a direct bond, and L 4 is -C(O)NHSO2-; L 3 is -O- and R 3 is pyrrolo[2,3-b]pyridin-5-yl; R 4 corresponds to the compound -NO2.
[0074] In one embodiment, ring A is 1,4-phenylene. In one embodiment, ring A is a 5- to 12-membered spiroheterocyclyl containing one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members; preferably, ring A is a 4-membered / 4-membered, 3-membered / 5-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, or 5-membered / 6-membered monospiroheterocyclyl containing one or two nitrogen or oxygen ring members; more preferably, ring A is [ka] (7-azaspiro[3.5]nonane-2,7-diyl), [ka] (2-azaspiro[3.5]nonane-2,7-diyl), [ka] (3-azaspiro[5.5]undecane-3,9-diyl), [ka] (2-azaspiro[3.3]heptane-2,6-diyl, wherein * 1 refers to the position attached to the pyrrolidinyl ring, and ** 2 refers to the position attached to the phenyl ring.
[0075] In certain embodiments, ring B is aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, azepan-1-yl, or azocan-1-yl, preferably substituted at the 2-position with a phenyl group and one, two, or three substituents R in the pyrrolidinyl ring. 1 and said phenyl group at the 2-position (i.e., ortho-position) is R as defined in formula (I). 1d is optionally replaced by
[0076] When ring B is pyrrolidin-1-yl substituted at the 2-position with a phenyl group, said phenyl group at the 2-position (i.e., ortho-position) is R defined in formula (I). 1d and the compound has the following formula (III): [ka] is expressed by
[0077] In one embodiment for formula (III), ring A is [ka] , [ka] (7-azaspiro[3.5]nonane-2,7-diyl), [ka] (2-azaspiro[3.5]nonane-2,7-diyl), [ka] (3-azaspiro[5.5]undecane-3,9-diyl), [ka] (2-azaspiro[3.3]heptane-2,6-diyl, wherein * 1 refers to the position attached to the pyrrolidinyl ring, and ** 2 refers to the position attached to the phenyl ring, whereby the compounds of formula (III) can be of the following subgenus of formula (III-A), (III-B), (III-C), (III-D) or (III-E): [ka] (wherein the variable R 1d , R 2 , R 5 and m is defined in formula (I) It can be represented by:
[0078] In certain embodiments of subgenus formula (II), (III), (III-A), (III-B), (III-C), (III-D), or (III-E), R 2 is hydrogen.
[0079] In certain embodiments of formula (II), (III), (III-A), (III-B), (III-C), (III-D), or (III-E), R 1d is defined in formula (I). Preferably, R 1d is substituted on the phenyl group at the 2-position of ring B (including an aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, azepan-1-yl or azocan-1-yl, preferably a pyrrolidin-1-yl group), independently represents a halogen, -C 1~8 Alkyl, -C 2~8Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -CN, -OR Ba , -SO2R Ba , -CONR Ba R Bb , -NO2, -NR Ba R Bb , -NR Ba COR Bb or -NR Ba SO2R Bb wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl each independently represent one to four substituents R as defined in formula (I). Bd , preferably one or two substituents R as defined in formula (I) Bd In another embodiment, one R 1d is at the 2-position of the phenyl ring at the 2-position of ring B.
[0080] In certain preferred embodiments of subgenus formula (II), (III), (III-A), (III-B), (III-C), (III-D), or (III-E), R 1d is methyl, ethyl, isopropyl, propyl or methoxymethyl or two methyls in positions on a phenyl ring; or propenyl; or cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; or ethoxy or isopropoxy; or amino or dimethylamino.
[0081] In certain preferred embodiments of subgenus formula (III), (III-A), (III-B), (III-C), (III-D), or (III-E), the 2-(2-substituted phenyl)pyrrolidin-1-yl moiety as ring B is [ka] [ka] is selected from the group consisting of:
[0082] In certain preferred embodiments of sub-genus formula (II), (III), (III-A), (III-B), (III-C), (III-D), or (III-E), m is 1; and L 5 is a direct bond, -(CR a R b ) t -or-NR a -, where t is a number from 1 to 7, and -(CR a R b ) t -One or two CRs a R b The moiety is unsubstituted or is selected from O and NR a wherein R a and R b is defined as in formula (I).
[0083] In a preferred embodiment, L 5 is a direct bond, -(CR a R b ) 1~4 -, -O-(CR a R b ) 1~3 -, -NH-(CR a R b ) 1~3 or -NH-, where R a and R b is defined as in formula (I), whereby -L 5 The -CyC moiety is CyC, -(CR a R b ) 1~4 -CyC, -O-(CR a R b ) 1~3 -CyC, -NH-(CR a R b ) 1~3 -CyC or -NH-CyC. More preferably, L 5 is a direct bond, -(CH2) 1~4 -, -O-(CH2) 1~3-, -NH-(CR a R b )-(CH2)2- or -NH-, where R a is hydrogen and R b is C optionally substituted with phenyl-S- 1~8 alkyl, whereby -L 5 The -CyC moieties are CyC and -(CH2), respectively. 1~4 -CyC, -O-(CH2) 1~3 -CyC, -NH-(CR a R b )-(CH2)2-CyC or -NH-CyC. More preferably, L 5 is a direct bond, -CH2-, -O-CH2-, -NH-CH2- or -NH-, whereby -L 5 The -CyC moiety is CyC, -CH2-CyC, -O-CH2-CyC, -NH-CH2-CyC, or -NH-CyC, respectively.
[0084] In one embodiment, CyC each contains one or two substituents R 5a is cycloalkyl or heterocyclyl optionally substituted with; R 5a are independently hydrogen, halogen, cyano, oxo, -OR 5b , -NR 5b R 5c , -COR 5b , -SO2R 5b , -C 1~8 Alkyl, -C 2~8 alkynyl, -cycloalkyl, or heterocyclyl; 1~8 Each of alkyl and heterocyclyl is selected from hydrogen, halogen, cyano, -OR 5f , -C 1~8 one or two substituents R selected from alkyl, cycloalkyl or heterocyclyl; 5e optionally replaced by; where R 5b and R 5c are each independently hydrogen, -C 1~8 alkyl or heterocyclyl, 1~8Alkyl is hydrogen, -NR 5f R 5g or one or two substituents R which are cycloalkyl 5e optionally replaced by; R 5f and R 5g are each independently hydrogen or -C 1~8 is alkyl; or Two adjacent R on a phenyl ring 5 together with the phenyl ring form a benzo ring, said ring being optionally substituted with heteroaryl.
[0085] In one embodiment, CyC each contains one or two substituents R 5a Monocyclic C optionally substituted with 3~8 Cycloalkyl or bridged cycloalkyl [ka] and preferably each CyC is selected from one or two substituents R 5a and cyclopentyl or cyclohexyl optionally substituted with
[0086] In one embodiment, CyC each has one or two R 5a optionally substituted with a) a monocyclic 4- to 9-membered heterocyclyl group containing one nitrogen, oxygen, or sulfur heteroatom as a ring member; b) a monocyclic 4- to 9-membered heterocyclyl group containing, as ring members, two heteroatoms selected from oxygen, sulfur, and nitrogen; and c) 5- to 20-membered spiroheterocyclyl containing one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members is a heterocyclyl selected from:
[0087] In a preferred embodiment, CyC is a monocyclic 4- to 6-membered heterocyclyl group containing one nitrogen, oxygen, or sulfur heteroatom as a ring member. More preferably, CyC is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, and piperidinyl. Even more preferably, CyC is selected from oxetan-2-yl, oxetan-3-yl, tetrahydrofuran-4-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, azetidin-3-yl, azetidin-2-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-4-yl, piperidin-2-yl, and piperidin-3-yl.
[0088] In a preferred embodiment, CyC is a monocyclic 6-membered heterocyclyl group containing, as ring members, two heteroatoms selected from oxygen and nitrogen. More preferably, CyC is dioxanyl, morpholino, morpholinyl, or piperidinyl, even more preferably 1,3-dioxan-2-yl, 1,3-dioxan-4-yl, 1,4-dioxan-2-yl, morpholin-1-yl, morpholin-2-yl, or morpholin-3-yl.
[0089] In preferred embodiments, CyC is a 4-membered / 4-membered, 3-membered / 5-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered or 5-membered / 6-membered monospiroheterocyclyl containing one or two nitrogen or oxygen ring members. [ka] (7-oxa-2-azaspiro[3.5]nonan-2-yl), or [ka] (2-oxaspiro[3.5]nonan-7-yl).
[0090] In a preferred embodiment, R 5aare independently hydrogen, halogen, cyano, oxo, -OR 5b , -NR 5b R 5c , -COR 5b , -SO2R 5b , -C 1~8 Alkyl, -C 2~8 Alkynyl, monocyclic C 3~8 cycloalkyl or a monocyclic 4- to 9-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen, oxygen, or sulfur heteroatoms as ring members, 1~8 Each of the alkyl and monocyclic 4- to 9-membered heterocyclyl groups may have one or two substituents R 5e Preferably, R 5a Cycloalkyl as C 3~6 Cycloalkyl; more preferably cyclopropyl. Preferably, R 5a The heterocyclyl as R is a 4- to 6-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen, oxygen, or sulfur heteroatoms as ring members. More preferably, R 5a Heterocyclyl as R is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl or morpholinyl. Even more preferably, R 5a Heterocyclyl as is oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydro-2H-pyran-4-yl or morpholin-4-yl.
[0091] In one embodiment, R 5e The heterocyclyl as R is a monocyclic 4- to 9-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen, oxygen, or sulfur heteroatoms as ring members. 5e Heterocyclyl as is tetrahydro-pyran-4-yl.
[0092] In one embodiment, R 5a is -NR 5b R 5c where R 5bis hydrogen and R 5c is heterocyclyl. In a more preferred embodiment, R 5a is -NR 5b R 5c where R 5b is hydrogen and R 5c is tetrahydro-pyran-4-yl. In one embodiment, R 5a is -NR 5b R 5c where R 5b and R 5c are each independently hydrogen or cycloalkyl-substituted -C 1~6 Alkyl, preferably monocyclic C 3~8 -C substituted with cycloalkyl 1~6 It is alkyl.
[0093] In one embodiment, R 5a -OR 5b or -SO2R 5b where R 5b is hydrogen or C 1~8 It is alkyl, preferably methyl.
[0094] In one embodiment, R 5a -COR 5b where R 5b is hydrogen or -NR 5f R 5g C optionally substituted with 1~8 alkyl, where R 5f and R 5g are each independently hydrogen or C 1~8 It is alkyl, preferably methyl.
[0095] In one embodiment, two adjacent R on the phenyl ring 5 together with the phenyl ring forms an indazolyl substituted with tetrahydropyranyl.
[0096] In some embodiments, m is 1 and R 5 teeth, [ka] [ka] -L selected from the group consisting of 5 -CyC.
[0097] In a preferred embodiment, m is 1 and R 5 teeth, [ka] is.
[0098] In certain embodiments, the carbon atom at position 2 of the pyrrolidinyl ring to which the phenyl ring in subgenus formula (III), (III-A), (III-B), (III-C), (III-D), or (III-E) is attached has the (S)-configuration.
[0099] In certain embodiments, the compound of formula (I) has formula (IV): [ka] (wherein the variable R 1 , R 1d , R 5 and m is defined in formula (I) It has.
[0100] In certain embodiments, the carbon atom at position 2 of the piperazinyl ring to which the phenyl ring in subgenus formula (IV) is attached has the (S)-configuration or the (R)-configuration.
[0101] The inventors of the present application have found that compounds of formula (III) and formula (IV), including the sub-genus formula (III-A), (III-B), (III-C), (III-D) or (III-E), are more potent and more selective due to the optimal combination of phenyl group substitution at the spiro or phenylene moiety and nitrogen-linked heterocyclyl position of the compounds disclosed herein (particularly the 2-(2-substituted phenyl)pyrrolidin-1-yl moiety for formula (III) and the 2-(2-substituted phenyl)piperazin-1-yl for formula (IV)).
[0102] [ka] Disclosed herein are intermediate compounds selected from compounds selected from:
[0103] Disclosed herein is a method for treating a disease of dysregulated apoptosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt or stereoisomer thereof. In one embodiment, the disease of dysregulated apoptosis is a cancer such as bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colon cancer, esophageal cancer, hepatocellular carcinoma, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myeloid leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, or splenic cancer, as disclosed in WO2005049593 and WO2005049594.
[0104] In one embodiment, the disease of dysregulated apoptosis is an autoimmune disease such as systemic lupus erythematosus (SLE).
[0105] Disclosed herein are pharmaceutical compositions comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and a pharmaceutically acceptable carrier.
[0106] definition The following terms have the meanings indicated below throughout this specification.
[0107] As used in this specification, including the appended claims, singular terms such as "a," "an," and "the" include their corresponding plural referents unless the context clearly dictates otherwise.
[0108] The term "or" is used to mean, and is used interchangeably with, the term "and / or," unless context clearly indicates otherwise.
[0109] The term "alkyl" refers to a hydrocarbon group selected from straight and branched chain saturated hydrocarbon groups containing 1 to 18, such as 1 to 12, further such as 1 to 10, even further such as 1 to 8, or 1 to 6, or 1 to 4 carbon atoms. Alkyl groups containing 1 to 6 carbon atoms (i.e., C 1~6 Examples of alkyl include, but are not limited to, methyl, ethyl, 1-propyl or n-propyl ("n-Pr"), 2-propyl or isopropyl ("i-Pr"), 1-butyl or n-butyl ("n-Bu"), 2-methyl-1-propyl or isobutyl ("i-Bu"), 1-methylpropyl or s-butyl ("s-Bu"), 1,1-dimethylethyl or t-butyl ("t-Bu"), 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl groups. The alkyl group can be optionally enriched with deuterium, eg, -CD3, -CD2CD3, and the like.
[0110] The term "halogen" refers to fluoro (F), chloro (Cl), bromo (Br) and iodo (I).
[0111] The term "haloalkyl" refers to an alkyl group in which one or more hydrogens have been replaced with one or more halogen atoms, such as fluoro, chloro, bromo, and iodo. Examples of haloalkyl include haloC 1~8 Alkyl, HaloC 1~6 Alkyl or haloC 1~4 Alkyl, including but not limited to, -CF3, -CH2Cl, -CH2CF3, -CCl2, CF3, and the like.
[0112] The term "alkenyl" refers to a hydrocarbon group selected from straight-chain and branched-chain hydrocarbon groups containing at least one C=C double bond and 2 to 18, such as 2 to 8, further such as 2 to 6 carbon atoms. Alkenyl groups, such as C 2~6 Examples of alkenyl include, but are not limited to, ethenyl or vinyl, prop-1-enyl, prop-2-enyl, 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, 2-methylbuta-1,3-dienyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, and hexa-1,3-dienyl groups.
[0113] The term "alkynyl" refers to a hydrocarbon group selected from straight and branched chain hydrocarbon groups containing at least one C≡C triple bond and 2 to 18, such as 2 to 8, further such as 2 to 6 carbon atoms. Alkynyl groups, such as C 2~6 Examples of alkynyl include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl (propargyl), 1-butynyl, 2-butynyl, and 3-butynyl groups.
[0114] The term "alkyloxy" or "alkoxy" refers to an alkyl group, as defined above, attached to the parent molecular moiety through an oxygen atom. 1~6 Alkyloxy or C 1~4 Examples of alkyloxy include, but are not limited to, methoxy, ethoxy, isopropoxy, propoxy, n-butoxy, tert-butoxy, pentoxy, and hexoxy.
[0115] The term "cycloalkyl" refers to a hydrocarbon group selected from saturated cyclic hydrocarbon groups, including monocyclic and polycyclic (eg, bicyclic and tricyclic) groups, including fused, bridged, or spirocycloalkyls.
[0116] For example, the cycloalkyl group can contain 3 to 12, such as 3 to 10, further such as 3 to 8, further such as 3 to 6, 3 to 5, or 3 to 4 carbon atoms. Further, for example, the cycloalkyl group can be selected from monocyclic groups containing 3 to 12, such as 3 to 10, further such as 3 to 8, 3 to 6 carbon atoms. Examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl groups. In particular, saturated monocyclic cycloalkyl groups, such as C 3~8 Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In preferred embodiments, cycloalkyl is a monocyclic ring (C) containing 3 to 6 carbon atoms, including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. 3~6 Examples of bicyclic cycloalkyl groups include those having 7 to 12 ring atoms arranged as a fused bicyclic ring selected from [4,4], [4,5], [5,5], [5,6], and [6,6] ring systems, or as a bridged bicyclic ring selected from bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, and bicyclo[3.2.2]nonane. Further examples of bicyclic cycloalkyl groups include those arranged as a bicyclic ring selected from [5,6] and [6,6] ring systems, such as [ka] (wherein the wavy line indicates the point of attachment) The rings may be saturated or have at least one double bond (i.e., partially unsaturated), but are not fully conjugated and are not aromatic, as aromatic is defined herein.
[0117] The term "spirocycloalkyl" refers to a ring structure containing carbon atoms and formed by at least two rings that share one atom. The term "7-10-membered spirocycloalkyl" refers to a ring structure containing 7-10 carbon atoms and formed by at least two rings that share one atom.
[0118] The term "fused cycloalkyl" refers to a fused ring formed by two or more rings containing carbon atoms and sharing two adjacent atoms. The term "4-10 membered fused cycloalkyl" refers to a fused ring formed by two or more rings containing 4 to 10 ring carbon atoms and sharing two adjacent atoms.
[0119] Examples include, but are not limited to, bicyclo[1.1.0]butyl, bicyclo[2.1.0]pentyl, bicyclo[3.1.0]hexyl, bicyclo[4.1.0]heptyl, bicyclo[3.3.0]octyl, bicyclo[4.2.0]octyl, decalin, and benzo 3-8 membered cycloalkyl, benzo C 4~6 Examples include cycloalkenyl, 2,3-dihydro-1H-indenyl, 1H-indenyl, 1,2,3,4-tetralyl, 1,4-dihydronaphthyl, etc. Preferred embodiments are 8-9 membered fused cyclyls, which refer to ring structures containing 8-9 ring atoms from the above examples.
[0120] The term "bridged cycloalkyl" refers to a cyclic structure formed by two rings containing 7 to 12 carbon atoms and sharing two non-adjacent atoms. The term "7-10 membered bridged cycloalkyl" refers to a cyclic structure formed by two rings containing 7 to 12 carbon atoms and sharing two non-adjacent atoms.
[0121] The term "cycloalkenyl" refers to a non-aromatic cyclic alkyl group of 3 to 10 carbon atoms having single or multiple rings and at least one double bond and preferably one to two double bonds. In one embodiment, cycloalkenyl is cyclopentenyl or cyclohexenyl, preferably cyclohexenyl.
[0122] The term "cycloalkynyl" refers to a non-aromatic cycloalkyl group of from 5 to 10 carbon atoms having single or multiple rings and at least one triple bond.
[0123] The term "aryl", used alone or in combination with other terms, refers to a group selected from: a) 5- and 6-membered carbocyclic aromatic rings, such as phenyl; b) bicyclic ring systems, such as 7-12 membered bicyclic ring systems (wherein at least one ring is carbocyclic and aromatic, such as naphthyl and indanyl); and c) Tricyclic ring systems, for example 10-15 membered tricyclic ring systems (wherein at least one ring is carbocyclic and aromatic, for example fluorenyl).
[0124] The terms "aromatic hydrocarbon ring" and "aryl" are used interchangeably throughout this disclosure. In certain embodiments, the monocyclic or bicyclic aromatic hydrocarbon ring has 5 to 10 ring-forming carbon atoms (i.e., C 5~10 (aryl). Examples of monocyclic or bicyclic aromatic hydrocarbon rings include, but are not limited to, phenyl, naphth-1-yl, naphth-2-yl, anthracenyl, phenanthrenyl, etc. In certain embodiments, the aromatic hydrocarbon ring is a naphthalene ring (naphth-1-yl or naphth-2-yl) or a phenyl ring. In certain embodiments, the aromatic hydrocarbon ring is a phenyl ring.
[0125] The term "heteroaryl" refers to a group selected from: a) a 5-, 6-, or 7-membered aromatic monocyclic ring containing at least one heteroatom selected from nitrogen (N), sulfur (S), and oxygen (O), for example, 1 to 4, or in some embodiments 1 to 3, and in some embodiments 1 to 2 heteroatoms, with the remaining ring atoms being carbon; b) an 8- to 12-membered bicyclic ring containing at least one heteroatom selected from N, O, and S, for example, 1 to 4, or in some embodiments 1 to 3, or in other embodiments 1 or 2 heteroatoms, the remaining ring atoms being carbon, and at least one ring being aromatic, with at least one heteroatom being in the aromatic ring; and c) 11- to 14-membered tricyclic rings containing at least one heteroatom selected from N, O, and S, for example 1 to 4, or in some embodiments 1 to 3, or in other embodiments 1 or 2 heteroatoms, the remaining ring atoms being carbon, and at least one ring being aromatic, with at least one heteroatom being in the aromatic ring.
[0126] When the total number of S and O atoms in the heteroaryl group exceeds 1, the heteroatoms are not adjacent to one another. In certain embodiments, the total number of S and O atoms in the heteroaryl group is 2 or less. In certain embodiments, the total number of S and O atoms in the aromatic heterocycle is 1 or less. When a heteroaryl group contains two or more heteroatom ring members, the heteroatoms can be the same or different. Nitrogen atoms in the ring of a heteroaryl group can be oxidized to form an N-oxide. As used herein, the term "C-linked heteroaryl" means that a heteroaryl group is attached to a core molecule by a bond from a C atom of the heteroaryl ring.
[0127] The terms "heteroaromatic ring" and "heteroaryl" are used interchangeably throughout this disclosure. In certain embodiments, a monocyclic or bicyclic heteroaromatic ring has 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen (N), sulfur (S), and oxygen (O), and has 5-, 6-, 7-, 8-, 9-, or 10 ring members, with the remaining ring members being carbon. In certain embodiments, a monocyclic or bicyclic heteroaromatic ring is a monocyclic or bicyclic ring containing 1 or 2 heteroatom ring members independently selected from nitrogen (N), sulfur (S), and oxygen (O). In certain embodiments, a monocyclic or bicyclic heteroaromatic ring is a 5- to 6-membered heteroaryl ring, which is monocyclic and has 1 or 2 heteroatom ring members independently selected from nitrogen (N), sulfur (S), and oxygen (O). In certain embodiments, the monocyclic or bicyclic aromatic heterocycle is an 8- to 10-membered heteroaryl ring, which is bicyclic and has 1 or 2 heteroatom ring members independently selected from nitrogen, sulfur, and oxygen.
[0128] Examples of heteroaryl groups or monocyclic or bicyclic heteroaromatic rings include, but are not limited to, (counting from the attachment position assigned priority 1) pyridyl (such as 2-pyridyl, 3-pyridyl, or 4-pyridyl), cinnolinyl, pyrazinyl, 2,4-pyrimidinyl, 3,5-pyrimidinyl, 2,4-imidazolyl, imidazopyridinyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl (1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, or 1,3,4-thiadiazolyl). azolyl, etc.), tetrazolyl, thienyl (thien-2-yl, thien-3-yl, etc.), triazinyl, benzothienyl, furyl or furanyl, benzofuryl, benzimidazolyl, indolyl, isoindolyl, indolinyl, oxadiazolyl (1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, or 1,3,4-oxadiazolyl, etc.), phthalazinyl, pyrazinyl, pyridazinyl, pyrrolyl, triazolyl (1,2,3-triazolyl, 1,2,4-triazolyl, or 1,3,4-triazolyl, etc.), thiazolyl, etc.), quinolinyl, isoquinolinyl, pyrazolyl, pyrrolopyridinyl (1H-pyrrolo[2,3-b]pyridin-5-yl, etc.), pyrazolopyridinyl (1H-pyrazolo[3,4-b]pyridin-5-yl, etc.), benzofuranyl, benzoxazolyl (benzo[d]oxazol-6-yl, etc.), pteridinyl, purinyl, 1-oxa-2,3-diazolyl, 1-oxa-2,4-diazolyl, 1-oxa-2,5-diazolyl, 1-oxa-3,4-diazolyl, 1-thia-2,3-diazolyl aryl, 1-thia-2,4-diazolyl, 1-thia-2,5-diazolyl, 1-thia-3,4-diazolyl, furazanyl (such as furazan-2-yl and furazan-3-yl), benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, furopyridinyl, benzothiazolyl (such as benzo[d]thiazol-6-yl), indazolyl (such as 1H-indazol-5-yl), and 5,6,7,8-tetrahydroisoquinoline.
[0129] "Heterocyclyl," "heterocycle," or "heterocyclic" are synonymous and refer to a non-aromatic heterocyclyl group containing, as ring members, one or more heteroatoms selected from the group consisting of NH, O, S, SO, or SO heteroatoms, with the remaining ring members being carbon, and this includes monocyclic, fused, bridged, and spiro rings, i.e., monocyclic heterocyclyl, bridged heterocyclyl, spiro heterocyclyl, and fused heterocyclic groups.
[0130] The term "monocyclic heterocyclyl" refers to a monocyclic group in which at least one ring member is a heteroatom selected from the group consisting of NH, O, S, SO, or SO. The heterocycle can be saturated or partially saturated.
[0131] Exemplary monocyclic 4- to 9-membered heterocyclyl groups include, but are not limited to, (counting from the attachment position assigned priority 1) pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, imidazolidin-2-yl, imidazolidin-4-yl, pyrazolidin-2-yl, pyrazolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, 2,5-piperazinyl, pyranyl, morpholinyl, morpholino, morpholinyl ... 2-thithietanyl, morpholin-3-yl, oxiranyl, 1-aziridinyl, 2-aziridinyl, azocan-1-yl, azocan-2-yl, azocan-3-yl, azocan-4-yl, azocan-5-yl, thiiranyl, 1-azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, oxetanyl, thietanyl, 1,2-dithietanyl, 1,3-dithietanyl, dihydropyridinyl, tetrahydropyridinyl, thiomorpholinyl, thi Oxanyl, piperazinyl, homopiperazinyl, homopiperidinyl, azepan-1-yl, azepan-2-yl, azepan-3-yl, azepan-4-yl, oxepanyl, thiepanyl, 1,4-oxathienyl, 1,4-dioxepanyl, 1,4-oxathiepanyl, 1,4-oxazepanyl, 1,4-dithiepanyl, 1,4-thiazepanyl and 1,4-diazepanyl, 1,4-dithianyl, 1,4-azathienyl, oxazepinyl, diazepinyl, thiazepinyl, dihydro Examples include thienyl, dihydropyranyl, dihydrofuranyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, 1,4-dioxanyl, 1,3-dioxolanyl, pyrazolinyl, pyrazolidinyl, dithianyl, dithiolanyl, pyrazolidinyl, imidazolinyl, pyrimidinonyl, and 1,1-dioxo-thiomorpholinyl.
[0132] The terms "spiroheterocyclyl" or "heterospirocyclyl" refer to a 5- to 20-membered polycyclic heterocyclyl having rings joined through a common carbon atom (called a spiroatom), containing as ring members one or more heteroatoms selected from the group consisting of NH, O, S, SO, or SO heteroatoms, with the remaining ring members being carbon. One or more rings of a spiroheterocyclyl group may contain one or more double bonds, but none of the rings have a completely conjugated π-electron system. Preferably, a spiroheterocyclyl is 6- to 14-membered, more preferably 7- to 10-membered. Depending on the number of common spiro atoms, spiroheterocyclyl is divided into monospiroheterocyclyl, dispiroheterocyclyl or polyspiroheterocyclyl, preferably monospiroheterocyclyl or dispiroheterocyclyl, more preferably 4-membered / 4-membered, 3-membered / 5-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered or 5-membered / 6-membered monospiroheterocyclyl.Representative examples of spiroheterocyclyl include, but are not limited to, the following groups: 2,3-dihydrospiro[indene-1,2'-pyrrolidine] (e.g., 2,3-dihydrospiro[indene-1,2'-pyrrolidine]-1'-yl), 1,3-dihydrospiro[indene-2,2'-pyrrolidine] (e.g., 1,3-dihydrospiro[indene-2,2'-pyrrolidine]-1'-yl), azaspiro[2.4]heptane (e.g., 5-azaspiro[2.4]heptan-5-yl), azaspiro[3.4]octane (e.g., 6-azaspiro[3.4]octan-6-yl), 2-oxa-6-azaspiro[3.4]octane (e.g., 2-oxa-6-azaspiro[3.4]octane). ]octan-6-yl), azaspiro[3.4]octane (e.g., 6-azaspiro[3.4]octan-6-yl), azaspiro[3.4]octane (e.g., 6-azaspiro[3.4]octan-6-yl), 7-azaspiro[3.5]nonane (e.g., 7-azaspiro[3.5]nonan-7-yl), 2-azaspiro[3.5]nonane (e.g., 2-azaspiro[3.5]nonan-2-yl), 1,7-dioxaspiro[4.5]decane, 2-oxa-7-aza-spiro[4.4]nonane (e.g., 2-oxa-7-aza-spiro[4.4]non-7-yl), 7-oxa-spiro[3.5]nonyl, and 5-oxa-spiro[2.4]heptyl.
[0133] The term "fused heterocyclic group" refers to a 5- to 20-membered polycyclic heterocyclyl group, in which each ring in the system shares an adjacent atom pair (carbon and carbon atoms or carbon and nitrogen atoms) with another ring and contains one or more heteroatoms selected from the group consisting of NH, O, S, SO, or SO heteroatoms as ring members, with the remaining ring members being carbon. One or more rings in the fused heterocyclic group may contain one or more double bonds, but none of the rings has a completely conjugated π-electron system. Preferably, the fused heterocyclyl has 6 to 14 members, more preferably 7 to 10 members. Depending on the number of membered rings, the fused heterocyclyl is divided into bicyclic, tricyclic, tetracyclic, or polycyclic fused heterocyclyl, and preferably refers to a bicyclic or tricyclic fused heterocyclyl, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclyl. Representative examples of fused heterocycles include, but are not limited to, the following groups: octahydrocyclopenta[c]pyrrole (e.g., octahydrocyclopenta[c]pyrrol-2-yl), octahydropyrrolo[3,4-c]pyrrolyl, octahydroisoindolyl, isoindolinyl (e.g., isoindolin-2-yl), octahydro-benzo[b][1,4]dioxin, dihydrobenzofuranyl, benzo[d][1,3]dioxolyl.
[0134] The term "bridged heterocyclyl" refers to a 5- to 14-membered polycyclic heterocyclic alkyl group, in which every other ring in the system shares two separated atoms and contains one or more heteroatoms selected from the group consisting of NH, O, S, SO, or SO heteroatoms as ring members, with the remaining ring members being carbon. One or more rings in a bridged heterocyclyl group may contain one or more double bonds, but none of the rings has a fully conjugated π-electron system. Preferably, the bridged heterocyclyl has 6 to 14 members, more preferably 7 to 10 members. Depending on the number of membered rings, the bridged heterocyclyl is divided into bicyclic, tricyclic, tetracyclic, or polycyclic bridged heterocyclyl, and preferably refers to bicyclic, tricyclic, or tetracyclic bridged heterocyclyl, more preferably bicyclic or tricyclic bridged heterocyclyl. Representative examples of bridged heterocyclyl include, but are not limited to, the following groups: 2-azabicyclo[2.2.1]heptyl, azabicyclo[3.1.0]hexyl, 2-azabicyclo[2.2.2]octyl, and 2-azabicyclo[3.3.2]decyl.
[0135] The heterocyclyl ring may be fused to an aryl, heteroaryl, or cycloalkyl ring, and the ring structures together are bound to the parent heterocyclic group.
[0136] "C-linked heterocyclyl," as used herein, refers to a heterocyclyl group that is attached to the rest of the molecule by a direct bond from a carbon atom of the heterocyclyl ring.
[0137] "N-linked heterocyclyl," as used herein, refers to a heterocyclyl group that is attached to the rest of the molecule by a direct bond from a nitrogen atom of the heterocyclyl ring.
[0138] The compounds disclosed herein may contain asymmetric centers and therefore may exist as enantiomers. "Enantiomer" refers to two stereoisomers of a compound that are non-superimposable mirror images of one another. When the compounds disclosed herein have two or more asymmetric centers, they may additionally exist as diastereomers. Enantiomers and diastereomers are included within the broader class of stereoisomers. All such possible stereoisomers are intended to be included, such as substantially pure resolved enantiomers, their racemic mixtures, and mixtures of diastereomers. All stereoisomers of the compounds disclosed herein and / or their pharmaceutically acceptable salts are intended to be included. Unless otherwise specified, a reference to one isomer applies to any of the possible isomers. Whenever the isomeric composition is not specified, all possible isomers are included.
[0139] As used herein, the term "substantially pure" means that the target stereoisomer contains 35% by weight or less, such as 30% by weight or less, further such as 25% by weight or less, further such as 20% by weight or less of any other stereoisomer. In one embodiment, the term "substantially pure" means that the target stereoisomer contains 10% by weight or less, such as 5% by weight or less, for example 1% by weight or less of any other stereoisomer.
[0140] When compounds disclosed herein contain olefinic double bonds, unless otherwise specified, such double bond is meant to include both E and Z geometric isomers.
[0141] When the compounds disclosed herein contain a disubstituted cyclohexyl or cyclobutyl group, the substituents found on the cyclohexyl or cyclobutyl ring may be in cis and trans configurations. A cis configuration would mean that both substituents are found on the top side of the arrangement of the two substituents on the carbon, while trans would mean that they were on opposite sides.
[0142] It may be advantageous to separate reaction products from one another and / or from starting materials. The desired products of each step or series of steps are separated and / or purified (hereinafter "separated") to the desired degree of homogeneity by techniques common in the art. Typically, such separations involve multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography. Chromatography can include any number of methods, including, for example, reverse-phase and normal-phase; size exclusion; ion exchange; high-pressure, medium-pressure, and low-pressure liquid chromatography methods and apparatus; small-scale analytical; simulated moving bed ("SMB") and preparative thin- or thick-layer chromatography, as well as small-scale thin-layer and flash chromatography techniques. Those skilled in the art will apply the technique most likely to achieve the desired separation.
[0143] "Diastereomer" refers to a stereoisomer of a compound having two or more chiral centers that are not mirror images of one another. Diastereomeric mixtures can be separated into their individual diastereomers based on the physical chemical differences of the individual diastereomers by methods well known to those skilled in the art, such as chromatography and / or fractional crystallization. Enantiomers can also be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with a suitable optically active compound (e.g., a chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers, and converting the individual diastereomers into the corresponding pure enantiomers (e.g., by hydrolysis). Enantiomers can also be separated by use of a chiral HPLC column.
[0144] Single stereoisomers, e.g., substantially pure enantiomers, can be obtained by resolution of racemic mixtures using methods such as the formation of diastereomers with optically active resolving agents (Eliel, E. and Wilen, S. Stereochemistry of Organic Compounds. New York: John Wiley & Sons, Inc., 1994; Lochmuller, C.H., et al. "Chromatographic resolution of enantiomers: Selective review", J. Chromatogr., 113(3)(1975): pp. 283-302). Racemic mixtures of chiral compounds of the present invention can be separated and isolated by any suitable method, including (1) the formation of ionic diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) the formation of diastereomeric compounds with chiral derivatizing agents, separation of diastereomers, and conversion to pure stereoisomers, and (3) the separation of substantially pure or enriched stereoisomers directly under chiral conditions. See Wainer, Irving W., Ed. Drug Stereochemistry: Analytical Methods and Pharmacology. New York: Marcel Dekker, Inc., 1993.
[0145] A "pharmaceutically acceptable salt" refers to a salt that, within the scope of sound medical judgment, is suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, etc., commensurate with a reasonable risk-benefit ratio. Pharmaceutically acceptable salts can be prepared in situ during the final isolation and purification of the compounds disclosed herein, or separately by reacting a free base function with a suitable organic acid, or by reacting an acidic group with a suitable base.
[0146] Furthermore, if the compounds disclosed herein are obtained as acid addition salts, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, for example a pharmaceutically acceptable addition salt, can be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid according to conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methods that can be used without undue experimentation to prepare non-toxic pharmaceutically acceptable addition salts.
[0147] As defined herein, "pharmaceutically acceptable salts thereof" includes salts of at least one compound of formula (I) and salts of stereoisomers of compounds of formula (I), such as salts of enantiomers and / or diastereomers.
[0148] The terms "administration," "administering," "treating," and "treatment," as used herein, when applied to an animal, human, experimental subject, cell, tissue, organ, or bodily fluid, refer to the contact of an exogenous pharmaceutical, therapeutic, diagnostic, or composition with an animal, human, subject, cell, tissue, organ, or bodily fluid. Treatment of a cell encompasses contact of a reagent with the cell as well as contact of a reagent with a fluid when the fluid is in contact with the cell. The terms "administration" and "treatment" also refer to in vitro and ex vivo treatments, e.g., of a cell, with a reagent, diagnostic, binding compound, or another cell. The term "subject," as used herein, includes any organism, preferably an animal, more preferably a mammal (e.g., rat, mouse, dog, cat, rabbit), and most preferably a human.
[0149] The term "effective amount" or "therapeutically effective amount" refers to an amount of an active ingredient, such as a compound, that, when administered to a subject to treat a disease or at least one clinical symptom of a disease or disorder, is sufficient to affect such treatment for the disease, disorder, or condition. A "therapeutically effective amount" may vary depending on the compound, the disease, disorder, and / or symptoms of the disease or disorder, the severity of the disease, disorder, and / or symptoms of the disease or disorder, the age of the subject being treated, and / or the weight of the subject being treated. The appropriate amount in any given case will be apparent to one of ordinary skill in the art or can be determined by routine experimentation. In certain embodiments, a "therapeutically effective amount" is an amount of at least one compound disclosed herein and / or at least one stereoisomer thereof and / or at least one pharmaceutically acceptable salt thereof that is effective to "treat" a disease or disorder in a subject as defined above. In the case of a combination therapy, a "therapeutically effective amount" refers to the total amount of the combination of the objects for effective treatment of a disease, disorder, or condition.
[0150] Pharmaceutical compositions comprising the compounds disclosed herein can be administered to subjects in need thereof by oral administration, inhalation, rectal administration, parenteral administration, or topical administration.For oral administration, pharmaceutical compositions can be conventional solid formulations such as tablets, powders, granules, capsules, or liquid formulations such as water or oil suspensions or other liquid formulations such as syrups, solutions, suspensions, etc.;For parenteral administration, pharmaceutical compositions can be liquids, aqueous solutions, oil suspension concentrates, freeze-dried powders, etc.Preferably, the pharmaceutical composition formulation is selected from tablets, coated tablets, capsules, suppositories, nasal sprays, or injections, more preferably tablets or capsules.The pharmaceutical composition can be a single unit administration with a precise dosage.In addition, the pharmaceutical composition can further comprise additional active ingredients.
[0151] All formulations of the pharmaceutical compositions disclosed herein can be prepared by conventional methods in the pharmaceutical field. For example, the active ingredient can be mixed with one or more excipients to produce the desired formulation. "Pharmaceutically acceptable excipients" refers to conventional pharmaceutical carriers suitable for the desired pharmaceutical formulation, such as diluents, vehicles such as water and various organic solvents, fillers such as starch and sucrose, binders such as cellulose derivatives, alginates, gelatin, and polyvinylpyrrolidone (PVP), humectants such as glycerol, disintegrants such as agar, calcium carbonate, and sodium bicarbonate, absorption enhancers such as quaternary ammonium compounds, surfactants such as hexadecanol, absorbent carriers such as kaolin and soap clay, and lubricants such as talc, calcium stearate, magnesium stearate, and polyethylene glycol. In addition, pharmaceutical compositions can further contain other pharmaceutically acceptable excipients, such as dispersants, stabilizers, thickeners, complexing agents, buffers, penetration enhancers, polymers, flavors, sweeteners, and dyes.
[0152] The term "disease" refers to any disease, ailment, illness, symptom, or sign, and may be synonymous with the term "disorder" or "condition."
[0153] Throughout this specification and the claims that follow, unless the context requires otherwise, the term "comprise" and variations such as "comprises" and "comprising" are intended to specify the presence of the feature that follows it, but do not exclude the presence or addition of one or more other features. As used herein, the term "comprise" can be substituted with the terms "contain," "include," or sometimes "have."
[0154] Throughout this specification and the claims that follow, "C n~m The term "" denotes a range inclusive of the endpoints, where n and m are integers and indicate the number of carbon atoms. Examples include C 1~8 , C 1~6 Examples include:
[0155] Unless otherwise defined elsewhere herein, all other technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs. [Brief explanation of the drawings]
[0156] [Figure 1] The co-crystal structure of A4a is shown. [Figure 2] An ABT-199 analog (PDB code: 4MAN) is shown. [Figure 3] A comparison of the binding pose of A4 with the ABT-199 analog (PDB code: 4MAN) to the Bcl2 protein is shown. [Figure 4] a) Co-crystal structure of F22 with Bcl-2. b) Co-crystal structure of ABT-199 analog with Bcl-2 (PDB code: 4MAN). c) Alignment of the binding pose between F22 and ABT-199 analog. [Figure 5] a. Induced subpocket of Bcl-2 by cyclopropyl of F22 in the crystal structure. b. None of the substituents in the ABT-199 analog induces a similar subpocket at the same position (PDB code: 4MAN). c. Alignment of the pocket surface between F22 and the ABT-199 analog is shown. [Figure 6] a Water bridge between F22 and Bcl-2 protein. b Such water bridges could not be observed between the ABT-199 analog and Bcl-2. [Figure 7] a) Sulfur-π interaction between Met115 and the 2-cyclopropylphenyl of F22 (4.41 Å). b) A similar interaction between Met115 and the 4-chlorophenyl of the ABT-199 analog (5.00 Å). DETAILED DESCRIPTION OF THE INVENTION
[0157] The following examples are intended to be merely illustrative and are not to be construed as limiting in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should be accounted for. Temperatures are given in °C unless otherwise indicated. Reagents were purchased from commercial suppliers such as Sigma-Aldrich, Alfa Aesar, or TCI, and were used without further purification unless otherwise indicated.
[0158] Unless otherwise indicated, reactions described below were carried out under a positive pressure of nitrogen or argon or in anhydrous solvents using drying tubes; reaction flasks were equipped with rubber septa for the introduction of substrates and reagents via syringe; and glassware was oven-dried and / or heat-dried.
[0159] 1 1 H NMR spectra were recorded on an Agilent instrument operating at 400 MHz. 1 H NMR spectra were obtained using CDCl3, CD2Cl2, CD3OD, DO, d6-DMSO, d6-acetone, or (CD3)2CO as solvents and tetramethylsilane (0.00 ppm) or residual solvent as reference standards (CDCl3: 7.25 ppm; CD3OD: 3.31 ppm; DO: 4.79 ppm; d6-DMSO: 2.50 ppm; d6-acetone: 2.05; (CD3)2CO: 2.05). When peak multiplicities are reported, the following abbreviations are used: s (singlet), d (doublet), t (triplet), q (quartet), qn (quintet), sx (sextet), m (multiplet), br (broad), dd (doublet of doublets), and dt (doublet of triplets). Coupling constants, when indicated, are reported in Hertz (Hz).
[0160] LC-MS spectrometer (Agilent 1260) Detector: MWD (190~400nm), Mass detector: 6120 SQ Mobile phase: A: acetonitrile containing 0.1% formic acid, B: water containing 0.1% formic acid Column: Poroshell 120 EC-C18, 4.6 x 50 mm, 2.7 μm Gradient method: Flow rate: 1.8 mL / min
[0161] [Table 1]
[0162] Preparative HPLC was performed on a column (150 x 21.2 mm id, 5 μm, Gemini NX-C18) at room temperature and UV detection at 214 nm and 254 nm at different flow rates and injection volumes.
[0163] In the examples below, the following abbreviations are used: AcOH or HOAc acetic acid aq. aqueous solution BINAP (2,2'-bis(diphenylphosphino)-1,1'-binaphthyl) BH3 Borane Salt water Saturated sodium chloride solution Boc2O Di(tert-butyl) carbonate BSA Bovine serum albumin DAST Diethylaminosulfur trifluoride DBN 1,5-diazabicyclo[4.3.0]non-5-ene DBU 1,8-diazabicyclo[5.4.0]undec-7-ene DCE 1,2-dichloroethane DCM dichloromethane DMAP 4-dimethylaminopyridine CH3MgBr Methylmagnesium Bromide DIPEA N,N-Diisopropylethylamine DMF N,N-dimethylformamide DMAC Dimethylacetamide DMSO dimethyl sulfoxide EA Ethyl acetate EDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Hydrochloride EDTA Ethylenediaminetetraacetic acid EtOH Ethyl alcohol h or hr Time HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate Hex 1 H NMR proton nuclear magnetic resonance H2O2 Hydrogen Peroxide HOBt Hydroxybenzotriazole IPA (i-PrOH) Isopropyl alcohol KOAc Potassium Acetate LAH Lithium aluminum hydride LC-MS Liquid Chromatography-Mass Spectrometry LDA Lithium diisopropylamide MeOH Methanol MsOH methanesulfonic acid min MTBE Methyl tert-butyl ether n-BuLi n-butyllithium NaH sodium hydride NaBH(OAc)3 Sodium triacetoxyborohydride NaBH3CN Sodium cyanoborohydride NH4Cl Ammonium chloride Pd / C Palladium / carbon powder Pd(dppf)Cl2 [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) Pd(PPh3)4 tetrakis(triphenylphosphine)palladium(0) Pd(OAc)2 Palladium Acetate Pd(OH)2 / C Palladium hydroxide / carbon powder PE Petroleum Ether pH -lg (hydrogen ion concentration) Preparative HPLC Preparative High Pressure Liquid Chromatography Preparative MPLC Preparative Medium Pressure Liquid Chromatography Preparative SFC Preparative Supercritical Fluid Chromatography Preparative TLC Preparative Thin-Layer Chromatography p-TsOH p-toluenesulfonic acid rt or RT room temperature sat. saturation t-BuOK Potassium tert-butoxide TBS tert-butyldimethylsilyl THF tetrahydrofuran TEA Triethylamine TFA trifluoroacetic acid TMSCF3 Trimethyl(trifluoromethyl)silane [Example]
[0164] Preparation of intermediates: Intermediate 1-a: Methyl 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-bromobenzoate [ka] A mixture of methyl 4-bromo-2-fluorobenzoate (116.5 g, 0.5 mol), 1H-pyrrolo[2,3-b]pyridin-5-ol (67 g, 0.5 mol), and K2CO3 (138 g, 1.0 mol) in DMF (500 mL) was heated at 95 °C for approximately 16 h. The reaction mixture was cooled to ambient temperature, filtered, and the filtrate was diluted with DCM (1 L). The resulting solution was washed with H2O (500 mL × 2) and concentrated. The residue was recrystallized from EA (200 mL) and PE (400 mL), and a cake (68 g) was collected as the first batch. The filtrate was concentrated and dissolved in EA (500 mL). The solution was washed with HO (200 mL x 2), concentrated, slurried with EA (25 mL) and PE (25 mL) at reflux for 1 h, cooled to ambient temperature, and filtered to give a second batch of product (38 g). The two batches of product were combined to give the product (106 g, 61.3%) as a brown solid. MS (ESI, m / e) [M+1] + 346.9, 348.9.
[0165] Intermediate 1-b: tert-butyl 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-bromobenzoate [ka] A mixture of tert-butyl 4-bromo-2-fluorobenzoate (238.5 g, 867.3 mmol), 1H-pyrrolo[2,3-b]pyridin-5-ol (116.2 g, 867.3 mmol), and K2CO3 (239.4 g, 1734.5 mmol) in DMF (1 L) was heated at 80 °C for approximately 16 h. Another batch of K2CO3 (100 g, 724.6 mmol) and 1H-pyrrolo[2,3-b]pyridin-5-ol (10 g, 74.6 mmol) was added to the reaction mixture, and the reaction mixture was stirred at 100 °C for an additional 4 h. The reaction mixture was cooled to ambient temperature, filtered, and the mother liquor was concentrated to remove approximately half the volume of DMF. DCM (200 mL) and EA (200 mL) were added and stirred, the resulting mixture was filtered, the filtrate was concentrated, and the residue was slurried in EA (200 mL) and PE (200 mL) for 1 h at ambient temperature. The precipitate was filtered and dried to give the product (155 g, 46.1%) as a yellow solid. MS (ESI, m / e) [M+1] + 389.0, 391.0.
[0166] Intermediate 1-c: tert-butyl 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate [ka] To a mixture of tert-butyl 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-bromobenzoate (130 g, 334.2 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (127 g, 501.3 mmol), and KOAc (98.3 g, 1002.3 mmol) in 1,4-dioxane (1.3 L) was added Pd(dppf)Cl (24.5 g, 66.8 mmol), and the mixture was stirred at 85 °C under N for about 4 h. The reaction mixture was cooled to ambient temperature and concentrated, and the residue was slurried in DCM (1 L), filtered, and the mother liquor was concentrated and purified by chromatography on silica (EA / DCM = 1 / 1) to give the crude product. The crude product was recrystallized from EA (100 mL) / PE (100 mL) and dried to give the product as a brown powder (114.5 g, 78.6%). MS (ESI, m / e) [M+1] + 437.2, 355.1
[0167] Intermediate 1-d: Methyl 2-((6-amino-5-chloropyridin-3-yl)oxy)-4-fluorobenzoate [ka] Step 1: Methyl 4-fluoro-2-((6-nitropyridin-3-yl)oxy)benzoate A mixture of 5-chloro-2-nitropyridine (2.5 g, 15.75 mmol), methyl 4-fluoro-2-hydroxybenzoate (2.44 g, 14.38 mmol), and K2CO3 (3.96 g, 28.65 mmol) in DMSO (30 mL) was stirred at 110 °C for 1 h. TLC showed that the reactants were completely consumed. The reaction mixture was cooled to room temperature, poured into water, and then extracted with EA (40 mL × 3). The combined organic layers were washed with brine (50 mL × 2), dried over Na2SO4, filtered, and concentrated to give a residue. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 50 / 1 to 1 / 1) to give methyl 4-fluoro-2-((6-nitropyridin-3-yl)oxy)benzoate (1.3 g). MS (ESI, m / e) [M+1] + 293.5.
[0168] Step 2: Methyl 2-((6-aminopyridin-3-yl)oxy)-4-fluorobenzoate A mixture of methyl 4-fluoro-2-((6-nitropyridin-3-yl)oxy)benzoate (50 g, 3.42 mmol) and Pd / C (0.8 g) in EtOH (20 mL) was stirred under H2 (50 Psi) at 25 °C for 3 h. TLC showed complete consumption of the reactants. The mixture was filtered and concentrated to remove the solvent. The residue was purified by preparative MPLC (eluent: PE / EA = 20 / 1 to 5 / 1) to give methyl 2-((6-aminopyridin-3-yl)oxy)-4-fluorobenzoate (1.3 g, 4.96 mmol, yield: 72.49%). MS (ESI, m / e) [M+1] + 263.3.
[0169] Step 3: Methyl 2-((6-amino-5-chloropyridin-3-yl)oxy)-4-fluorobenzoate To a solution of methyl 2-((6-aminopyridin-3-yl)oxy)-4-fluorobenzoate (1 g, 38.14 μmol) in DMF (10 mL) was added NCS (1 g, 76.28 μmol). The mixture was stirred at 25° C. for 4 hours. TLC showed that the reactants were completely consumed. The mixture was concentrated to remove the solvent. The residue was purified by preparative MPLC (eluent: PE / EA=20 / 1 to 5 / 1) to give methyl 2-((6-amino-5-chloropyridin-3-yl)oxy)-4-fluorobenzoate (169 mg). 1 H NMR (400MHz, CDCl3) δppm:7.84-7.98(m,2H), 7.77(d,J=2.6Hz, 1H), 7.26(d,J=2.6Hz, 1H), 6.77(ddd ,J=8.7, 7.6, 2.4Hz, 1H), 6.48(dd,J=10.0, 2.4Hz, 1H), 4.88(s,2H), 3.81(s,3H).MS(ESI, m / e)[M+1] + 297.2.
[0170] Intermediate 2-a: 2-(2-cyclopropylphenyl)pyrrolidine [ka] Step 1: tert-butyl 2-(2-bromophenyl)pyrrolidine-1-carboxylate [ka] A mixture of 2-(2-bromophenyl)pyrrolidine (1.13 g, 5 mmol), BocO (2.16 g, 10 mmol), TEA (1.01 g, 10 mmol), and DMAP (catalytic amount) in DCM (20 mL) was stirred at room temperature for 16 h. The mixture was then concentrated, and the residue was purified by silica gel chromatography (eluting with 100% PE to PE / EA = 5 / 1) to give the product (1.6 g, 98.1%) as a colorless oil. MS (ESI, m / e) [M+1] + 270.0, 272.0
[0171] Step 2: tert-butyl 2-(2-cyclopropylphenyl)pyrrolidine-1-carboxylate [ka] Under a nitrogen atmosphere, a mixture of tert-butyl 2-(2-bromophenyl)pyrrolidine-1-carboxylate (1.56 g, 4.7 mmol), cyclopropylboronic acid (1.23 g, 14.3 mmol), Pd(PPh) (540 mg, 0.47 mmol), and KCO (1.99 g, 14.3 mmol) in 1,4-dioxane / HO (9:1, 20 mL) was stirred at 90 °C for 16 h. The reaction mixture was then filtered and concentrated, and the crude product (1.4 g) was used directly in the next step without purification. MS (ESI, m / e) [M+1] + 232.1.
[0172] Step 3: 2-(2-cyclopropylphenyl)pyrrolidine [ka] A mixture of tert-butyl 2-(2-cyclopropylphenyl)pyrrolidine-1-carboxylate (1.4 g) and TFA (5 mL) in DCM (50 mL) was stirred at room temperature for 16 hours. The mixture was then concentrated to give the product (1.2 g, crude) as a yellow oil. MS (ESI, m / e) [M+1] + 188.1.
[0173] Intermediate 2-b: 2-(2-isopropylphenyl)pyrrolidine [ka] Step 1: tert-butyl 2-(2-(prop-1-en-2-yl)phenyl)pyrrolidine-1-carboxylate [ka] tert-Butyl 2-(2-(prop-1-en-2-yl)phenyl)pyrrolidine-1-carboxylate was prepared using a similar procedure as tert-butyl 2-(2-cyclopropylphenyl)pyrrolidine-1-carboxylate. 1 H NMR (400MHz, DMSO-d6) δppm:7.32-7.14(m,2H), 7.14-6.99(m,2H), 5.25(s,1H), 4.95-4.81(m,2H), 3.67-3.54(m,1H), 3.53 -3.40(m,1H), 2.29-2.23(m,1H), 2.05(s,3H), 1.92-1.73(m,2H), 1.64(s,1H), 1.36(s,3H), 1.07(s,6H).MS(ESI, m / e)[M+1] + 232.1.
[0174] Step 2: tert-butyl 2-(2-isopropylphenyl)pyrrolidine-1-carboxylate [ka] A mixture of tert-butyl 2-(2-(prop-1-en-2-yl)phenyl)pyrrolidine-1-carboxylate (983 mg, 3.41 mmol) and Pd(OH) / C (100 mg) in MeOH (20 mL) was stirred under a balloon of H at room temperature overnight. The reaction mixture was then filtered and concentrated to give the desired product as a colorless oil (803 mg, 81%) without further purification for the next deprotection step with TFA. 1 H NMR (400MHz, DMSO-d6) δppm:7.27(d,J=7.0Hz, 1H), 7.15(t,J=2.5, 7.0Hz, 2H), 6.97(d,J=7.0Hz, 1H), 5.10-5.05(m,1H), 3.64-3.52(m,1H), 3.49-3 .43(m,1H), 3.24-3.10(m,1H), 2.31-2.26(m,1H), 1.84-1.80(m,2H), 1.59 -1.53(m,1H), 1.38(s,3H), 1.28-1.16(m,6H), 1.09(s,3H), 1.08(s,3H)..
[0175] Step 3: 2-(2-isopropylphenyl)pyrrolidine [ka] A solution of tert-butyl 2-(2-isopropylphenyl)pyrrolidine-1-carboxylate (803 mg, 2.77 mmol) in DCM (5 mL) and TFA (2 mL) was stirred at room temperature for 4 hours. After removing the solvent, the resulting residue was dissolved in DCM (50 mL) and washed with aqueous NaHCO (30 mL × 2). The organic layer was collected, dried over anhydrous NaSO, filtered, and concentrated to give the desired product as a colorless oil (522 mg). 1 H NMR (400MHz, DMSO-d6) δppm:7.52(d,J=6.7Hz, 1H), 7.24-7.22(m,1H), 7.19-7.05(m,2H), 4.29(t,J=7.6Hz, 1H), 3.30-3.23(m,1H), 3.27 -3.02(m,1H), 2.91-2.82(m,1H), 2.14-2.06(m,1H), 1.79-1.71(m,2H), 1.41-1.32(m,1H), 1.19(s,3H), 1.17(s,3H).MS(ESI, m / e)[M+1] + 190.1.
[0176] Intermediate 2-c: 2-(4-cyclopropylphenyl)pyrrolidine [ka] Step 1: tert-butyl 2-(4-bromophenyl)pyrrolidine-1-carboxylate [ka] A mixture of 2-(4-bromophenyl)pyrrolidine (2.0 g, 8.85 mmol), BocO (2.9 g, 13.3 mmol), EtN (1.8 g, 17.7 mmol), and DMAP (110 mg, 0.9 mmol) in 20 mL of DCM was stirred at room temperature for 16 hours. The mixture was concentrated and purified by column chromatography on silica gel using EA / PE (1 / 10) as the eluent to give 2.2 g (78.6%) of tert-butyl 2-(4-bromophenyl)pyrrolidine-1-carboxylate as a yellow oil. MS (ESI) m / e [M+1] + 325.0, 327.0.
[0177] Step 2: tert-butyl 2-(4-cyclopropylphenyl)pyrrolidine-1-carboxylate [ka] A mixture of tert-butyl 2-(4-bromophenyl)pyrrolidine-1-carboxylate (1.0 g, 3.07 mmol), cyclopropylboronic acid (790 mg, 9.21 mmol), Pd(PPh) (358 mg, 0.31 mmol), and KCO (1.27 g, 9.21 mmol) in dioxane (10 mL) was heated to 100 °C for 16 h under N. The mixture was filtered, and the filtrate was concentrated to give the crude product, which was further purified by column chromatography on silica gel using EA / PE (1 / 10, v / v) as eluent to give 600 mg (68.1%) of tert-butyl 2-(4-cyclopropylphenyl)pyrrolidine-1-carboxylate as a yellow oil. MS (ESI) m / e [M+1-56] + 232.1.
[0178] Step 3: 2-(4-cyclopropylphenyl)pyrrolidine [ka] A solution of tert-butyl 2-(4-cyclopropylphenyl)pyrrolidine-1-carboxylate (1.2 g, 4.18 mmol) in TFA / DCM (2 mL / 10 mL) was stirred at room temperature for 16 h. The mixture was concentrated to remove the solvent, and the residue was partitioned between NaHCO3 solution (10 mL) and DCM (10 mL). The organic layer was collected, dried over Na2SO4, and concentrated to give 620 mg (79.2%) of 2-(4-cyclopropylphenyl)pyrrolidine. MS (ESI, m / e) [M+1] + 188.0.
[0179] Intermediate 2-d: 2-(2-methoxyphenyl)pyrrolidine [ka] To a solution of 2-(2-bromophenyl)pyrrolidine (500 mg, 2.2 mmol) in MeOH (50 mL) was added cuprous bromide (158.6 mg, 1.1 mmol) and sodium methanolate (358 mg, 6.6 mmol). The mixture was heated to reflux and stirred overnight. After cooling to room temperature, the mixture was filtered, concentrated, and purified by chromatography on silica (EA / PE=1 / 1) to give the product (300 mg, 76.6%) as a yellow oil. MS (ESI, m / e) [M+1] + 178.1.
[0180] Intermediate 2-e: 2-(2-chloro-6-fluorophenyl)pyrrolidine [ka] Step 1: 3-(2-chloro-6-fluorobenzoyl)-1-vinylpyrrolidin-2-one [ka] A dry 100 mL three-necked round-bottom flask equipped with a mechanical stirrer, dropping funnel, heating mantle, and reflux condenser was charged with 60% sodium hydride (0.6 g, 15 mmol) and 25 mL of dry toluene. The stirred suspension was heated at reflux while a mixture of 1.1 g (10 mmol) of vinylpyrrolidin-2-one and 1.9 g (10 mmol) of methyl 2-chloro-6-fluorobenzoate was slowly added. Heating was continued for 10 hours. The reaction mixture was cooled to room temperature, and the resulting thick slurry was carefully diluted with 25 mL of saturated aqueous ammonium chloride solution. The layers were separated, and the aqueous layer was extracted again with 25 mL of toluene. The combined organic layers were dried (MgSO4) and concentrated under reduced pressure to give crude 3-(2-chloro-6-fluorobenzoyl)-1-vinylpyrrolidin-2-one. [M+1] + 268.0.
[0181] Step 2: 5-(2-chloro-6-fluorophenyl)-3,4-dihydro-2H-pyrrole [ka] A mixture of 3-(2-chloro-6-fluorobenzoyl)-1-vinylpyrrolidin-2-one (1 g, crude) and HCl (6 M, 10 ml) was heated to reflux for 10 hours. The mixture was cooled to room temperature, basified to pH = 10, and extracted with DCM. The organic layer was dried over anhydrous Na2SO4 and concentrated. The residue was used in the next step without further purification (300 mg, crude). MS (ESI, m / e) [M+1] + 198.0
[0182] Step 3: 2-(2-chloro-6-fluorophenyl)pyrrolidine [ka] To a solution of 5-(2-chloro-6-fluorophenyl)-3,4-dihydro-2H-pyrrole (300 mg, crude) in MeOH, NaBH4 (50 mg) was added and stirred at room temperature for 1 hour, then excess MeOH was removed under reduced pressure. The residue was taken up in water and extracted with DCM. The organic layer was concentrated to give 2-(2-chloro-6-fluorophenyl)pyrrolidine, which was used in the next step without further purification (100 mg, crude). MS (ESI, m / e) [M+1] + 200.1.
[0183] Intermediate 2-f: 2-cyclohexylpyrrolidine [ka] A mixture of 2-phenylpyrrolidine (3.5 g, 23.77 mmol), PtO (1.08 g, 4.75 mmol), and AcOH (1.14 g, 19.02 mmol, 1.09 mL) in THF (60 mL) was degassed and purged with H three times, and then the mixture was stirred at 65 °C under an H atmosphere (50 psi) for 12 h. LC-MS showed the reaction was complete, with one major peak having the desired mass. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (TFA conditions) to give the product (4 g, TFA salt) as a yellow oil. The product (1 g, TFA salt) was released on Amberlyst A-21 ion exchange resin in MeOH (60 mL), filtered, and concentrated to give the product. The product was neutralized with saturated Na.sub.2CO.sub.3 (5 mL), extracted with DCM (80 mL), dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure to give the product (640 mg) as a yellow oil. 1 H NMR (400MHz, CDCl3)δppm:4.37(br s,1H), 3.13-3.01(m,1H), 2.95-2.90(m,1H), 2.83-2.72(m,1H), 2.00-1.59(m,8H), 1.48-1.06(m,5H), 1.06-0.88(m,2H).
[0184] Intermediate 2-g: 2-(2-(trifluoromethyl)phenyl)pyrrolidine [ka] Step 1: tert-butyl (4-oxo-4-(2-(trifluoromethyl)phenyl)butyl)carbamate [ka] To a solution of 1-bromo-2-(trifluoromethyl)benzene (2 g, 8.89 mmol, 1.21 mL) in THF (15 mL) at −78° C. was added n-BuLi (2.5 M, 3.56 mL). The reaction was stirred at −78° C. for 15 min, then a solution of tert-butyl 2-oxopyrrolidine-1-carboxylate (1.65 g, 8.89 mmol, 1.51 mL) in THF (15 mL) was added at −78° C. After the addition, the reaction mixture was warmed to 15° C. and stirred at 15° C. for 1 h. TLC showed the reaction was successful. The mixture was quenched with saturated NH4Cl (20 mL) and EA (20 mL). * The mixture was extracted with 2). The organic layer was separated, washed with brine, dried over NaSO, filtered, and concentrated. The residue was purified by silica gel (PE:EA = 50:1 to 10:1) to give tert-butyl (4-oxo-4-(2-(trifluoromethyl)phenyl)butyl)carbamate (2 g, 6.04 mmol, 67.91% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δppm:7.72(d,J=7.4Hz, 1H), 7.64-7.53(m,2H), 7.44(d,J=7.4Hz, 1H), 4.63(br s,1H), 3.23(q,J=6.4Hz, 2H), 2.90(t,J=7.0Hz, 2H), 1.93(quin,J=7.0Hz, 2H), 1.44(s,9H).
[0185] Step 2: 4-amino-1-(2-(trifluoromethyl)phenyl)butan-1-one [ka] To a mixture of tert-butyl (4-oxo-4-(2-(trifluoromethyl)phenyl)butyl)carbamate (2.8 g, 8.45 mmol) in DCM (30 mL) was added TFA (30.80 g, 270.13 mmol, 20 mL). The mixture was stirred at 15° C. for 1 h. The solvent was removed to give 4-amino-1-(2-(trifluoromethyl)phenyl)butan-1-one (3.5 g, 7.24 mmol, 85.67%, TFA) as a brown oil. 1 H NMR (400MHz, CDCl3)δppm:9.14(br s,3H), 7.87-7.83(m,1H), 7.80-7.73(m,2H), 7.69-7.64(m,1H), 4.44-4.29(m,2H), 3.45(t,J=7.9Hz, 2H), 2.58-2.43(m,2H).
[0186] Step 3: 2-(2-(trifluoromethyl)phenyl)pyrrolidine [ka] To a mixture of 4-amino-1-(2-(trifluoromethyl)phenyl)butan-1-one (3 g, 6.53 mmol, 2 TFA) in EtOH (72 mL) and AcOH (8 mL) was added NaBHCN (697.85 mg, 11.10 mmol). The mixture was stirred at 15 °C for 12 h. The reaction mixture was quenched with saturated NaHCO solution in water (100 mL). The mixture was concentrated. The residue was dissolved in EA (100 mL), washed with water and brine, dried over NaSO, filtered, and concentrated to give 2-(2-(trifluoromethyl)phenyl)pyrrolidine (0.71 g, 3.16 mmol, 48.33%) as a yellow oil. 1H NMR (400MHz, CDCl3) δppm:7.83(d,J=7.8Hz, 1H), 7.63-7.52(m,2H), 7.38-7.29(m,1H), 4.54(t,J=7.8Hz, 1H), 3.27-3.25(m,1H) ), 3.18-3.03(m,2H), 2.27(td,J=4.9, 7.8Hz, 1H), 2.07-1.97(m,1H), 1.94-1.80(m,1H), 1.69-1.59(m,1H).MS(ESI, m / e)[M+1] + 216.1 / 217.1.
[0187] Intermediate 2-h: 4,4-dimethyl-2-phenylpyrrolidine [ka] Step 1: 2,2-dimethyl-4-oxo-4-phenylbutanoic acid [ka] To a solution of 3,3-dimethyldihydrofuran-2,5-dione (15.3 g, 120 mmol) and AlCl (31.92 g, 240 mmol) in DCM (200 mL) was added dropwise benzene (14.04 g, 180 mmol) using an ice-water bath. The mixture was slowly warmed to room temperature and stirred overnight. It was poured onto ice, diluted with DCM (400 mL), and concentrated HCl (50 mL) was added and stirred until no precipitate remained. The organic layer was dried over anhydrous NaSO, filtered, and concentrated. The residue was slurried with MTBE and PE to give the desired product as a white solid (22.52 g, 99%). 1 H NMR(400MHz, CDCl3)δppm:7.95(d,J=8.0Hz, 2H), 7.56(t,J=8.0Hz, 1H), 7.46(t,J=8.0Hz, 2H), 3.31(s,2H), 1.36(s,6H).MS(ESI, m / e)[M+1] + 205.1.
[0188] Step 2: N-(2,4-dimethoxybenzyl)-2,2-dimethyl-4-oxo-4-phenylbutanamide [ka] A solution of 2,2-dimethyl-4-oxo-4-phenylbutanoic acid (18.03 g, 87.5 mmol), (2,4-dimethoxyphenyl)methanamine (14.62 g, 87.5 mmol), HATU (33.25 g, 87.5 mmol), and EtN (13.3 g, 131.25 mmol) in DCM (200 mL) was stirred overnight at room temperature. The DCM was removed. The residue was purified by flash column chromatography on silica gel eluted with EA / PE = 1 / 4 to 1 / 1 (v / v) to give the desired product as a brown oil (30.2 g, 97%). MS (ESI, m / e) [M+1] + 356.1.
[0189] Step 3: 1-(2,4-dimethoxybenzyl)-3,3-dimethyl-5-phenyl-1,3-dihydro-2H-pyrrol-2-one [ka] A solution of N-(2,4-dimethoxybenzyl)-2,2-dimethyl-4-oxo-4-phenylbutanamide (30.2 g, 85.1 mmol) in toluene (180 mL) and AcOH (10 mL) was refluxed overnight. It was cooled to room temperature, and the solvent was removed. The residue was purified by flash column on silica gel eluted with EA / PE = 1 / 10 to 1 / 1 (v / v) to give the crude product as a yellow oil (10 g, 30% yield). MS (ESI, m / e) [M+1] + 388.1.
[0190] Step 4: 3,3-dimethyl-5-phenyl-1,3-dihydro-2H-pyrrol-2-one [ka] A solution of 1-(2,4-dimethoxybenzyl)-3,3-dimethyl-5-phenyl-1,3-dihydro-2H-pyrrol-2-one (9 g, 26.6 mmol) in TFA (50 mL) was stirred at 95 °C for 1 h. It was cooled to room temperature, and the TFA was removed. The residue was purified by column flash on silica gel eluted with A / PE = 1 / 1 to give the crude product as a brown oil (4.4 g, 88% yield). MS (ESI, m / e) [M+1] + 188.1.
[0191] Step 5: 4,4-Dimethyl-2-phenylpyrrolidine [ka] A solution of 1-(2,4-dimethoxybenzyl)-3,3-dimethyl-5-phenyl-1,3-dihydro-2H-pyrrol-2-one (2.4 g, 12.8 mmol) in THF (100 mL) and BH3-THF (64 mL, 1 mol / L) was refluxed for 2 hours. It was cooled to room temperature, and HCl acid (6 M, 20 mL) was slowly added. Then, it was refluxed for 30 minutes. The solvent was removed, and the residue was used directly in the next step.
[0192] Intermediate 2-i: 1-phenylpyrrolidine-2-carbaldehyde [ka] Step 1: Phenylproline [ka] To a sealed tube flushed with nitrogen, L-proline (11.5 g, 100 mmol), potassium carbonate (27.6 g, 200 mmol), copper(I) iodide (3.8 g, 20 mmol), iodobenzene (24.4 g, 120 mmol), and DMF (150 ml) were added. The mixture was heated at 90 °C for 48 h and then cooled to room temperature. Water was added, and the pH was adjusted to less than 3 with concentrated HCl. The aqueous phase was extracted four times with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. Purification by silica gel chromatography (0-100% EtOAc / hexane gradient) gave the crude product, which was used directly in the next step. MS (ESI, m / e) [M+1] + 192.1
[0193] Step 2: (1-phenylpyrrolidin-2-yl)methanol [ka] To a solution of phenylproline (1.5 g, 7.8 mmol) in THF (50 mL) was added BH3-THF (1 M, 15.6 mL). The reaction was refluxed for 1 h. The reaction was then cooled to room temperature and quenched with MeOH (5 mL). The solvent was removed and the residue was purified by chromatography to give (1-phenylpyrrolidin-2-yl)methanol (1.3 g) as a colorless oil. MS (ESI, m / e) [M+1] + 192.1
[0194] Step 3: 1-Phenylpyrrolidine-2-carbaldehyde [ka] To a solution of (1-phenylpyrrolidin-2-yl)methanol (531 mg, 3 mmol) in DCM (25 mL) was added Dess-Martin reagent (1.9 g, 4.5 mmol) in portions. The mixture was stirred at room temperature overnight, then washed with saturated NaHCO3 solution. The organic layer was concentrated and purified by chromatography to give 1-phenylpyrrolidine-2-carbaldehyde (100 mg) as a colorless oil. MS (ESI, m / e) [M+1] + 176.1
[0195] Intermediate 2-j: 1-(4-bromophenyl)-2-methyl-2-phenylpyrrolidine [ka] Step 1: tert-butyl (4-oxo-4-phenylbutyl)carbamate [ka] A solution of PhBr (8 g, 50.95 mmol, 5.37 mL) in THF (150 mL) was cooled to −78 °C, and n-BuLi (2.5 M, 26.50 mL) was added. The mixture was stirred at −78 °C for 15 min. Then, tert-butyl 2-oxopyrrolidine-1-carboxylate (10.38 g, 56.05 mmol, 9.52 mL) in THF (20 mL) was added at −78 °C. The mixture was stirred at −78 °C for 15 min. TLC and LC-MS showed that the reaction was complete and the main peak was the title product. HO (100 mL) was added. The mixture was extracted with EA (200 mL). The organic layer was washed with water and brine, dried over NaSO, filtered, and concentrated to give tert-butyl (4-oxo-4-phenylbutyl)carbamate (14 g, crude) as a yellow solid.
[0196] Step 2: 5-phenyl-3,4-dihydro-2H-pyrrole [ka] To a mixture of tert-butyl (4-oxo-4-phenylbutyl)carbamate (12.3 g, 46.71 mmol) in toluene (61.5 mL) was added HCl (12 M, 8.56 mL). The mixture was stirred at 65 °C for 12 h. TLC showed the reaction was complete. The reaction mixture was extracted with EA (50 mL). The aqueous layer was collected, adjusted to pH = 10 with saturated NaHCO3 solution, and extracted with EA (50 mL). The organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel (eluent: PE:EA = 50:1 to 10:1) to give 5-phenyl-3,4-dihydro-2H-pyrrole (3.5 g, 22.90 mmol, 49.03% yield) as a pale yellow solid. 1 H NMR (400MHz, CDCl3) δppm:7.89-7.81(m,2H), 7.44-7.41(m,2H), 4.08(br t,J=7.4Hz, 2H), 2.96(br t,J=8.2Hz, 2H), 2.05(dd,J=7.4, 8.5Hz, 2H).
[0197] Step 3: 2-methyl-2-phenylpyrrolidine [ka] To a stirred solution of 5-phenyl-3,4-dihydro-2H-pyrrole (2 g, 13.77 mmol) in THF (60 mL) was added BF3.Et2O (7.82 g, 55.10 mmol, 6.80 mL) at −78 °C. The mixture was stirred at −78 °C for 45 minutes. Then, MeLi (1.6 M, 34.44 mL) was added at −78 °C. The mixture was stirred at −78 °C for 2.5 hours, then warmed to 15 °C, and stirred at 15 °C for 12 hours. TLC showed that the reaction was complete. The mixture was poured into water (100 mL), adjusted to pH = 12 with saturated NaOH solution, and extracted with DCM (100 mL × 2). The organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel (eluent: PE:EA=100:1 to 20:1) to give 2-methyl-2-phenylpyrrolidine (0.9 g, 5.30 mmol, 38.50% yield) as a red oil. 1H NMR (400MHz, CDCl3) δppm:7.52-7.46(m,2H), 7.36-7.29(m,2H), 7.2-7.18(m,1H), 3.17-3.09(m ,1H), 3.04-2.96(m,1H), 2.14-2.05(m,1H), 1.94-1.85(m,2H), 1.80-1.70(m,2H), 1.45(s,3H).
[0198] Step 4: 1-(4-bromophenyl)-2-methyl-2-phenylpyrrolidine [ka] A solution of 1-bromo-4-iodobenzene (4.21 g, 14.88 mmol), 2-methyl-2-phenylpyrrolidine (0.6 g, 3.72 mmol), Pd(dba) (340.75 mg, 372.11 mmol), BINAP (463.40 mg, 744.22 mmol), and t-BuOK (1.25 g, 11.16 mmol) in toluene (40 mL) was stirred at 90 °C for 12 h. After cooling to room temperature, the reaction mixture was filtered and concentrated. The residue was purified by preparative HPLC. After removal of the mobile phase, the residue was dissolved in EA (20 mL), adjusted to pH = 8 with saturated NaHCO solution, separated, and concentrated to give 1-(4-bromophenyl)-2-methyl-2-phenylpyrrolidine (0.43 g, 33.31% yield) as a brown oil. 1 H NMR (400MHz, CDCl3) δppm:7.34-7.29(m,2H), 7.27-7.22(m,3H), 7.14-7.12(m,2H), 6.31-6.26( m,2H), 3.64-3.55(m,2H), 2.15-2.10(m,2H), 2.01-1.96(m,2H), 1.77(s,3H).MS(ESI, m / e)[M+1] + 316.1, 318.1.
[0199] Intermediate 2-k: 1-(azetidin-3-ylmethyl)-2-(2-cyclopropylphenyl)pyrrolidine [ka] Step 1: tert-butyl 3-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)azetidine-1-carboxylate 2-(2-Cyclopropylphenyl)pyrrolidine (0.195 g, 647.19 mmol) was dissolved in DCE (6 mL), and tert-butyl 3-formylazetidine-1-carboxylate (359.62 mg, 1.94 mmol) and NaBH(OAc) (274.33 mg, 1.29 mmol) were added. After stirring at 15 °C for 4 h, HOAc (116.59 mg, 1.94 mmol) was added. Stirring was continued at 15 °C for 24 h. The reaction mixture was then poured into saturated aqueous NaHCO (4 mL). The mixture was extracted three times with CHCl (3 × 5 mL). The combined organic extracts were washed with brine (5 mL), dried over NaSO, and concentrated. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 20 / 1 to 5 / 1). tert-Butyl 3-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)azetidine-1-carboxylate (0.18 g) was obtained as a yellow liquid.
[0200] Step 2: 1-(Azetidin-3-ylmethyl)-2-(2-cyclopropylphenyl)pyrrolidine To a solution of tert-butyl 3-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)azetidine-1-carboxylate (0.7 g, 1.96 mmol) in CHCl (4.8 mL) was added TFA (2.24 g, 19.64 mmol) under N at 0° C. The mixture was stirred at 15° C. for 2 h. The solution was concentrated under reduced pressure. The residue was adjusted to pH 14 with 1N NaOH solution and extracted with CHCl (3×5 mL). The combined organic layers were dried and concentrated under reduced pressure. 1-(azetidin-3-ylmethyl)-2-(2-cyclopropylphenyl)pyrrolidine (475 mg) was obtained as a yellow liquid.
[0201] Intermediate 2-l: 1-methyl-4-(2-(pyrrolidin-2-yl)phenyl)-1,2,3,6-tetrahydropyridine [ka] Step 1: 1-(2-(2-bromophenyl)pyrrolidin-1-yl)-2,2,2-trifluoroethan-1-one To a solution of 2-(2-bromophenyl)pyrrolidine (4 g, 17.68 mmol) in DCM (100 mL) under an inert N atmosphere was added TEA (3.57 g, 35.36 mmol) and then trifluoroacetic anhydride (4.46 g, 21.22 mmol) dropwise at 0 °C. The mixture was stirred at room temperature overnight. The reaction mixture was then poured into 100 mL of water, extracted with DCM (100 mL), washed with 50 mL of brine, and dried over anhydrous NaSO. The solution was filtered and concentrated to give crude 1-(2-(2-bromophenyl)pyrrolidin-1-yl)-2,2,2-trifluoroethan-1-one (5.0 g) as a brown oil, which was used in the next step without further purification.
[0202] Step 2: tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)phenyl)-3,6-dihydropyridine-1(2H)-carboxylate To a solution of 1-(2-(2-bromophenyl)pyrrolidin-1-yl)-2,2,2-trifluoroethan-1-one (5 g, 15.5 mmol) in toluene (10 mL) was added tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (7.2 g, 23.25 mmol), Pd(OAc) (350 mg, 1.55 mmol), tricyclohexylphosphine (870 mg, 3.1 mmol), and KPO (11.5 g, 54.25 mmol). The suspension was stirred at 100° C. under a N atmosphere for 12 hours. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was further purified by column chromatography on silica gel (eluent: petroleum ether / ethyl acetate=50 / 1 to 10 / 1) to give tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)phenyl)-3,6-dihydropyridine-1(2H)-carboxylate (6.1 g) as a yellow oil.
[0203] Step 3: 2,2,2-trifluoro-1-(2-(2-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)pyrrolidin-1-yl)ethan-1-one To a solution of tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)phenyl)-3,6-dihydropyridine-1(2H)-carboxylate (6.1 g, 14.5 mmol) in DCM (100 mL) was added TFA (20 mL) at 0 °C, and the mixture was then stirred at room temperature for 1 h. The pH of the reaction mixture was adjusted to 8-9 using aqueous NaCO solution and then extracted with DCM. The organic layer was dried, filtered, and the filtrate was concentrated under reduced pressure to give 2,2,2-trifluoro-1-(2-(2-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)pyrrolidin-1-yl)ethan-1-one (3.8 g) as a brown oil, which was used in the next step without further purification.
[0204] Step 4: 2,2,2-trifluoro-1-(2-(2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)pyrrolidin-1-yl)ethan-1-one To a solution of 2,2,2-trifluoro-1-(2-(2-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)pyrrolidin-1-yl)ethan-1-one (1 g, 3.08 mmol) in MeOH (50 mL) was added HCHO (37%, 1.5 g 18.49 mmol) and NaBHCN (774 mg, 12.32 mmol). The suspension was stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure, and then the residue was diluted with water (15 mL) and EA (30 mL) with stirring. The organic layer was separated and washed with brine, then dried, filtered, and concentrated. The residue was purified by column chromatography on silica gel (eluent: DCM / MeOH=20 / 1) to give 2,2,2-trifluoro-1-(2-(2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)pyrrolidin-1-yl)ethan-1-one (0.8 g) as a brown oil.
[0205] Step 5: 1-methyl-4-(2-(pyrrolidin-2-yl)phenyl)-1,2,3,6-tetrahydropyridine To a solution of 2,2,2-trifluoro-1-(2-(2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)pyrrolidin-1-yl)ethan-1-one (0.8 g, 2.36 mmol) in MeOH (50 mL) and HO (50 mL) was added LiOH.HO (0.2 g, 4.73 mmol). After the addition, the mixture was heated to 60 °C and stirred for 2 h. The reaction mixture was concentrated under reduced pressure, and then the residue was diluted with water (15 mL) and EA (30 mL) with stirring. The organic layer was separated and washed with brine, then dried, filtered, and concentrated. The residue was purified by column chromatography on silica gel (eluent: DCM / MeOH=50 / 1) to give 1-methyl-4-(2-(pyrrolidin-2-yl)phenyl)-1,2,3,6-tetrahydropyridine (500 mg) as a brown oil. 1H NMR (400MHz, CDCl3) δppm:7.51(dd,J=0.98, 7.83Hz, 1H), 7.24-7.29(m,1H), 7.18(dt,J=1.34, 7.40H z, 1H), 7.08(dd,J=1.22, 7.58Hz, 1H), 5.55(td,J=1.60, 3.27Hz, 1H), 4.29(t,J=7.83Hz, 1H), 3.23(dd d,J=5.14, 7.43, 9.93Hz, 1H), 3.10(q,J=2.81Hz, 2H), 2.94-3.04(m,1H), 2.63-2.70(m,2H), 2.43(s, 3H), 2.12(dtd,J=4.89, 7.81, 12.50Hz, 1H), 1.80-1.90(m,1H), 1.59-1.70(m,1H).MS(ESI, m / e)[M+1] + 243.1.
[0206] Intermediate 2-m: 2-(2-cyclopropylphenyl)-4-fluoropyrrolidine [ka] Step 1: tert-butyl 2-(2-bromophenyl)-4-fluoropyrrolidine-1-carboxylate To a solution of tert-butyl 2-(2-bromophenyl)-4-hydroxypyrrolidine-1-carboxylate (2.5 g, 7.31 mmol) in DCM (30 mL) was added DAST (1.77 g, 10.96 mmol) dropwise. The solution was then stirred at 20 °C for 12 h. The reaction mixture was quenched with ice water (30 mL). The organic layer was separated and then washed with saturated NaHCO solution (30 mL), brine (30 mL), dried over NaSO, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 20 / 1 to 10 / 1) to give tert-butyl 2-(2-bromophenyl)-4-fluoropyrrolidine-1-carboxylate (1.6 g) as a yellow oil.
[0207] Step 2: tert-butyl 2-(2-cyclopropylphenyl)-4-fluoropyrrolidine-1-carboxylate To a solution of tert-butyl 2-(2-bromophenyl)-4-fluoropyrrolidine-1-carboxylate (1.5 g, 4.36 mmol) and cyclopropylboronic acid (1.1 g, 13.1 mmol) in toluene (20 mL) was added Pd(OAc) (98 mg, 0.436 mmol), tricyclohexylphosphine (245 mg, 0.872 mmol), KPO (3.2 g, 15.3 mmol), and HO (1 mL). The suspension was heated to 100 °C and stirred for 12 h under a N atmosphere. To the reaction mixture was added water (20 mL) and EtOAc (20 mL). The organic layer was separated, washed with brine (20 mL), dried over NaSO, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA=20 / 1) to give tert-butyl 2-(2-cyclopropylphenyl)-4-fluoropyrrolidine-1-carboxylate (1.1 g) as a brown oil.
[0208] Step 3: 2-(2-cyclopropylphenyl)-4-fluoropyrrolidine A solution of tert-butyl 2-(2-cyclopropylphenyl)-4-fluoropyrrolidine-1-carboxylate (1.1 g, 3.6 mmol) in HCl solution (20 mL, 4 M in EA) was stirred at room temperature for 2 hours. The reaction mixture was concentrated. The residue was diluted with saturated Na2CO3 solution (20 mL) and EA (20 mL). The organic layer was separated, dried over anhydrous Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 4 / 1 to 1 / 1) to give 2-(2-cyclopropylphenyl)-4-fluoropyrrolidine (620 mg) as a yellow oil. 1H NMR (400MHz, CDCl3) δppm:7.55(dd,J=7.5, 1.4Hz, 1H), 7.15-7.28(m,2H), 7.01-7.09(m,1H), 5.22-5.48(m,1H), 4.71-5.10(m,1H), 3 .31-3.61(m,1H), 2.91-3.11(m,1H), 2.52-2.75(m,1H), 1.70-2.14(m,3H), 0.89-1.06(m,2H), 0.60-0.82(m,2H).MS(ESI, m / e)[M+1] + 206.1.
[0209] Intermediate 2-n: 2-chloro-N,N-dimethyl-6-(pyrrolidin-2-yl)aniline [ka] Step 1: tert-butyl (4-(3-chloro-2-(dimethylamino)phenyl)-4-oxobutyl)carbamate To a solution of 2-bromo-6-chloro-N,N-dimethylaniline (3.5 g, 14.92 mmol) and tert-butyl 2-oxopyrrolidine-1-carboxylate (2.76 g, 14.92 mmol) in THF (50 mL) was added n-BuLi (6 mL, 2.5 M in hexane) at −70° C., followed by stirring for 2 h. Aqueous NH4Cl solution (50 mL) was added to the reaction mixture, which was then extracted with EA (50 mL × 3). The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 5 / 1) to give tert-butyl (4-(3-chloro-2-(dimethylamino)phenyl)-4-oxobutyl)carbamate (1.8 g) as a yellow oil.
[0210] Step 2: 4-amino-1-(3-chloro-2-(dimethylamino)phenyl)butan-1-one To a solution of tert-butyl (4-(3-chloro-2-(dimethylamino)phenyl)-4-oxobutyl)carbamate (1.7 g, 4.99 mmol) in DCM (10 mL) was added TFA (1 mL) and stirred at room temperature for 4 h. The reaction mixture was concentrated under reduced pressure to give crude 4-amino-1-(3-chloro-2-(dimethylamino)phenyl)butan-1-one (1.2 g, crude) as a yellow oil.
[0211] Step 3: 2-chloro-N,N-dimethyl-6-(pyrrolidin-2-yl)aniline To a solution of 4-amino-1-(3-chloro-2-(dimethylamino)phenyl)butan-1-one (1.2 g, 4.98 mmol) in EtOH (20 mL) was added NaBHCN (939.77 mg, 14.95 mmol) and HOAc (2 mL), followed by stirring at room temperature for 36 h. The reaction mixture was quenched with water (80 mL) and extracted with EA (50 mL × 3). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC (HCl). The pH of the target peak solution was adjusted to 10 and extracted with DCM (30 mL × 3). The organic phase was dried over NaSO and concentrated to give 2-chloro-N,N-dimethyl-6-(pyrrolidin-2-yl)aniline (297 mg) as a colorless oil. 1 H NMR (400MHz, CDCl3) δppm:7.40(dd,J=1.3, 7.7Hz, 1H), 7.19(dd,J=1.5, 7.9Hz, 1H), 7.12-7.05(m,1H), 4.56(t,J=7.9Hz, 1H), 3.19(ddd,J=5.4 , 7.4, 9.9Hz, 1H), 3.09-2.99(m, 1H), 2.85(s, 6H), 2.24(dtd,J=5.0, 7.7 , 12.6Hz, 1H), 1.95-1.80(m,2H), 1.58-1.45(m,1H).MS(ESI, m / e)[M+1] + 225.2.
[0212] Intermediate 2-o: 1-(4-bromophenyl)-2-(2-cyclopropylphenyl)-2-(trifluoromethyl)pyrrolidine [ka] Step 1: N-(4-bromophenyl)-1-(2-cyclopropylphenyl)-2,2,2-trifluoroethan-1-imine A solution of N-(4-bromophenyl)-1,1,1-triphenyl-15-phosphanimine (1.8 g, 4.16 mmol) and 1-(2-cyclopropylphenyl)-2,2,2-trifluoroethan-1-one (891.83 mg, 4.16 mmol) in toluene (20 mL) was stirred at 110 °C for 12 hours. The reaction mixture was cooled and concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 50 / 1 to 10 / 1) to give N-(4-bromophenyl)-1-(2-cyclopropylphenyl)-2,2,2-trifluoroethan-1-imine (1.1 g, 2.99 mmol) as a yellow oil.
[0213] Step 2: 4-Bromo-N-(2-(2-cyclopropylphenyl)-1,1,1-trifluoropent-4-en-2-yl)aniline To a solution of N-(4-bromophenyl)-1-(2-cyclopropylphenyl)-2,2,2-trifluoroethan-1-imine (1.1 g, 2.99 mmol) in DCM (10 mL) was added allylmagnesium bromide (1 M, 14.94 mL) at −20° C. and stirred for 2 h. The reaction mixture was then quenched with aqueous NHCl (10 mL) and extracted with EA (10 mL × 3). The organic layer was dried over NaSO, filtered, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE) to give 4-bromo-N-(2-(2-cyclopropylphenyl)-1,1,1-trifluoropent-4-en-2-yl)aniline (1.20 g) as a white solid.
[0214] Step 3: 4-((4-bromophenyl)amino)-4-(2-cyclopropylphenyl)-5,5,5-trifluoropentan-1-ol To a solution of 4-bromo-N-(2-(2-cyclopropylphenyl)-1,1,1-trifluoropent-4-en-2-yl)aniline (1.20 g, 2.92 mmol) in THF (10 mL) was added BH3.THF (1 M, 14.62 mL) at 0 °C and stirred for 1 h. Then, NaOH (2.5 M, 2.92 mL) and HO2 (1.49 g, 43.87 mmol) were added to the reaction mixture at 0 °C. After the addition, the mixture was further stirred at room temperature for 1.5 h. Then, the reaction mixture was quenched with aqueous NH4Cl (10 mL) and extracted with EA (10 mL × 3). The organic layer was dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA=50 / 1 to 5 / 1) to give 4-((4-bromophenyl)amino)-4-(2-cyclopropylphenyl)-5,5,5-trifluoropentan-1-ol (0.6 g) as a yellow oil.
[0215] Step 4: 1-(4-bromophenyl)-2-(2-cyclopropylphenyl)-2-(trifluoromethyl)pyrrolidine To a solution of 4-((4-bromophenyl)amino)-4-(2-cyclopropylphenyl)-5,5,5-trifluoropentan-1-ol (0.6 g, 1.55 mmol) in dioxane (10 mL), TEA (469.17 mg, 4.64 mmol) and MsCl (265.56 mg, 2.32 mmol) were added, and the mixture was stirred at room temperature for 1.5 h. The mixture was then heated to 80 °C and stirred for 1 h. The reaction mixture was then quenched with aqueous NH4Cl (10 mL), extracted with DCM (10 mL × 3), dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 10 / 1) to give 1-(4-bromophenyl)-2-(2-cyclopropylphenyl)-2-(trifluoromethyl)pyrrolidine (306 mg) as a white solid. 1H NMR (400MHz, CDCl3) δppm:7.63(td,J=2.6, 6.6Hz, 1H), 7.26-7.22(m,2H), 7.06(d,J=9.3Hz, 2H), 6.88-6.83(m,1H), 6.32(d,J=9.0Hz, 2H), 3.73-3 .56(m,2H), 2.94-2.68(m,2H), 2.44-2.31(m,1H), 2.27-2.16(m,1H), 1.6 3-1.58(m,1H), 0.96-0.85(m,1H), 0.60-0.47(m,3H).MS(ESI, m / e)[M+1] + 410.0.
[0216] Intermediate 2-p: 2-(2-cyclopropylbenzyl)pyrrolidine [ka] Step 1: tert-butyl 2-((2-cyclopropylphenyl)(hydroxy)methyl)pyrrolidine-1-carboxylate To a solution of 1-bromo-2-cyclopropylbenzene (4.50 g, 22.84 mmol) in THF (50 mL) was added n-BuLi (9.84 mL, 2.5 M) under N at −70° C. and stirred for 10 min. Then, tert-butyl 2-formylpyrrolidine-1-carboxylate (3.5 g, 17.57 mmol) was added to the mixture and further stirred for 2 h. The mixture was quenched with saturated NH4Cl solution (30 mL) and extracted with ethyl acetate (50 mL × 3). The organic phase was dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 200 / 1 to 5 / 1) to give tert-butyl 2-((2-cyclopropylphenyl)(hydroxy)methyl)pyrrolidine-1-carboxylate (3.40 g, 10.72 mmol) as a yellow oil.
[0217] Step 2: tert-butyl 2-(((1H-imidazole-1-carbonothioyl)oxy)(2-cyclopropylphenyl)methyl)pyrrolidine-1-carboxylate A solution of tert-butyl 2-((2-cyclopropylphenyl)(hydroxy)methyl)pyrrolidine-1-carboxylate (3.40 g, 10.72 mmol), di(1H-imidazol-1-yl)methanethione (5.73 g, 32.16 mol), and DMAP (1.32 g, 1072 mmol) in DCM (30 mL) was stirred at room temperature for 24 h. The mixture was poured into HCl acid (30 mL, 1 M) and extracted with DCM (50 mL × 3). The organic phase was dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA=200 / 1 to 5 / 1) to give tert-butyl 2-(((1H-imidazole-1-carbonothioyl)oxy)(2-cyclopropylphenyl)methyl)pyrrolidine-1-carboxylate (3.0 g, 7.02 mmol) as a yellow oil.
[0218] Step 3: tert-butyl 2-(2-cyclopropylbenzyl)pyrrolidine-1-carboxylate To a solution of tert-butyl 2-(((1H-imidazole-1-carbonothioyl)oxy)(2-cyclopropylphenyl)methyl)pyrrolidine-1-carboxylate (2.5 g, 5.852 mmol) in toluene (10 mL) was added tributyltin hydride (2.55 g, 8.778 mmol) and a catalytic amount of AIBN (192.06 g, 1.1704 mmol). The mixture was stirred at 100° C. for 2 h. The mixture was washed with saturated aqueous KF solution (50 mL) and extracted with EA (50 mL × 3). The organic phase was dried over NaSO, filtered, and concentrated. The residue was purified by preparative HPLC (NaHCO) to give tert-butyl 2-(2-cyclopropylbenzyl)pyrrolidine-1-carboxylate (650 mg) as a yellow oil.
[0219] Step 4: 2-(2-cyclopropylbenzyl)pyrrolidine tert-Butyl 2-(2-cyclopropylbenzyl)pyrrolidine-1-carboxylate (600.00 mg, 1.992 mmol) was added to a solution of MTBE / HCl (10 mL, 4 M). The mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated, and the pH was adjusted to 10 with saturated Na2CO3 solution, then stirred for 15 minutes and extracted with EA (30 mL × 3). The organic phase was dried over Na2SO4, filtered, and concentrated to give 2-(2-cyclopropylbenzyl)pyrrolidine (302.00 mg) as a yellow oil. 1 H NMR (400MHz, CDCl3) δppm:7.22-7.18(m,1H), 7.15-7.10(m,2H), 6.98-6.92(m,1H), 3.43-3.32(m,1H), 3.13-2.80(m,4) H), 2.05-1.96(m,1H), 1.93-1.66(m,6H), 1.52-1.40(m,1H), 1.01-0.90(m,2H), 0.74-0.62(m,2H).MS(ESI, m / e)[M+1] + 202.2.
[0220] Intermediate 2-q: 2-(2-(azetidin-1-yl)phenyl)-1-(4-bromophenyl)pyrrolidine [ka] Step 1: 2-(azetidin-1-yl)benzaldehyde To a solution of 2-fluorobenzaldehyde (10 g, 80.6 mmol) and azetidine (9.04 g, 96.7 mmol) in DMSO (50 mL) was added K2CO3 (33.4 g, 241.17 mmol) and stirred at 80 °C for 24 h. The mixture was poured into water (300 mL) and extracted with EA (100 mL × 3). The combined organic phase was washed with brine (400 mL), dried over anhydrous Na2SO4, filtered, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 100 / 1 to 20 / 1) to give 2-(azetidin-1-yl)benzaldehyde (9 g, crude) as a yellow oil.
[0221] Step 2: 1-(2-(azetidin-1-yl)phenyl)-N-(4-bromophenyl)methanimine To a mixture of 2-(azetidin-1-yl)benzaldehyde (4 g, 24.81 mmol) and 4-bromoaniline (4.27 g, 24.81 mmol) in toluene (40 mL) was added 4-methylbenzenesulfonic acid (854 mg, 4.96 mmol) and 4 Å molecular sieves (4 g). The mixture was stirred at 140° C. for 6 hours and then concentrated under reduced pressure. Crude 1-(2-(azetidin-1-yl)phenyl)-N-(4-bromophenyl)methanimine (9 g) was obtained as a yellow solid, which was used in the next step without further purification.
[0222] Step 3: N-(1-(2-(azetidin-1-yl)phenyl)but-3-en-1-yl)-4-bromoaniline To a mixture of 1-(2-(azetidin-1-yl)phenyl)-N-(4-bromophenyl)methanimine (9 g, 28.55 mmol) in DCM (50 mL) was added allylmagnesium bromide (128.5 mL, 1 M) at −20° C. under N. The mixture was stirred at room temperature for 2 h. Then, the mixture was poured into saturated NH.sub.4Cl (200 mL) and extracted with EA (200 mL × 3). The combined organic phases were washed with brine (400 mL), dried over anhydrous Na.sub.2SO.sub.4, filtered, and concentrated. The residue was purified by column chromatography on silica gel (PE / EA = 20 / 1 to 1 / 1) to give N-(1-(2-(azetidin-1-yl)phenyl)but-3-en-1-yl)-4-bromoaniline (3 g) as a yellow oil.
[0223] Step 4: 4-(2-(azetidin-1-yl)phenyl)-4-((4-bromophenyl)amino)butan-1-ol To a solution of N-(1-(2-(azetidin-1-yl)phenyl)but-3-en-1-yl)-4-bromoaniline (3 g, 8.4 mmol) in THF (20 mL) was added BHTHF (25 g, 25.19 mmol) at 0 °C under a N atmosphere. The mixture was stirred at 25 °C for 2 h. NaOH (1.01 g, 25.19 mmol) and HO (9.5 g, 83.97 mmol) were added at 0 °C, and then the mixture was stirred for 3 h. The mixture was poured into HO (50 mL) and extracted with EA (100 mL × 3). The combined organic phase was washed with brine (200 mL), dried over anhydrous NaSO, filtered, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE:EA = 1 / 1 to 0 / 1) to give 4-(2-(azetidin-1-yl)phenyl)-4-((4-bromophenyl)amino)butan-1-ol (0.9 g) as a yellow oil.
[0224] Step 5: 2-(2-(azetidin-1-yl)phenyl)-1-(4-bromophenyl)pyrrolidine To a solution of 4-(2-(azetidin-1-yl)phenyl)-4-((4-bromophenyl)amino)butan-1-ol (0.9 g, 2.4 mmol) in THF (5 mL) was added TEA (960 mg, 9.59 mmol) and MsCl (329 mg, 2.88 mmol) at 0° C. After stirring at 25° C. for 2 h, the reaction mixture was concentrated under reduced pressure. The residue was purified by preparative TLC (silica gel, eluent: PE / EA=1 / 1) to give 2-(2-(azetidin-1-yl)phenyl)-1-(4-bromophenyl)pyrrolidine (388.6 mg) as a yellow oil. 1H NMR (400MHz, CDCl3) δppm:7.24-7.18(m,2H), 7.17-7.11(m,1H), 6.94(dd,J=1.4, 7.6Hz, 1H), 6.74-6.66(m,1H), 6.55(dd,J=0.8, 8.0Hz, 1H), 6.39-6.3 1(m,2H), 4.80(d,J=7.5Hz, 1H), 4.11-3.91(m,4H), 3.69-3.57(m,1H), 3.36 (q,J=8.8Hz, 1H), 2.38-2.21(m,3H), 2.17-1.89(m,4H).MS(ESI, m / e)[M+1] + 357.1.
[0225] Intermediate 2r: 2-(2-(1,1-difluoroethyl)phenyl)pyrrolidine [ka] Step 1: 1-Bromo-2-(1,1-difluoroethyl)benzene To DAST (25 mL) was added 1-(2-bromophenyl)ethan-1-one (5 g, 25.120 mmol) portionwise at room temperature. The resulting mixture was stirred overnight at 50 °C under a nitrogen atmosphere. The reaction mixture was diluted with CHCl (100 mL) and then poured into ice / saturated aqueous NaHCO (250 mL) and extracted with CHCl (2 × 100 mL). The combined organic layers were dried over anhydrous NaSO and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 50 / 1) to give 1-bromo-2-(1,1-difluoroethyl)benzene (3.5 g) as a yellow liquid.
[0226] Step 2: tert-butyl 2-(2-(1,1-difluoroethyl)phenyl)-1H-pyrrole-1-carboxylate To a stirred solution of 1-bromo-2-(1,1-difluoroethyl)benzene (1.5 g, 6.786 mmol) in THF (18 mL) and HO (1.8 mL) was added [1-[(tert-butoxy)carbonyl]-1H-pyrrol-2-yl]boronic acid (1.44 g, 6.824 mmol), X-Phos (0.65 g, 1.363 mmol), KPO (4.34 g, 20.446 mmol), and Pd(OAc) (152.8 mg, 0.680 mmol). After stirring at 70 °C under a nitrogen atmosphere for 4.5 h, the reaction mixture was diluted with water (50 mL) and extracted with EA (3 × 30 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous NaSO, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA=50 / 1) to give 2.2729 g (crude) of tert-butyl 2-[2-(1,1-difluoroethyl)phenyl]-1H-pyrrole-1-carboxylate as a dark yellow oil.
[0227] Step 3: tert-butyl 2-(2-(1,1-difluoroethyl)phenyl)pyrrolidine-1-carboxylate To a stirred solution of tert-butyl 2-[2-(1,1-difluoroethyl)phenyl]-1H-pyrrole-1-carboxylate (2.2729 g, 7.395 mmol) in EtOH (45 mL) was added PtO (1.1365 g, 5.005 mmol) and concentrated HCl (4 mL) in portions. The resulting mixture was stirred under a H atmosphere (1 atm) at room temperature for 5 h. After filtering off the PtO, the filtrate was concentrated. The residue was diluted with saturated aqueous NaHCO (200 mL) at 0 °C and then extracted with EA (3 × 100 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous NaSO, and concentrated to give 1.7408 g (crude) of tert-butyl 2-[2-(1,1-difluoroethyl)phenyl]pyrrolidine-1-carboxylate as a dark yellow oil.
[0228] Step 4: 2-(2-(1,1-difluoroethyl)phenyl)pyrrolidine To a solution of tert-butyl 2-[2-(1,1-difluoroethyl)phenyl]pyrrolidine-1-carboxylate (1.7408 g, 5.591 mmol) in DCM (35 mL) was added HCl solution (4 mL, 4N in 1,4-dioxane) portionwise. The resulting mixture was stirred at room temperature under a N atmosphere for 4 hours. After adjusting the pH to 8 with saturated aqueous NaHCO3, the resulting mixture was extracted with DCM (3 × 50 mL). The combined organic layers were washed with brine (150 mL), dried over anhydrous Na2SO4, and concentrated. The residue was purified by reverse-phase flash chromatography under the following conditions: column, C18 silica gel; mobile phase, CH3CN (0.05% NH4HCO3) in water, 10% to 61% gradient in 25 min; detector, UV 220 nm. The resulting eluate was extracted with DCM (3 × 100 mL). The combined organic layers were then concentrated to give (2-[2-(1,1-difluoroethyl)phenyl]pyrrolidine) (703.1 mg) as a yellow oil. 1 H NMR (400MHz, chloroform-d) δppm:7.74(d,J=7.9Hz, 1H), 7.50-7.39(m,2H), 7.27(t,J=7.7Hz, 2H), 4.56(t,J=7.8Hz, 1H), 3.27(ddd,J=9.8, 7.4, 5.1Hz, 1H), 3 .06(dt,J=9.8, 7.4Hz, 1H), 2.23(dtd,J=12.8, 7.8, 4.9Hz, 1H), 2.05(s,1H), 2.03-1.94(m,5H), 1.94-1.81(m,1H), 1.78-1.58(m,1H).MS(ESI, m / e)[M+1] + 212.1.
[0229] Intermediate 2s: 1-(4-bromophenyl)-2-(2-cyclopropylphenyl)piperidine [ka] Step 1: 1-Bromo-2-cyclopropylbenzene To a stirred solution of 1-bromo-2-iodobenzene (40 g, 141.390 mmol) in dioxane (400 mL) was added KCO (58.62 g, 424.151 mmol), cyclopropylboronic acid (36.44 g, 424.214 mmol), and Pd(dppf)Cl (10.35 g, 14.14 mmol). The mixture was stirred at 70 °C for 48 h under a N atmosphere. The mixture was diluted with water (1000 mL) and extracted with EA (3 × 400 mL). The combined organic layers were washed with brine (400 mL), dried over anhydrous NaSO, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 100 / 1) to give 1-bromo-2-cyclopropylbenzene (22.0 g) as a colorless oil.
[0230] Step 2: 2-(2-cyclopropylphenyl)pyridine To a stirred solution of 1-bromo-2-cyclopropylbenzene (12 g, 60.891 mmol) in dioxane (120 mL) were added 2-(tributylstannyl)pyridine (26.90 g, 73.069 mmol) and Pd(PPh3)4 (7.04 g, 6.089 mmol). The mixture was stirred overnight at 100 °C under a N2 atmosphere. The reaction was quenched by the addition of water (100 mL). The resulting mixture was extracted with EA (3 × 50 mL). The combined organic layers were washed with 50 mL of brine, dried over anhydrous Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 70 / 1) to give 2-(2-cyclopropylphenyl)pyridine (5.80 g) as a pale yellow oil.
[0231] Step 3: 2-(2-cyclopropylphenyl)piperidine To a stirred solution of 2-(2-cyclopropylphenyl)pyridine (2.5 g, 12.820 mmol) in EtOH (100 mL) was added HCl acid (concentrated, 3.5 mL) and PtO (0.875 g, 3.846 mmol). The resulting mixture was stirred under an atmosphere of H (1 atm) at room temperature for 4 h. After filtering off the PtO, the filtrate was concentrated. The residue was purified by reverse-phase flash chromatography under the following conditions: column, C18 silica gel, mobile phase, water and 0.05% TFA in CH3CN, gradient 0% to 10% in 30 min; detector, UV 220 nm to give 900 mg of crude product, which was purified by preparative HPLC under the following conditions (column: XBridge Prep OBD C18 Column 30 × 150 mm 5 μm; mobile phase A: water (10 mMOL / L NH4HCO3), mobile phase B: CH3CN; flow rate: 60 mL / min; gradient: 25% B to 37% B in 9 min; 254 and 220 nm; Rt: 7.92 min) to give 2-(2-cyclopropylphenyl)piperidine (280 mg) as a yellow oil.
[0232] Step 4: 1-(4-bromophenyl)-2-(2-cyclopropylphenyl)piperidine To a stirred mixture of 2-(2-cyclopropylphenyl)piperidine (2.50 g, 12.437 mmol), (4-bromophenyl)boronic acid (4.975 g, 24.874 mmol), Cu(OAc) (5.627 g, 31.093 mmol), and activated 4 Å molecular sieves (2.0 g) in DCM (250 mL) was added DIPEA (4.011 g, 31.093 mmol) dropwise at room temperature. The resulting mixture was stirred at room temperature under an O atmosphere for 3 hours. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC under the following conditions (Column: XBridge Prep OBD C18 Column 30 × 150 mm 5 μm; Mobile phase A: water (0.05% TFA), Mobile phase B: CH3CN; Flow rate: 60 mL / min; Gradient: 43% B to 46% B in 9 min; 254 and 220 nm; Rt: 7.40 min) to give 1-(4-bromophenyl)-2-(2-cyclopropylphenyl)piperidine (310 mg) as a brown solid.1 H NMR (300MHz, methanol-d4) δppm:7.46(s,2H), 7.31(d,J=8.5Hz, 2H), 7.21-7.09(m,2H), 6.91(d,J=7.3Hz, 1H), 5.30(s,1H), 3. 78(s,2H), 2.20(s,1H), 2.13(s,4H), 1.00(d,J=8.4Hz, 2H), 0.60(d,J=6.0Hz, 1H), 0.50(d,J=5.6Hz, 1H).MS(ESI, m / e)[M+1] + 357.9.
[0233] Intermediate 2-t: 2-(2-cyclopropylphenyl)-4-methylpyrrolidine [ka] Step 1: Methyl 3-methyl-4-nitrobutanoate To a solution of (E)-methylbut-2-enoate (20 g, 199.77 mmol) and CHNO (48.78 g, 799.07 mmol) in MeOH (200 mL) was added DBN (4.60 mg, 39.95 mmol). The mixture was stirred at 60 °C under a N atmosphere for 6 h. TLC showed that the reactants were completely consumed. To the reaction mixture was added MTBE (700 mL) and washed with 1 M HCl (500 mL) and HO (500 mL). The organic phase was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 50 / 1). Methyl 3-methyl-4-nitrobutanoate (23 g, yield: 71.44%) was obtained as a yellow liquid. 1 H NMR (400MHz, CDCl3) δppm: 4.27-4.49(m,2H), 3.66(s,3H), 2.75(m,1H), 2.28-2.48(m,2H), 1.06(d,J=6.84Hz, 3H).
[0234] Step 2: 4-Methylpyrrolidin-2-one To a solution of methyl 3-methyl-4-nitrobutanoate (20 g, 124.10 mmol) in MeOH (200 mL) was added Raney Ni (728.41 mg, 12.41 mmol). The mixture was stirred under an H atmosphere at 50° C. for 4 hours. TLC showed the reaction was complete. The reaction mixture was filtered and concentrated under reduced pressure to give 4-methylpyrrolidin-2-one (10 g) as a yellow solid, which was used in the next step without further purification.
[0235] Step 3: tert-butyl 4-methyl-2-oxopyrrolidine-1-carboxylate To a mixture of 4-methylpyrrolidin-2-one (10 g, 100.88 mmol), DMAP (6.16 g, 50.44 mmol), and TEA (10.21 g, 100.88 mmol) in THF (100 mL) was added (Boc)2O (44.03 g, 201.75 mmol). The mixture was stirred at 25 °C for 3 h. TLC showed the reaction was complete. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate = 100 / 1 to 50 / 1). tert-Butyl 4-methyl-2-oxopyrrolidine-1-carboxylate (13 g, 64.68% yield) was obtained as a white solid. 1 H NMR(400MHz, CDCl3)δppm:3.87(dd,J=10.7, 7.6Hz, 1H), 3.29(dd,J=10.7, 6.9Hz, 1H), 2.64(dd,J=17.0, 8 .1Hz, 1H), 2.39(dd,J=14.6, 7.5Hz, 1H)2.16(dd,J=17.0, 8.1Hz, 1H), 1.53(s,9H), 1.14(d,J=6.6Hz, 3H).
[0236] Step 4: tert-butyl (4-(2-cyclopropylphenyl)-2-methyl-4-oxobutyl)carbamate A mixture of 1-bromo-2-cyclopropylbenzene (3.5 g, 17.76 mmol) in THF (50 mL) was degassed and purged with N three times, then n-BuLi (1.04 g, 16.28 mmol) was added dropwise to the mixture at −68° C. After stirring for 10 min, tert-butyl 4-methyl-2-oxopyrrolidine-1-carboxylate (2.95 g, 14.80 mmol) in THF (10 mL) was added to the mixture. The mixture was then stirred at −68° C. for 2 h under a N atmosphere. TLC showed that the reaction was complete. The reaction was quenched with aqueous NH4Cl (20 mL) and extracted with EA (50 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate=50 / 1 to 10 / 1) to obtain tert-butyl (4-(2-cyclopropylphenyl)-2-methyl-4-oxobutyl)carbamate (3.6 g, 76.63% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δppm:7.44(dd,J=7.7, 1.10Hz, 1H), 7.32-7.38(m,1H), 7.17- 7.24(m,1H), 7.03(d,J=7.9Hz, 1H), 4.68(s,1H), 3.12(t,J=6.3Hz, 2H), 3.00(dd, J=16.8, 5.51Hz, 2H), 2.77(dd,J=16.8, 7.72Hz, 1H), 2.24-2.50(m,3H), 1.44(s,1 0H), 1.24-1.36(m,1H), 0.94-1.03(m,5H), 0.88-0.94(m,2H), 0.61-0.72(m,2H).
[0237] Step 5: 4-amino-1-(2-cyclopropylphenyl)-3-methylbutan-1-one A solution of tert-butyl (4-(2-cyclopropylphenyl)-2-methyl-4-oxobutyl)carbamate (3.5 g, 11.03 mmol) in DCM (50 mL) was degassed and purged with N three times, then TFA (12.57 g, 110.26 mmol) was added. The mixture was stirred under N atmosphere at 20 °C for 1 h. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product (2.0 g) was used in the next step without purification. 1 H NMR (400MHz, CDCl3) δppm:7.52(d,J=7.7Hz, 1H), 7.27-7.44(m,8H), 7.24(d,J =1.1Hz, 1H), 7.08-7.19(m,4H), 6.97(d,J=7.7Hz, 3H), 4.46(t,J=7.2Hz, 1H), 4 .11-4.25(m,3H), 3.61-3.75(m,3H), 3.08-3.19(m,3H), 2.48-2.71(m,9H), 2. 37(d,J=5.5Hz, 3H), 1.08-1.20(m,12H), 0.89-0.98(m,9H), 0.65-0.71(m,4H).
[0238] Step 6: 2-(2-cyclopropylphenyl)-4-methylpyrrolidine A solution of 4-amino-1-(2-cyclopropylphenyl)-3-methylbutan-1-one (2.0 g, 9.20 mmol) in EtOH (20 mL) and HOAc (2 mL) was degassed and purged with N three times. Then, NaBHCN (983.23 mg, 15.56 mmol) was added portionwise to the solution. The mixture was stirred under N at 25 °C for 2 h. LC / MS showed that the reaction was complete. The reaction mixture was adjusted to pH = 10 with aqueous NaCO (1 N) and extracted with EA (20 mL × 5). The combined organic layers were washed with brine (50 mL), dried over NaSO, and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (TFA conditions). 2-(2-cyclopropylphenyl)-4-methylpyrrolidine (421 mg) was obtained as a yellow oil. 1H NMR (400MHz, CDCl3) δppm:7.48-7.59(m,1H), 7.11-7.25(m,2H), 7.01(d,J=7.3Hz, 1H ), 4.82-4.91(m,1H), 3.39(dd,J=9.9, 6.8Hz, 1H), 3.24(dd,J=10.1, 7.5Hz, 1H), 2.77( dd,J=10.2, 7.8Hz, 1H), 2.29-2.51(m,2H), 2.00(dd,J=8.3, 5.5Hz, 1H), 1.35(d,J=9. 8Hz, 1H), 1.08-1.15(m,3H), 0.88-0.98(m,2H), 0.61-0.71(m,2H).MS(ESI, m / e)[M+1] + 202.1.
[0239] Intermediate 2-u: (S)-2-(2-cyclopropylphenyl)-1-(7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[3.5]non-6-en-2-yl)pyrrolidine [ka] Step 1: (S)-2-(2-cyclopropylphenyl)-1-(8,11-dioxadispiro[3.2.47.24]tridecan-2-yl)pyrrolidine A solution of 8,11-dioxadispiro[3.2.47.24]tridecan-2-one (2.5 g, 13.35 mmol), (S)-2-(2-cyclopropylphenyl)pyrrolidine (2.36 g, 12.01 mmol), and HOAc (2.4 g, 40.05 mmol) in DCE (30 mL) was stirred at 15 °C for 2 h. Then, Na(OAc) BH (5.6 g, 26.7 mmol) was added to the mixture, which was then stirred at 15 °C for 12 h. TLC showed that the reaction was complete. The mixture was adjusted to pH = 10 with saturated aqueous NaCO solution. The organic layer was washed with brine, dried over NaSO, filtered, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 20 / 1 to 7 / 1) to give the target product (2.5 g, crude) as a yellow oil.
[0240] Step 2: (S)-2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)spiro[3.5]nonan-7-one To a solution of (S)-2-(2-cyclopropylphenyl)-1-(8,11-dioxadispiro[3.2.47.24]tridecan-2-yl)pyrrolidine (2 g, 5.45 mmol) in acetone (27 mL) was added 1 N HCl acid (27 mL, 27.25 mmol). The mixture was stirred at 15 °C for 6 h. TLC showed the reaction was complete. After removal of the solvent, the residue was dissolved in EA (20 mL) and adjusted to pH = 9 with saturated aqueous NaHCO3. The organic layer was washed with water and brine, dried over Na2SO4, filtered, and concentrated to give (S)-2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)spiro[3.5]nonan-7-one (1.7 g, crude) as a yellow oil.
[0241] Step 3: (S)-2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)spiro[3.5]non-6-en-7-yl trifluoromethanesulfonate A mixture of (S)-2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)spiro[3.5]nonan-7-one (1.6 g, 4.95 mmol) and 1,1,1-trifluoro-N-phenyl-N-((trifluoromethyl)sulfonyl)methanesulfonamide (2.12 g, 5.94 mmol) in THF (20 mL) was cooled to −78° C. Then, LDA (2.97 mL, 5.94 mmol) was added and stirred for 2 h. The mixture was warmed to 15° C. and stirred for 12 h. TLC showed that the reaction was complete. The mixture was poured into saturated aqueous NH4Cl and extracted with EA. The organic layer was washed with water and brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA=50 / 1 to 5 / 1) to give (S)-2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)spiro[3.5]non-6-en-7-yl trifluoromethanesulfonate (2.4 g, crude) as a yellow oil.
[0242] Step 4: (S)-2-(2-cyclopropylphenyl)-1-(7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[3.5]non-6-en-2-yl)pyrrolidine A mixture of (S)-2-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)spiro[3.5]non-6-en-7-yl trifluoromethanesulfonate (2.2 g, 4.83 mmol), B2PIN2 (1.84 g, 7.25 mmol), KOAc (1.42 g, 14.49 mmol), and Pd(dppf)Cl2 (351 mg, 0.48 mmol) in dioxane (20 mL) was stirred at 85 °C for 3 h. TLC showed the reaction was complete. The mixture was filtered and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA=10 / 1 to 5 / 1) to give (S)-2-(2-cyclopropylphenyl)-1-(7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[3.5]non-6-en-2-yl)pyrrolidine (700 mg, 33% yield) as a yellow solid. 1 H NMR (400MHz, CDCl3) δppm:7.66(t,J=6.1Hz, 1H), 7.33-7.28(m,1H), 7.25-7.12( m,4H), 7.04-6.99(m,1H), 6.35(s,1H), 4.39(s,1H), 3.40(s,1H), 3.28-3.10(m, 1H), 2.73(s,1H), 2.38-2.25(m,1H), 2.05(s,2H), 1.99-1.80(m,5H), 1.78-1.31 (m,4H), 1.25(s,13H), 1.00-0.86(m,2H), 0.71-0.57(m,2H).MS(ESI, m / e)[M+1] + 434.1.
[0243] Intermediate 2-v: tert-butyl 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)phenyl)piperazine-1-carboxylate [ka] Step 1: tert-butyl 4-(2-formylphenyl)piperazine-1-carboxylate To a solution of 2-fluorobenzaldehyde (13.33 g, 107.38 mmol) and tert-butyl piperazine-1-carboxylate (30.0 g, 161.07 mmol) in DMSO (150 mL) was added K2CO3 (44.52 g, 322.15 mmol). The mixture was stirred at 100 °C for 12 h. TLC showed that the reactants were completely consumed. The reaction mixture was cooled to room temperature, poured into H2O (150 mL), extracted with EA (150 mL × 3), dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography (silica gel, PE / EA = 100 / 1 to 30 / 1). tert-Butyl 4-(2-formylphenyl)piperazine-1-carboxylate (8.5 g) was obtained as a yellow solid. 1 H NMR (400MHz, CDCl3) δppm:1.50(s,9H), 3.02-3.08(m,4H), 3.61-3.66(m,4H), 7.11(d,J=8.2 Hz, 1H), 7.17(t,J=7.5Hz, 1H), 7.52-7.58(m,1H), 7.83(dd,J=7.7, 1.8Hz, 1H), 10.36(s,1H).
[0244] Step 2: (E)-tert-butyl 4-(2-(((4-bromophenyl)imino)methyl)phenyl)piperazine-1-carboxylate To a solution of tert-butyl 4-(2-formylphenyl)piperazine-1-carboxylate (8 g, 27.55 mmol) and 4-bromoaniline (4.74 g, 27.55 mmol) in toluene (100 mL) was added 4 Å molecular sieves (5 g) and TsOH (474.45 mg, 2.76 mmol). The mixture was stirred at 120° C. for 12 hours. TLC showed complete consumption of the reactants. The reaction mixture was concentrated under reduced pressure to remove the solvent. (E)-tert-butyl 4-(2-(((4-bromophenyl)imino)methyl)phenyl)piperazine-1-carboxylate (8 g, crude) was obtained as a brown oil. 1H NMR (400MHz, CDCl3) δppm: 1.49(s,9H), 2.98(br,4H), 3.60(br,4H), 7.08-7.13(m,3 H), 7.17-7.26(m,2H), 7.46(td,J=7.7, 1.6Hz, 1H), 7.50-7.54(m,2H), 8.83(s,1H).
[0245] Step 3: tert-butyl 4-(2-(1-((4-bromophenyl)amino)but-3-en-1-yl)phenyl)piperazine-1-carboxylate To a solution of (E)-tert-butyl-4-(2-(((4-bromophenyl)imino)methyl)phenyl)piperazine-1-carboxylate (8 g, 18.0 mmol) in DCM (100 mL) was added allylmagnesium bromide (1 M, 18.0 mL) at −20° C. The mixture was stirred at −20° C. for 2 h. TLC showed that the reactants were completely consumed. The reaction mixture was poured into aqueous NH4Cl (150 mL), extracted with EA (150 mL × 3), dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography (silica gel, petroleum ether). tert-butyl 4-(2-(1-((4-bromophenyl)amino)but-3-en-1-yl)phenyl)piperazine-1-carboxylate (6.0 g) was obtained as a yellow oil. 1 H NMR(400MHz, CDCl3)δppm:1.51(s,9H), 2.47-2.66(m,2H), 2.83-2.98(m,5H), 3.48-3.75(m,3H), 4.23(s,1H), 4.89(dd,J=8.1, 4.9Hz, 1H), 5.10- 5.21(m,2H), 5.79(ddt,J=17.0, 10.1, 6.9Hz, 1H), 6.40-6.44(m,2H), 7.1 0-7.20(m,4H), 7.24(dd,J=7.2, 1.5Hz, 1H), 7.34(dd,J=7.6, 1.5Hz, 1H).
[0246] Step 4: tert-butyl 4-(2-(1-((4-bromophenyl)amino)-4-hydroxybutyl)phenyl)piperazine-1-carboxylate To a solution of tert-butyl 4-(2-(1-((4-bromophenyl)amino)but-3-en-1-yl)phenyl)piperazine-1-carboxylate (6 g, 12.33 mmol) in THF (100 mL) was added BH3.THF (1 M, 185.02 mL) at 0 °C. The mixture was stirred at 25 °C for 12 h. Then, NaOH (1.23 g, 30.84 mmol) and HO2 (6.29 g, 185.02 mmol) were added to the mixture at 0 °C. The mixture was stirred at 25 °C for 8 h. TLC showed that reactant 4 was completely consumed. The reaction mixture was poured into aqueous NH4Cl (150 mL), extracted with EA (150 mL × 3), dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography (silica gel, PE / EA = 100 / 1 to 30 / 1). tert-Butyl 4-(2-(1-((4-bromophenyl)amino)-4-hydroxybutyl)phenyl)piperazine-1-carboxylate (3.5 g) was obtained as a yellow solid. 1 H NMR (400MHz, CDCl3)δppm:1.50(s,10H), 1.56-1.80(m,3H), 1.83-1.99(m,2H), 2.80-2.94(m,4H), 3.38-3.76(m ,5H), 4.88(dd,J=7.9, 5.5Hz, 1H), 6.46-6.51(m,2H), 7.11-7.18(m,4H), 7.21-7.24(m,1H), 7.31-7.34(m,1H).
[0247] Step 5: tert-butyl 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)phenyl)piperazine-1-carboxylate To a solution of tert-butyl 4-(2-(1-((4-bromophenyl)amino)-4-hydroxybutyl)phenyl)piperazine-1-carboxylate (3.5 g, 6.94 mmol) in DCM (50 mL) and TEA (3.51 g, 34.69 mmol) was added MsCl (715.29 mg, 6.24 mmol) at 0 °C, and the mixture was stirred at 25 °C for 1.5 h. LCMS showed that the reactants were completely consumed, and one major peak with the desired MS was observed. The reaction mixture was poured into aqueous NH Cl (150 mL), extracted with EA (150 mL × 3), dried over Na SO , filtered, and concentrated. The residue was purified by column chromatography (silica gel, PE / EA = 10 / 1). tert-Butyl 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)phenyl)piperazine-1-carboxylate (3.0 g) was obtained as a white solid. 1 H NMR (400MHz, CDCl3) δppm: 1.47-1.54(m,9H), 1.90-1.98(m,1H), 1.98-2. 17(m,2H), 2.40-2.52(m,1H), 2.86-3.02(m,4H), 3.35-3.43(m,1H), 3.55- 3.67(m,3H), 3.67-3.75(m,1H), 5.07-5.12(m,1H), 6.27-6.34(m,2H), 7. 01-7.07(m,1H), 7.08-7.12(m,1H), 7.15-7.26(m,4H).MS(ESI, m / e)[M+1] + 486.1.
[0248] Intermediate 2-w: 6-(2-cyclopropylphenyl)-5-azaspiro[2.4]heptane [ka] Step 1: tert-butyl 2-(2-cyclopropylphenyl)-4-hydroxypyrrolidine-1-carboxylate To a solution of 5-(2-cyclopropylphenyl)pyrrolidin-3-ol (1.8 g, 8.9 mmol) and EtN (0.9 g, 8.9 mmol) in DCM (20 mL) was added BocO (1.9 g, 8.9 mmol). The mixture was then stirred at 20 °C for 12 h. TLC showed the reaction was complete. The reaction mixture was washed with HCl acid (1 N, 20 mL), saturated aqueous NaHCO (20 mL), brine (20 mL), dried over NaSO, and concentrated to give tert-butyl 2-(2-cyclopropylphenyl)-4-hydroxypyrrolidine-1-carboxylate (2.3 g, crude) as a yellow oil.
[0249] Step 2: tert-butyl 2-(2-cyclopropylphenyl)-4-oxopyrrolidine-1-carboxylate To a solution of tert-butyl 2-(2-cyclopropylphenyl)-4-hydroxypyrrolidine-1-carboxylate (2.3 g, 7.6 mmol) in DCM (30 mL) was added NaHCO (640 mg, 7.6 mmol) and Dess-Martin periodinane (3.2 g, 7.6 mmol). The mixture was stirred at 20 °C for 12 h. TLC showed the reaction was complete. The reaction mixture was quenched with saturated aqueous NaSO (30 mL). The organic layer was washed with brine (30 mL), dried over NaSO, and concentrated to give tert-butyl 2-(2-cyclopropylphenyl)-4-oxopyrrolidine-1-carboxylate (2.1 g, crude) as a yellow oil.
[0250] Step 3: tert-butyl 2-(2-cyclopropylphenyl)-4-methylenepyrrolidine-1-carboxylate Ph3P in THF (25 mL) + MeBr -To a mixture of (5.5 g, 15.3 mmol) and t-BuOK (1.7 g, 15.3 mmol) was added in one portion. The mixture was stirred at 20 °C for 1 h. Then, tert-butyl 2-(2-cyclopropylphenyl)-4-oxopyrrolidine-1-carboxylate (2.3 g, 7.64 mmol) was added, and the mixture was stirred at 20 °C for 12 h. TLC showed that the reaction was complete. The reaction mixture was quenched with saturated aqueous NH4Cl (25 mL) and then extracted with EA (25 mL). The organic layer was washed with brine (25 mL), dried over Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel eluted with PE / EA = 10 / 1 to give tert-butyl 2-(2-cyclopropylphenyl)-4-methylenepyrrolidine-1-carboxylate (1.3 g, yield: 56%).
[0251] Step 4: tert-Butyl 6-(2-cyclopropylphenyl)-5-azaspiro[2.4]heptane-5-carboxylate To a mixture of tert-butyl 2-(2-cyclopropylphenyl)-4-methylenepyrrolidine-1-carboxylate (1.3 g, 4.3 mmol) and EtZn (1 M in toluene, 15 mL, 15 mmol) was added ClCHI (5.3 g, 30 mmol) at 0 °C. The mixture was then stirred at 20 °C for 12 h. TLC showed that a new spot had formed and that no material remained. The reaction mixture was quenched with saturated aqueous NHCl (50 mL) and extracted with EA (50 mL). The organic layer was washed with brine (50 mL), dried over NaSO, and concentrated to give tert-butyl 6-(2-cyclopropylphenyl)-5-azaspiro[2.4]heptane-5-carboxylate (1 g, crude) as a yellow oil, which was used directly in the next step.
[0252] Step 5: 6-(2-cyclopropylphenyl)-5-azaspiro[2.4]heptane A solution of tert-butyl 6-(2-cyclopropylphenyl)-5-azaspiro[2.4]heptane-5-carboxylate (1 g, 3.2 mmol) in HCl / EA (10 mL, 4 M) was stirred at 20 °C for 2 h. LC / MS showed the reaction was complete. The mixture was concentrated. The residue was purified by preparative HPLC (0.1% TFA). The target eluent was basified with saturated aqueous NaCO solution to pH = 10, then extracted with EA (200 mL × 4). The organic layers were combined, dried over NaSO, and concentrated to give 6-(2-cyclopropylphenyl)-5-azaspiro[2.4]heptane (293 mg) as a pale yellow oil. 1 H NMR (400MHz, CDCl3)δppm:7.60(dd,J=7.6, 1.3Hz, 1H), 7.13-7.25(m,2H), 7.01(d,J=7.5Hz, 1H), 4.97(t,J=7.8Hz, 1H), 3.02-3.13(m,2H), 2.34(s,1H), 2.14(dd,J=12.3, 7.2Hz, 1H), 2.04(t,J=8.4, 1H), 1.81-1.90(m,1H), 0.87-1.02(m,2H), 0.53-0.76(m,6H).MS(ESI, m / e)[M+1] + 214.1.
[0253] Intermediate 2-x: (R)-1-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)benzyl)-4-methylpiperazine [ka] Step 1: (R)-1-(2-(2-bromophenyl)pyrrolidin-1-yl)-2,2,2-trifluoroethanone To a mixture of (R)-2-(2-bromophenyl)pyrrolidine (10 g, 44.23 mmol) and TFAA (18.58 g, 88.45 mmol) in DCM (100 mL) was added TEA (13.5 g, 132.69 mmol) dropwise at 0 °C. The mixture was stirred at 20 °C for 10 h. TLC showed that the reactants were completely consumed. The reaction mixture was washed with saturated aqueous NH4Cl (100 mL × 2), and the organic phase was dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, PE / EA = 100 / 1 to 50 / 1). (R)-1-(2-(2-bromophenyl)pyrrolidin-1-yl)-2,2,2-trifluoroethanone (13 g) was obtained as a yellow solid.
[0254] Step 2: (R)-2,2,2-trifluoro-1-(2-(2-vinylphenyl)pyrrolidin-1-yl)ethenone To a mixture of (R)-1-(2-(2-bromophenyl)pyrrolidin-1-yl)-2,2,2-trifluoroethanone (5 g, 15.52 mmol), potassium trifluoro(vinyl)borate (2.91 g, 21.73 mmol), and CsCO (10.11 g, 31.04 mmol) in dioxane (120 mL), HO (12 mL) was added Pd(dppf)Cl (567 mg, 776 mmol) at 20 °C. The mixture was purged with N three times and then heated to 100 °C for 5 h. TLC and LC / MS showed that the reactants were completely consumed. The reaction mixture was concentrated under reduced pressure (ca. 30 mL). The residue was poured into ice water (50 mL). The aqueous phase was extracted with EA (50 mL × 3). The combined organic phase was dried over anhydrous Na2SO4, filtered, and concentrated. The crude product was purified by column chromatography (silica gel, PE / EA = 100 / 1 to 50 / 1). (R)-2,2,2-trifluoro-1-(2-(2-vinylphenyl)pyrrolidin-1-yl)ethanone (3.4 g, 12.63 mmol, 81.34% yield) was obtained as a yellow oil. 1H NMR (400MHz, CDCl3) δppm:7.44-7.51(m,1H), 7.21-7.27(m,2H), 6.88-7.07(m,2H), 5.61-5.71(m,1H), 5.46- 5.60(m,1H), 5.33-5.45(m,1H), 3.75-4.03(m,2H), 2.27-2.41(m,1H), 1.82-2.12(m,3H).MS(ESI, m / e)[M+1] + 270.1.
[0255] Step 3: (R)-2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)benzaldehyde (R)-2,2,2-trifluoro-1-(2-(2-vinylphenyl)pyrrolidin-1-yl)ethanone (3.4 g, 12.63 mmol) and KO in THF (60 mL), HO (60 mL). S To a mixture of 04.2H2O (186 mg, 505.1 umol), NaIO4 (10.8 g, 50.51 mmol) was added portionwise at 10 °C. The mixture was stirred at 10 °C for 2 h. TLC showed that the reactants were completely consumed. The reaction mixture was concentrated to remove THF. The aqueous phase was extracted with EA (50 mL × 3). The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated. (R)-2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)benzaldehyde (3.4 g, crude) was obtained as a brown oil. MS (ESI, m / e) [M+1] + 272.1.
[0256] Step 4: (R)-tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)benzyl)piperazine-1-carboxylate To a mixture of (R)-2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)benzaldehyde (3.4 g, 12.54 mmol) and tert-butyl piperazine-1-carboxylate (4.67 g, 25.07 mmol) in DCE (100 mL) was added NaBH(OAc) (10.6 g, 50.16 mmol) in portions at 10 °C. The mixture was stirred at 10 °C for 10 h. TLC showed that the reactants were completely consumed. The reaction mixture was washed with NaHCO (50 mL), and then the organic phase was separated. The organic phase was dried over anhydrous NaSO, filtered, and concentrated. (R)-tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)benzyl)piperazine-1-carboxylate (3.5 g) was obtained as a yellow oil. MS(ESI, m / e)[M+1] + 442.3.
[0257] Step 5: (R)-tert-butyl 4-(2-(pyrrolidin-2-yl)benzyl)piperazine-1-carboxylate To a solution of (R)-tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)benzyl)piperazine-1-carboxylate (3.3 g, 7.47 mmol) in EtOH (50 mL) was added NaBH (662.13 mg, 16.44 mmol) portionwise at 20 °C. The mixture was stirred at 20 °C for 4 h. TLC showed that the reactants were completely consumed. The reaction mixture was concentrated to remove EtOH (ca. 10 mL) and poured into ice-water (20 mL). The aqueous phase was extracted with EA (50 mL × 3). The combined organic phases were washed with brine, dried over anhydrous NaSO, filtered, and concentrated. (R)-tert-butyl 4-(2-(pyrrolidin-2-yl)benzyl)piperazine-1-carboxylate (2.55 g, crude) was obtained as a yellow oil. MS(ESI, m / e)[M+1] + 346.3.
[0258] Step 6: (R)-tert-butyl 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)benzyl)piperazine-1-carboxylate To a mixture of (R)-tert-butyl 4-(2-(pyrrolidin-2-yl)benzyl)piperazine-1-carboxylate (2.55 g, 7.38 mmol), 1-bromo-4-iodobenzene (3.13 g, 11.07 mmol), X-phos (703 mg, 1.48 mmol), and CsCO (4.81 g, 14.76 mmol) in toluene (100 mL) was added Pd(OAc) (166 mg, 738 mmol) at 20 °C. The mixture was purged with N three times and then heated to 105 °C for 10 h. TLC showed that the reactants were completely consumed. The reaction mixture was poured into ice water (50 mL), and the organic phase was separated. The organic phase was dried over anhydrous NaSO, filtered, and concentrated. (R)-tert-butyl 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)benzyl)piperazine-1-carboxylate (1.25 g) was obtained as an orange solid. 1 H NMR (400MHz, CDCl3) δppm:7.05-7.24(m,6H)6.40(d,J=8.9Hz,2H)5.28-5.37(m,1H)3.68-3.86( m,2H)3.29-3.53(m,6H)2.35-2.59(m,5H)1.98-2.15(m,2H)1.79-1.88(m,1H)1.41-1.51(m,9H).
[0259] Step 7: (R)-1-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)benzyl)piperazine A solution of (R)-tert-butyl 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)benzyl)piperazine-1-carboxylate (1.25 g, 2.50 mmol) in TFA (20 mL) and DCM (60 mL) was stirred at 20° C. for 12 h. LC / MS showed that the reactants were completely consumed and the desired compound was formed. The reaction solution was concentrated. The residue was diluted with EA (50 mL). The organic phase was washed with saturated aqueous NaHCO (50 mL) and the organic phase was separated. The organic phase was dried over anhydrous NaSO, filtered, and concentrated. (R)-1-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)benzyl)piperazine (1 g, crude) was obtained as a yellow oil. MS (ESI, m / e) [M+1] + 400.2.
[0260] Step 8: (R)-1-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)benzyl)-4-methylpiperazine To a mixture of (R)-1-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)benzyl)piperazine (1 g, 2.50 mmol) and HCHO (374.99 mg, 12.49 mmol) in DCE (50 mL) was added NaBH(OAc)3 (2.1 g, 10 mmol) portionwise at 20 °C. The mixture was stirred at 20 °C for 1 h. LC / MS showed that the reactants were completely consumed and the desired compound was formed. The reaction mixture was filtered and the filtrate was concentrated. The crude product was purified by preparative HPLC (Phenomenex luna C18 250 mm * 100mm * The mixture was purified by filtration (10 μm; mobile phase: [water (0.1% TAF)-ACN]). The purified solution was concentrated. The aqueous phase was basified with saturated NaHCO and then extracted with EA (50 mL × 3). The combined organic phase was dried over anhydrous NaSO, filtered, and concentrated. (R)-1-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)benzyl)-4-methylpiperazine (440 mg) was obtained as a yellow solid. 1H NMR (400MHz, CDCl3)δppm:7.01-7.24(m,6H), 6.36(d,J=8.8Hz, 2H), 5.22(d,J=8.2Hz, 1H), 3.88(d,J=12.8Hz, 1H), 3 .72(t,J=7.4Hz, 1H), 3.33-3.50(m,2H), 2.34-3.14(m,12H), 2.06(s,2H), 1.84(d,J=5.7Hz, 1H).MS(ESI, m / e)[M+1] + 414.2.
[0261] Intermediate 2-y: tert-butyl (R)-4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)benzyl)piperidine-1-carboxylate [ka] Step 1: (E)-tert-butyl 4-((2-tosylhydrazono)methyl)piperidine-1-carboxylate A mixture of tert-butyl 4-formylpiperidine-1-carboxylate (1.75 g, 9.38 mmol) and 4-methylbenzenesulfonohydrazide (2.0 g, 9.38 mmol) in EtOH (30 mL) was stirred at 20 °C for 15 h. TLC showed complete consumption of the reactants. The reaction mixture was concentrated under reduced pressure. (E)-tert-butyl 4-((2-tosylhydrazono)methyl)piperidine-1-carboxylate (3.4 g, crude) was obtained as a colorless oil.
[0262] Step 2: (R)-tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)benzylidene)piperidine-1-carboxylate To a mixture of (R)-1-(2-(2-bromophenyl)pyrrolidin-1-yl)-2,2,2-trifluoroethanone (3 g, 9.31 mmol), (E)-tert-butyl 4-((2-tosylhydrazono)methyl)piperidine-1-carboxylate (5.33 g, 13.97 mmol), and t-BuOLi (2.98 g, 37.24 mmol) in dioxane (100 mL) was added Pd(PPh3)2Cl2 (670.5 mg, 931 mmol) at 20 °C. The mixture was purged with N2 three times and then heated to 100 °C for 3 h. TLC showed that the reactants were completely consumed. The reaction mixture was concentrated under reduced pressure (ca. 20 mL). The residue was poured into ice water (30 mL) and extracted with EA (50 mL × 3). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated. The crude product was purified by column chromatography (silica gel, PE / EA = 30 / 1 to 10 / 1). (R)-tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)benzylidene)piperidine-1-carboxylate (2.17 g, 4.95 mmol, 53.08% yield) was obtained as a red oil. 1 H NMR (400MHz, CDCl3) δppm:7.16-7.25(m,2H), 7.04-7.11(m,1H), 6.92-7.01(m,1H), 6.29-6.46(m,1H), 5.29-5.45(m,1H), 3. 75-4.00(m,2H), 3.12-3.69(m,4H), 2.16-2.41(m,4H), 1.83-2.15(m,3H), 1.70-1.82(m,1H), 1.47(s,9H).MS(ESI, m / e)[M+1] + 339.2.
[0263] Step 3: (R)-tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)benzyl)piperidine-1-carboxylate To a solution of (R)-tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)benzylidene)piperidine-1-carboxylate (2.3 g, 5.25 mmol) in MeOH (30 mL) was added Pd / C (300 mg, 10% wet). The mixture was purged with H 3 times and then stirred under 15 Psi of H 2 at 20° C. for 10 h. LC / MS showed complete consumption of the reactants and formation of the desired compound. The reaction mixture was filtered through Celite and washed with MeOH. The filtrate was concentrated. (R)-tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)benzyl)piperidine-1-carboxylate (2.3 g, crude) was obtained as a brown solid. 1 H NMR (400MHz, CDCL3) δppm:7.07-7.23(m,3H), 6.86-6.98(m,1H), 5.34-5.52(m,1H), 3.73-4.24(m,4 H), 2.44-2.83(m,4H), 2.31-2.44(m,1H), 1.56-2.21(m,6H), 1.37-1.55(m,9H), 1.05-1.33(m,2H).
[0264] Step 4: (R)-tert-butyl 4-(2-(pyrrolidin-2-yl)benzyl)piperidine-1-carboxylate To a solution of (R)-tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)benzyl)piperidine-1-carboxylate (2.3 g, 5.22 mmol) in MeOH (10 mL), HO (10 mL), THF (10 mL) was added LiOH.HO (438.5 mg, 10.44 mmol) at 20 °C. The mixture was heated to 50 °C for 1 h. TLC showed that the reactants were completely consumed. The reaction mixture was concentrated under reduced pressure to remove MeOH and THF. The aqueous phase was extracted with EA (30 mL × 3). The combined organic phases were dried over anhydrous NaSO, filtered, and concentrated. (R)-tert-butyl 4-(2-(pyrrolidin-2-yl)benzyl)piperidine-1-carboxylate (1.76 g, crude) was obtained as a yellow oil. MS(ESI, m / e)[M+1] + 345.2.
[0265] Step 5: (R)-tert-butyl 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)benzyl)piperidine-1-carboxylate To a mixture of (R)-tert-butyl 4-(2-(pyrrolidin-2-yl)benzyl)piperidine-1-carboxylate (1.4 g, 4.06 mmol), 1-bromo-4-iodobenzene (1.72 g, 6.10 mmol), X-phos (387 mg, 812 mmol), and CsCO (2.64 g, 8.12 mmol) in toluene (50 mL) was added Pd(OAc) (90 mg, 406 mmol) at 20 °C. The mixture was purged with N three times and then heated to 100 °C for 5 h. TLC showed that the reactants were completely consumed. The reaction mixture was cooled to room temperature and poured into ice water (30 mL), then separated. The organic phase was washed with brine, dried over anhydrous NaSO, filtered, and concentrated. The crude product was purified by column chromatography (silica gel, eluent: PE / EA=100 / 1 to 50 / 1) to obtain (R)-tert-butyl 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)benzyl)piperidine-1-carboxylate (720 mg) as a yellow solid. 1H NMR (400MHz, CDCl3) δppm:7.00-7.24(m,6H)6.27(d,J=9.0Hz,2H)4.80-4.92(m,1H)4.02-4.27(m,2H)3.65-3.78(m,1H)3.35-3.47(m,1H)2.5 7-2.83(m,4H)2.36-2.51(m,1H)1.97-2.12(m,2H)1.80-1.95(m,2H)1.71(d,J=12.1Hz, 2H)1.48(s,9H)1.23-1.31(m,2H).MS(ESI, m / e)[M+1] + 498.9.
[0266] Intermediate 2-z: (S)-N,N-dimethyl-2-(pyrrolidin-2-yl)aniline [ka] Step 1: (S)-tert-butyl 2-(2-((diphenylmethylene)amino)phenyl)pyrrolidine-1-carboxylate To a solution of (S)-tert-butyl 2-(2-bromophenyl)pyrrolidine-1-carboxylate (2.0 g, 6.13 mmol) in 1,4-dioxane (50 mL) was added diphenylmethanimine (1.67 g, 9.20 mmol), CsCO (3.99 g, 12.26 mmol), Pd(dba) (561.4 mg, 6.13 mmol), and Xant-phos (1.06 g, 1.84 mmol). The mixture was stirred at 105 °C under N protection for 36 h. LC / MS showed complete consumption of (S)-tert-butyl 2-(2-bromophenyl)pyrrolidine-1-carboxylate and one major peak with the desired mass signal. The mixture was evaporated under reduced pressure. The residue was used directly in the next step. MS (ESI, m / e) [M-1] - 427.2.
[0267] Step 2: (S)-tert-butyl 2-(2-aminophenyl)pyrrolidine-1-carboxylate To a solution of (S)-tert-butyl 2-(2-((diphenylmethylene)amino)phenyl)pyrrolidine-1-carboxylate (262 mg, 613 μmol, 1 equiv.) in THF (5 mL) was added 10 mL of 0.5 N HCl acid. The mixture was stirred at 20 °C overnight. TLC showed that (S)-tert-butyl 2-(2-((diphenylmethylene)amino)phenyl)pyrrolidine-1-carboxylate was completely consumed. The mixture was adjusted to pH 8 with saturated aqueous NaHCO3 solution and then extracted with EA (20 ml). The organic phase was washed with brine, dried over Na2SO4, and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 10 / 1 to 1 / 1) to give (S)-tert-butyl 2-(2-aminophenyl)pyrrolidine-1-carboxylate (50 mg). 1 H NMR (400MHz, CDCl3)δppm:6.91-7.16(m,2H), 6.70-6.87(m,1H), 6.62-6.70(m,1H), 4.60- 5.06(m,1H), 3.36-3.97(m,4H), 2.13-2.35(m,1H), 1.83-2.01(m,3H), 1.16-1.54(m,9H).
[0268] Step 3: (S)-tert-butyl 2-(2-(dimethylamino)phenyl)pyrrolidine-1-carboxylate To a solution of (S)-tert-butyl 2-(2-aminophenyl)pyrrolidine-1-carboxylate (6.5 g, 22.87 mmol) in MeOH (200 mL) was added aqueous HCHO (37%, 11.14 g, 137.22 mmol) and NaHCN (5.95 g, 114.35 mmol). The mixture was stirred at 20 °C for 14 h. TLC showed that (S)-tert-butyl 2-(2-aminophenyl)pyrrolidine-1-carboxylate was completely consumed. The mixture was evaporated under reduced pressure. The residue was dissolved in DCM (100 mL), washed with brine, dried over NaSO, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA=100 / 1 to 30 / 1) to give (S)-tert-butyl 2-(2-(dimethylamino)phenyl)pyrrolidine-1-carboxylate (5.9 g). 1 H NMR(400MHz, CDCl3)δppm:6.93-7.15(m,4H), 5.12-5.37(m,1H), 3.36-3.69(m,2 H), 2.60(s,6H), 2.20-2.37(m,1H), 1.64-1.87(m,3H), 1.39(s,2H), 1.10(s,6H).
[0269] Step 4: (S)—N,N-dimethyl-2-(pyrrolidin-2-yl)aniline To a solution of (S)-tert-butyl 2-(2-(dimethylamino)phenyl)pyrrolidine-1-carboxylate (5.90 g, 20.32 mmol) in DCM (30 mL) was added TFA (30 mL). The mixture was stirred at 20 °C for 2 h. TLC showed that (S)-tert-butyl 2-(2-(dimethylamino)phenyl)pyrrolidine-1-carboxylate was completely consumed. The mixture was poured into water, and then the pH was adjusted to about 10 using aqueous NaOH (2 N). The mixture was extracted with DCM (50 mL × 3), washed with brine and water, and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give (S)-N,N-dimethyl-2-(pyrrolidin-2-yl)aniline (3.248 g). 1H NMR (400MHz, CDCl3) δppm:7.38-7.52(m,1H)7.18-7.24(m,1H)7.03-7.16(m,2H)4.59(t,J=7.9Hz,1H),3.24(ddd,J=10.0,7.6,5.1Hz,1 H), 3.00(dt,J=9.8, 7.7Hz, 1H), 2.71(br,6H), 2.17-2.33(m,1H), 2.14(s,1H), 1.80-2.04(m,2H), 1.54-1.77(m,1H).MS(ESI, m / e)[M+1] + 191.3.
[0270] Intermediate 2-z1: (S)-N,N-bis(methyl-d3)-2-(pyrrolidin-2-yl)aniline [ka] Step 1: (S)-tert-butyl 2-(2-(d6-dimethylamino)phenyl)pyrrolidine-1-carboxylate To a solution of (S)-tert-butyl 2-(2-aminophenyl)pyrrolidine-1-carboxylate (6.5 g, 22.87 mmol) in DMF (20 mL) was added NaH (457.4 mg, 11.44 mmol) and CD3I (2.21 g, 15.25 mmol) at 0 °C. The mixture was stirred at 45 °C for 14 h. TLC showed that (S)-tert-butyl 2-(2-aminophenyl)pyrrolidine-1-carboxylate was completely consumed. The mixture was poured into water (50 mL), extracted with EA, and concentrated under reduced pressure to give tert-butyl (S)-2-(2-(bis(methyl-d3)amino)phenyl)pyrrolidine-1-carboxylate (880 mg), which was used in the next step without further purification. 1 H NMR (400MHz, CDCl3)δppm:7.00-7.22(m,4H), 5.20-5.43(m,1H), 3.49-3.72(m,2H), 2.26-2.45(m,1H), 1.72-1.95(m,3H), 1.47(s,2H), 1.18(s,7H).MS(ESI, m / e)[M+1] + 297.4.
[0271] Step 2: (S)—N,N-bis(methyl-d3)-2-(pyrrolidin-2-yl)aniline To a solution of (S)-2-(2-(bis(methyl-d3)amino)phenyl)pyrrolidine-1-carboxylate (275 mg, 927.68 μmol) in DCM (10 mL) was added TFA (5 mL). The mixture was stirred at 20° C. for 2 hours. TLC showed that the reactants were completely consumed. The mixture was concentrated under reduced pressure to give a residue. The residue was dissolved in DCM (20 mL), washed with saturated aqueous Na2CO3 (20 mL), dried over Na2SO4, and concentrated under reduced pressure to give (S)-N,N-bis(methyl-d3)-2-(pyrrolidin-2-yl)aniline (100 mg). 1 H NMR (400MHz, CDCl3) δppm:7.42(dd,J=7.7, 1.3Hz, 1H), 7.19-7.26(m,1H), 7.07-7.18(m,2H), 4.63(t,J=7.9Hz, 1H), 3.24(d dd,J=10.3, 7.4, 5.4Hz, 1H), 3.04-3.11(m,1H), 2.18-2.30(m,1H), 1.87-2.06(m,2H), 1.66-1.77(m,1H).MS(ESI, m / e)[M+1] + 197.3.
[0272] Intermediate 2-z2: 2-((1-(2-cyclopropylphenyl)pyrrolidin-2-yl)methyl)-2,6-diazaspiro[3.3]heptane [ka] Step 1: (1-(2-cyclopropylphenyl)pyrrolidin-2-yl)methanol To a solution of 2-(((tert-butyldimethylsilyl)oxy)methyl)-1-(2-cyclopropylphenyl)pyrrolidine (1.5 g, 4.52 mmol) in MeOH / HCl (20 mL) at 20° C., the mixture was stirred for 1 h. TLC showed complete consumption of the reactant. The reaction mixture was concentrated to give (1-(2-cyclopropylphenyl)pyrrolidin-2-yl)methanol (0.8 g, crude). 1H NMR (400MHz, CDCl3) δppm:7.81(d,J=7.7Hz, 1H), 7.34-7.40(m,1H), 7.28-7. 34(m,1H), 7.04(dd,J=7.7, 1.2Hz, 1H), 4.55(br,1H), 4.19(s,1H), 4.11(d,J= 13.9Hz, 1H), 3.85-4.15(m,2H), 3.59-3.81(m,3H), 2.52-2.64(m,1H), 2.48( s,2H), 2.37(s,2H), 1.22-1.35(m,2H), 0.77-0.98(m,2H).MS(ESI, m / e)[M+1] + 217.9.
[0273] Step 2: 1-(2-cyclopropylphenyl)pyrrolidine-2-carbaldehyde To a solution of (COCl)2 (700.9 mg, 5.52 mmol) in DCM (20 mL) was added DMSO (862.93 mg, 11.04 mmol) dropwise at −65° C. The mixture was stirred at −65° C. for 0.5 h. Then, (1-(2-cyclopropylphenyl)pyrrolidin-2-yl)methanol (800.0 mg, 3.68 mmol) in DCM (2 mL) was added dropwise at −65° C. The mixture was further stirred at −65° C. for 1 h. TLC showed that the reactants were completely consumed. To the reaction mixture was added TEA (2.89 g, 29.45 mmol) and warmed to 20° C. over 0.5 h. The reaction mixture was poured into water, extracted with DCM, dried over anhydrous Na.sub.2SO.sub.4 and concentrated under reduced pressure to give 1-(2-cyclopropylphenyl)pyrrolidine-2-carbaldehyde (1.2 g, crude). 1H NMR (400MHz, CDCl3) δppm:12.10(s,1H), 9.39(d,J=3.8Hz, 1H), 7.06-7.16(m,1 H), 6.85-7.03(m,3H), 4.19(td,J=7.1, 3.9Hz, 1H), 3.86-3.96(m,1H), 3.05-3.1 6(m,6H), 2.62(s,1H), 2.12-2.26(m,2H), 2.00-2.12(m,2H), 1.90-2.00(m,1H), 1.42(t,J=7.3Hz, 9H), 1.00-1.10(m,1H), 0.75-0.94(m,2H), 0.59-0.67(m,1H).
[0274] Step 3: tert-butyl 6-((1-(2-cyclopropylphenyl)pyrrolidin-2-yl)methyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate To a solution of 1-(2-cyclopropylphenyl)pyrrolidine-2-carbaldehyde (600 mg, 2.79 mmol) in DCM (10 mL) was slowly added NaBH(OAc) (1.18 g, 5.57 mmol) at 0 °C. Then, tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate oxalate (803.46 mg, 2.79 mmol) was added to the mixture at 0 °C. The mixture was stirred at 20 °C for 1 h. TLC showed that the reactants were completely consumed. The reaction mixture was poured into water, extracted with DCM (10 mL), and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO, PE / EA = 100 / 1 to 0 / 1). tert-Butyl 6-((1-(2-cyclopropylphenyl)pyrrolidin-2-yl)methyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate (600 mg) was obtained. 1H NMR (400MHz, CDCl3) δppm:7.07-7.14(m,1H), 7.01(d,J=7.9Hz, 1H), 6.90-6.97(m,1H), 6.8 3-6.88(m,1H), 3.95(s,4H), 3.61-3.75(m,2H), 3.16-3.43(m,4H), 2.86(td,J=8.5, 5.1Hz, 1 H), 2.11-2.21(m,2H), 2.06(s,1H), 1.87-1.99(m,2H), 1.74-1.87(m,2H), 1.57-1.74(m,1H) ), 1.42(s,9H), 0.95-1.13(m,1H), 0.70-0.95(m,3H), 0.52-0.62(m,1H).MS(ESI, m / e)[M+1] + 398.1.
[0275] Step 4: 2-((1-(2-cyclopropylphenyl)pyrrolidin-2-yl)methyl)-2,6-diazaspiro[3.3]heptane To a solution of tert-butyl 6-((1-(2-cyclopropylphenyl)pyrrolidin-2-yl)methyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate (600 mg, 1.51 mmol) in DCM (8 mL) was added TFA (2 mL) at 20° C. The mixture was stirred at 20° C. for 1 hour. TLC showed that the reactants were completely consumed. The reaction mixture was concentrated to give 2-((1-(2-cyclopropylphenyl)pyrrolidin-2-yl)methyl)-2,6-diazaspiro[3.3]heptane (326 mg) as a yellow oil. 1 H NMR (400MHz, CDCl3) δppm:7.10(t,J=7.3Hz, 1H), 6.99-7.04(m,1H), 6.91(s ,1H), 6.80-6.88(m,1H), 3.78(br,4H), 3.57-3.74(m,2H), 3.22-3.40(m,4H) , 2.80-3.03(m,3H), 2.55(d,J=12.6Hz, 1H), 2.10-2.28(m,3H), 1.90(s,1H), 1.67-1.84(m,2H), 0.82-1.10(m,2H), 0.51-0.81(m,2H).MS(ESI, m / e)[M+1] + 298.2.
[0276] Intermediate 2-z3: (S)-4-(3-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)cyclobutyl)piperidine [ka] Step 1: tert-butyl 4-(2,2-dichloro-3-oxocyclobutyl)piperidine-1-carboxylate Under a N2 atmosphere, tert-butyl 4-vinylpiperidine-1-carboxylate (5.0 g, 23.66 mmol) was added to a mixture of Zn (4.64 g, 70.99 mmol) in dioxane (50 mL) at 20 °C. Then, CCl3COCl (6.45 g, 35.49 mmol) was added at 20 °C. The mixture was stirred at 20 °C for 12 h. To the reaction mixture, aqueous NaHCO3 solution (50 mL) was added at 0 °C. The mixture was then extracted with EA (50 mL × 5), and the combined organic phases were dried over anhydrous Na2SO4 and concentrated. The residue was purified by column chromatography (SiO2, PE / EA = 50 / 1 to 20 / 1). tert-Butyl 4-(2,2-dichloro-3-oxocyclobutyl)piperidine-1-carboxylate (3.0 g) was obtained. 1 H NMR (400MHz, CDCl3) δppm:4.05-4.21(m,2H)3.04-3.27(m,2H)2.77(br,2H)2.60(q,J=10.4 Hz, 1H)2.03-2.10(m,1H)1.84-1.97(m,1H)1.52-1.63(m,1H)1.46(s,9H)1.16-1.41(m,3H).
[0277] Step 2: tert-Butyl 4-(3-oxocyclobutyl)piperidine-1-carboxylate Under a N2 atmosphere, a mixture of Zn (1.22 g, 18.62 mmol) in HOAc (3.73 g, 62.07 mmol) was added with tert-butyl 4-(2,2-dichloro-3-oxocyclobutyl)piperidine-1-carboxylate (2.0 g, 6.21 mmol) in Diox (15 mL) at 15 °C, and the mixture was stirred at 15 °C for 12 h. The mixture was adjusted to pH 9 with 33% aqueous NaOH and extracted with EA (50 mL × 3). After drying and concentration, the residue was purified by column chromatography (SiO2, PE / EA = 50 / 1 to 10 / 1). tert-Butyl 4-(3-oxocyclobutyl)piperidine-1-carboxylate (1.0 g, 3.95 mmol) was obtained. 1 H NMR (400MHz, CDCl3) δppm:4.14(s,2H)3.02-3.17(m,2H)2.64-2.83(m,4H)2.05-2.18( m,1H)1.72(d,J=12.8Hz,2H)1.35-1.36(m,1H)1.47(s,8H)1.15(d,J=12.3,4.3Hz,2H).
[0278] Step 3: (S)-tert-butyl 4-(3-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)cyclobutyl)piperidine-1-carboxylate To a solution of tert-butyl 4-(3-oxocyclobutyl)piperidine-1-carboxylate (0.7 g, 2.76 mmol, 1 equiv.) and (S)-2-(2-cyclopropylphenyl)pyrrolidine (569.23 mg, 3.04 mmol) in DCE (20 mL) was added AcOH (331.86 mg, 5.53 mmol) and NaBH(OAc) (1.17 mg, 5.53 mmol). The mixture was stirred at 25 °C for 1 h. TLC showed that the reactants were completely consumed. The reaction mixture was quenched with aqueous NaCO (20 mL), extracted with EA (20 mL × 3), dried over NaSO, filtered, and concentrated. The residue was purified by preparative MPLC. (S)-tert-butyl 4-(3-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)cyclobutyl)piperidine-1-carboxylate (1.1 g) was obtained. MS (ESI, m / e) [M+1] + 425.3.
[0279] Step 4: (S)-4-(3-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)cyclobutyl)piperidine A mixture of (S)-tert-butyl 4-(3-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)cyclobutyl)piperidine-1-carboxylate (0.9 g, 2.12 mmol) in DCM (5 mL) and TFA (5 mL) was stirred at 25 °C for 1 h. LC / MS showed complete consumption of the reactants and one major peak with the desired mass signal. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with HO (10 mL) and adjusted to pH 9 with saturated aqueous NaCO solution. The mixture was extracted with EA (10 mL × 3), dried over NaSO, filtered, and concentrated. (S)-4-(3-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)cyclobutyl)piperidine (643 mg) was obtained. 1H NMR (400MHz, CDCl3) δppm:7.66-7.56(m,1H), 7.21-7.08(m,2H), 6.97(d,J=7.5Hz, 1H), 6.34(s,1H), 3.96(q,J=7.7Hz, 1H), 3.30-2.83(m,4H), 2.75- 2.60(m,2H), 2.46-2.31(m,1H), 2.29-2.14(m,1H), 2.06-1.44(m,10H), 1. 40-1.03(m,4H), 0.98-0.85(m,2H), 0.74-0.55(m,2H).MS(ESI, m / e)[M+1] + 325.3.
[0280] Intermediate 2-z4: 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)phenoxy)-1-methylpiperidine [ka] Step 1: tert-butyl 4-(2-formylphenoxy)piperidine-1-carboxylate To a solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (5.0 g, 24.84 mmol) and 2-fluorobenzaldehyde (6.17 g, 49.69 mmol) in DMSO (150 mL) was added K2CO3 (10.15 g, 74.53 mmol). The mixture was stirred at 100 °C for 6 h. TLC showed that the reactants were completely consumed. The reaction mixture was cooled to room temperature, poured into H2O (50 mL), extracted with EA (50 mL × 3), dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography (SiO2, PE / EA = 20 / 1 to 10 / 1) to give tert-butyl 4-(2-formylphenoxy)piperidine-1-carboxylate (6 g). MS (ESI, m / e) [M+1] + 306.1.
[0281] Step 2: (E)-tert-butyl 4-(2-(((4-bromophenyl)imino)methyl)phenoxy)piperidine-1-carboxylate A mixture of tert-butyl 4-(2-formylphenoxy)piperidine-1-carboxylate (4.30 g, 14.08 mmol), 4-bromoaniline (2.42 g, 14.08 mmol), TsOH (133.93 mg, 0.7 mmol), and 4 Å molecular sieves (2.15 g) in toluene (43 mL) was stirred at 140° C. for 12 hours. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give crude (E)-tert-butyl 4-(2-(((4-bromophenyl)imino)methyl)phenoxy)piperidine-1-carboxylate (7.5 g, crude), which was used directly in the next step.
[0282] Step 3: tert-butyl 4-(2-(1-((4-bromophenyl)amino)but-3-en-1-yl)phenoxy)piperidine-1-carboxylate To a solution of (E)-tert-butyl 4-(2-(((4-bromophenyl)imino)methyl)phenoxy)piperidine-1-carboxylate (5.7 g) in DCM (50 mL) was added allylmagnesium bromide (49.63 mL, 1 M in THF) dropwise at 0 °C. The mixture was stirred at 0–15 °C for 3 h. TLC showed the reaction was complete. The reaction mixture was poured into aqueous NH4Cl (50 mL) and extracted with EA (50 mL × 2). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 50 / 1 to 20 / 1) to give tert-butyl 4-(2-(1-((4-bromophenyl)amino)but-3-en-1-yl)phenoxy)piperidine-1-carboxylate (4.2 g). MS (ESI, m / e) [M+1] + 502.2.
[0283] Step 4: tert-butyl 4-(2-(1-((4-bromophenyl)amino)-4-hydroxybutyl)phenoxy)piperidine-1-carboxylate To a solution of tert-butyl 4-(2-(1-((4-bromophenyl)amino)but-3-en-1-yl)phenoxy)piperidine-1-carboxylate (3.3 g, 6.58 mmol) in THF (50 mL) was added BH3.THF (65.8 mL, 1 M in THF) at 0 °C. The mixture was stirred at 0 °C for 3 h. Then, HO (6.58 mL, 65.81 mmol) was added dropwise and stirred at 0 °C for 1 h. Aqueous NaOH (2.63 g, 65.81 mmol, 4 M) was added dropwise and stirred at 0–15 °C for 2 h. TLC showed the reaction was complete. The mixture was poured into saturated aqueous NaSO (50 mL), stirred for 0.5 h, and extracted with EA (100 mL × 2). The combined organic layers were washed with saturated aqueous NaSO (50 mL), aqueous NaHCO (50 mL), and brine (50 mL), dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (SiO, PE / EA = 5 / 1 to 2 / 1) to give tert-butyl 4-(2-(1-((4-bromophenyl)amino)-4-hydroxybutyl)phenoxy)piperidine-1-carboxylate (2.4 g). MS (ESI, m / e) [M+1] + 520.3.
[0284] Step 5: tert-butyl 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)phenoxy)piperidine-1-carboxylate To a mixture of tert-butyl 4-(2-(1-((4-bromophenyl)amino)-4-hydroxybutyl)phenoxy)piperidine-1-carboxylate (2.3 g, 4.43 mmol) and TEA (1.34 g, 13.28 mmol) in DCM (23 mL) was added MsCl (1.01 mg, 8.86 mmol) at 0 °C, and the mixture was stirred at 25 °C for 5 h. TLC showed that the reaction was complete. The reaction mixture was poured into HO (20 mL) and extracted with DCM (20 mL × 2). The combined organic layers were washed with brine (20 mL), dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 10 / 1 to 2 / 1) to give tert-butyl 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)phenoxy)piperidine-1-carboxylate. MS (ESI, m / e) [M+1] + 502.2.
[0285] Step 6: 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)phenoxy)piperidine To a mixture of tert-butyl 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)phenoxy)piperidine-1-carboxylate (1.8 g, 3.59 mmol) in DCM (20 mL) was added TFA (7 mL) and stirred at 15° C. for 3 h. TLC showed the reaction was complete. The mixture was concentrated under reduced pressure to give 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)phenoxy)piperidine (1.8 g, TFA salt, crude). MS (ESI, m / e) [M+1] + 402.2.
[0286] Step 7: 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)phenoxy)-1-methylpiperidine To a solution of 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)phenoxy)piperidine (1.0 g, 2.49 mmol) in MeOH (10 mL) was added aqueous HCHO (37%, 1.01 g, 12.46 mmol) and NaBHCN (496.74 mg, 4.47 mmol) and stirred at 15 °C for 3 h. TLC showed the reaction was complete. The reaction mixture was concentrated under reduced pressure. The residue was poured into saturated aqueous NaHCO (20 mL) and extracted with EA (30 mL × 3). The combined organic layers were dried over NaSO, filtered, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 1 / 1 to 1 / 10) to give 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)phenoxy)-1-methylpiperidine. 1 H NMR (400MHz, CDCl3) δppm:7.15-7.24(m,3H)6.99(dd,J=7.5, 1.3Hz, 1H)6.88 (d,J=8.1Hz, 1H)6.79-6.85(1H,m)6.30(2H,d,J=9.0Hz)4.96(1H,d,J=7.9Hz )4.60(1H,s)3.63-3.70(m,1H)3.32-3.41(m,1H)2.64-2.87(m,4H)2.46(s,3 H)2.29-2.40(m,1H)2.14-2.24(m,2H)1.92-2.10(m,5H).MS(ESI, m / e)[M+1] + 415.1.
[0287] Intermediate 2-z5: (S)-2-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)-7-azaspiro[3.5]nonane [ka] Step 1: tert-Butyl 2-(methoxymethylene)-7-azaspiro[3.5]nonane-7-carboxylate To a solution of (methoxymethyl)triphenylphosphonium chloride (3.72 g, 10.86 mmol) in toluene (30 mL) was added t-BuOK (1 M in THF, 10.86 mL, 10.86 mmol). The mixture was stirred at 25 °C for 20 min under N protection. Next, tert-butyl 2-oxo-7-azaspiro[3.5]nonane-7-carboxylate (2 g, 8.36 mmol) in toluene (20 mL) was added. The mixture was stirred at 70 °C for 4 h. TLC showed that the reactants were completely consumed. The reaction mixture was quenched with aqueous NH4Cl (30 mL), extracted with EA (50 mL × 3), dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative MPLC to give tert-butyl 2-(methoxymethylene)-7-azaspiro[3.5]nonane-7-carboxylate (1.2 g). MS (ESI, m / e) [M+1] + 268.3.
[0288] Step 2: tert-Butyl 2-formyl-7-azaspiro[3.5]nonane-7-carboxylate A mixture of tert-butyl 2-(methoxymethylene)-7-azaspiro[3.5]nonane-7-carboxylate (1 g, 3.74 mmol) in ACN (36 mL), HO (9 mL), and TFA (0.3 mL) was stirred at 25 °C for 4 h. TLC showed that the reactants were completely consumed. The reaction mixture was quenched with aqueous NaHCO (20 mL), extracted with EA (20 mL × 3), dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by preparative MPLC. tert-butyl 2-formyl-7-azaspiro[3.5]nonane-7-carboxylate (390 mg) was obtained. 1 H NMR (400MHz, CDCl3) δppm:9.76(d,J=1.5Hz, 1H), 3.39-3.32(m,2H), 3.31-3.25 (m,2H), 3.20-3.10(m,1H), 2.11-1.95(m,4H), 1.64-1.56(m,2H), 1.44(s,9H).
[0289] Step 3: (S)-tert-butyl 2-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)-7-azaspiro[3.5]nonane-7-carboxylate To a solution of tert-butyl 2-formyl-7-azaspiro[3.5]nonane-7-carboxylate (0.3 g, 1.18 mmol) and (S)-2-(2-cyclopropylphenyl)pyrrolidine (184.81 mg, 986.83 mmol) in DCE (5 mL) was added AcOH (118.52 mg, 1.97 mmol) and NaBH(OAc) (418.30 mg, 1.97 mmol). The mixture was stirred at 25 °C for 2 h. TLC showed that the reactants were completely consumed. The reaction mixture was poured into aqueous NaCO (5 mL), extracted with EA (5 mL × 3), dried over NaSO, filtered, and concentrated. The residue was purified by preparative MPLC. (S)-tert-Butyl 2-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)-7-azaspiro[3.5]nonane-7-carboxylate (300 mg, 0.7 mmol, 59.66% yield) was obtained. MS (ESI, m / e) [M+1] + 425.3.
[0290] Step 4: (S)-2-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)-7-azaspiro[3.5]nonane A mixture of (S)-tert-butyl 2-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)-7-azaspiro[3.5]nonane-7-carboxylate (0.3 g, 0.7 mmol) in DCM (1.5 mL) and TFA (1.5 mL) was stirred at 25 °C for 1 h. LC / MS showed complete consumption of the reactants and one major peak with the desired mass signal. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with HO (10 mL) and adjusted to pH 9 with NaCO. The mixture was extracted with EA (10 mL × 3), dried over NaSO, filtered, and concentrated. (S)-2-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)-7-azaspiro[3.5]nonane (180 mg) was obtained.1 H NMR (400MHz, CDCl3) δppm:7.58(d,J=7.7Hz, 1H), 7.23-7.17(m,1H), 7.17-7.11(m,1H), 7.00(d,J=7.1Hz, 1H), 3.81(t, J=8 .3Hz, 1H), 3.27(t,J=7.7Hz, 1H), 2.95-2.84(m,2H), 2.83-2.72(m,2H), 2.58(dd,J=8.0, 11.8Hz, 1H), 2.41(td,J=7.8, 15. 3Hz, 1H), 2.30-2.15(m,2H), 2.13-1.98(m,2H), 1.97-1.87(m,3H), 1.83(d,J=14.3Hz, 1H), 1.74-1.64(m,2H), 1.63-1.53( m,1H), 1.53-1.45(m,2H), 1.44-1.31(m,2H), 0.98-0.85(m,2H), 0.77-0.67(m,1H), 0.66-0.55(m,1H).MS(ESI, m / e)[M+1] + 325.3.
[0291] Intermediate 2-z6: 1-(2-cyclopropylphenyl)-1,9-diazaspiro[5.5]undecane [ka] Step 1: tert-butyl 4-(but-3-en-1-yl)-4-((2-cyclopropylphenyl)amino)piperidine-1-carboxylate To a solution of tert-butyl 4-((2-cyclopropylphenyl)imino)piperidine-1-carboxylate (5 g, 15.90 mmol) in DCM (50 mL) was added but-3-en-1-ylmagnesium bromide (0.5 M, 159 mL, 79.51 mmol) at −20° C. The mixture was stirred at −20° C. for 2 h. TLC showed that the reactants were completely consumed. The reaction mixture was quenched with aqueous HN4Cl (100 mL), extracted with DCM (100 mL × 3), dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative MPLC to give tert-butyl 4-(but-3-en-1-yl)-4-((2-cyclopropylphenyl)amino)piperidine-1-carboxylate (2.5 g) as a yellow oil. MS (ESI, m / e) [M+1] + 371.3.
[0292] Step 2: tert-butyl 4-((2-cyclopropylphenyl)amino)-4-(4-hydroxybutyl)piperidine-1-carboxylate To a solution of tert-butyl 4-(but-3-en-1-yl)-4-((2-cyclopropylphenyl)amino)piperidine-1-carboxylate (2.5 g, 6.75 mmol) in THF (25 mL) was added BH3.THF (1 M, 33.74 mL, 33.74 mmol) at 0 °C. The mixture was stirred at 25 °C for 2 h. Then, to the mixture were added NaOH (2.5 M, 6.75 mL, 6.75 mmol) and HO (11.48 g, 101.21 mmol) at 0 °C. The mixture was stirred at 25 °C for 2 h. TLC showed that the reactants were completely consumed. The reaction mixture was poured into aqueous Na2SO3 (100 mL), extracted with EA (100 mL × 3), dried over Na2SO4, filtered, and concentrated. After the residue was purified by preparative MPLC, tert-butyl 4-((2-cyclopropylphenyl)amino)-4-(4-hydroxybutyl)piperidine-1-carboxylate (1.2 g) was obtained. 1H NMR (400MHz, CDCl3) δppm:7.09(d,J=7.5Hz, 1H), 7.07-7.01(m,1H), 6.74(d,J=7.9H) z, 1H), 6.61(t,J=7.4Hz, 1H), 3.95(s,1H), 3.77-3.67(m,1H), 3.63-3.50(m,1H), 3. 11-2.93(m,2H), 2.55-2.41(m,1H), 2.00(d,J=11.7Hz, 1H), 1.92-1.70(m,4H), 1.66 -1.56(m,1H), 1.46(s,9H), 1.36-1.29(m,1H), 0.98-0.86(m,5H), 0.67-0.57(m,2H).
[0293] Step 3: tert-Butyl 1-(2-cyclopropylphenyl)-1,9-diazaspiro[5.5]undecane-9-carboxylate To a solution of tert-butyl 4-((2-cyclopropylphenyl)amino)-4-(4-hydroxybutyl)piperidine-1-carboxylate (1 g, 2.57 mmol) in DCM (10 mL) and TEA (520.87 mg, 5.51 mmol) was added MsCl (294.82 mg, 2.57 mmol) at 0 °C, and the mixture was stirred at 25 °C for 2 h. TLC showed that the reactants were completely consumed. The reaction mixture was quenched with aqueous HN4Cl (10 mL), extracted with DCM (10 mL × 3), dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative MPLC to give tert-butyl 1-(2-cyclopropylphenyl)-1,9-diazaspiro[5.5]undecane-9-carboxylate (0.7 g) as a yellow oil. MS (ESI, m / e) [M+1] + 371.4.
[0294] Step 4: 1-(2-cyclopropylphenyl)-1,9-diazaspiro[5.5]undecane A mixture of tert-butyl 1-(2-cyclopropylphenyl)-1,9-diazaspiro[5.5]undecane-9-carboxylate (0.7 g, 1.89 mmol) in DCM (4 mL) and TFA (4 mL) was stirred at 20 °C for 1 h. LC / MS showed complete consumption of the reagent and one major peak with the desired mass signal. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with HO (10 mL) and adjusted to pH 9 with NaCO. The mixture was then extracted with EA (10 mL × 3). The combined organic layers were washed with brine, dried over NaCO, filtered, and concentrated to give 1-(2-cyclopropylphenyl)-1,9-diazaspiro[5.5]undecane (452 mg). 1 H NMR (400MHz, CDCl3) δppm:7.25-7.20(m,1H), 7.11-7.04(m,2H), 6.73-6.66(m,1H), 3.40 -3.27(m,2H), 3.04-2.92(m,2H), 2.81-2.58(m,3H), 2.48-2.42(m,1H), 2.33-2.22(m,1H) , 1.82-1.67(m,2H), 1.67-1.54(m,2H), 1.22(dt,J=4.0, 12.8Hz, 1H), 1.11(d,J=6.8Hz, 3 H), 0.94(dd,J=1.8, 8.6Hz, 2H), 0.75-0.66(m,1H), 0.61-0.54(m,1H).MS(ESI, m / e)[M+1] + 271.4.
[0295] Intermediate 2-z7: 5-(2-cyclopropylphenyl)-N,N-dimethylpyrrolidin-3-amine [ka] Step 1: 1-(tert-butylsulfonyl)-5-(2-cyclopropylphenyl)pyrrolidin-3-one A mixture of 1-(tert-butylsulfonyl)-5-(2-cyclopropylphenyl)pyrrolidin-3-ol (5.0 g, 15.46 mmol), DMP (8.52 g, 20.1 mmol), and NaHCO (1.43 g, 17.0 mmol) in DCM (50 mL) was stirred at 20 °C for 3 h. TLC showed the reaction was complete. The mixture was quenched with NaSO (20 mL) and adjusted to pH 10 with aqueous NaCO. The mixture was extracted with DCM (50 mL × 3), and the combined organic layers were dried over NaSO, filtered, and concentrated. The residue was purified by column chromatography (SiO, PE / EA = 50 / 1 to 15 / 1) to give 1-(tert-butylsulfonyl)-5-(2-cyclopropylphenyl)pyrrolidin-3-one (3.5 g). 1 H NMR (400MHz, CDCl3) δppm:7.18-7.23(m,2H), 7.12-7.16(m,1H), 7.02-7.08(m,1H), 6.33(d,J=8.8Hz, 1H), 4.54(d,J=18.7Hz, 1H), 3.83(d,J=18.7Hz, 1H), 3.21(dd,J=17.9, 10.03Hz, 1H), 2.50(d,J=17.9Hz, 1H), 1.85-1.95(m, 1H), 1.26(s,8H), 0.93-1.08(m,2H), 0.70-0.79(m,1H), 0.58-0.65(m,1H).
[0296] Step 2: 1-(tert-butylsulfonyl)-5-(2-cyclopropylphenyl)-N,N-dimethylpyrrolidin-3-amine To a mixture of 1-(tert-butylsulfonyl)-5-(2-cyclopropylphenyl)pyrrolidin-3-one (3.5 g, 10.89 mmol) and dimethylamine hydrochloride (3.55 g, 43.55 mmol) in DCE (40 mL) was added NaBH(OAc) (6.92 g, 32.67 mmol). The mixture was stirred under a N atmosphere at 20 °C for 2 h. TLC showed the reaction was complete. The mixture was concentrated and purified by preparative HPLC (TFA conditions). 1-(tert-butylsulfonyl)-5-(2-cyclopropylphenyl)-N,N-dimethylpyrrolidin-3-amine (2.2 g, 6.28 mmol, 57.64% yield) was obtained. MS (ESI, m / e) [M+1] + 351.3.
[0297] Step 3: 5-(2-cyclopropylphenyl)-N,N-dimethylpyrrolidin-3-amine A mixture of 1-(tert-butylsulfonyl)-5-(2-cyclopropylphenyl)-N,N-dimethylpyrrolidin-3-amine (1.0 g, 2.85 mmol) in TFA (10 mL) was stirred at 70° C. for 12 hours. TLC showed the reaction was complete. The mixture was concentrated and adjusted to pH 10 with saturated aqueous NaCO (10 mL). The mixture was extracted with EA (10 mL × 5), and the combined organic layers were dried over anhydrous NaSO and then concentrated. 5-(2-cyclopropylphenyl)-N,N-dimethylpyrrolidin-3-amine (170 mg) was obtained. 1 H NMR (400MHz, CDCl3) δppm:7.52-7.63(m,1H), 7.11-7.24(m,2H), 7.00(d,J=7.5Hz, 1H), 4.70-4.92(m,1H), 3.07-3.42(m,2H), 2.81-2.9 9(m,1H), 2.38-2.50(m,1H), 2.25-2.35(m,4H), 1.63(dt,J=11.9, 9.8Hz, 1H), 0.89-0.98(m,2H), 0.62-0.76(m,1H).MS(ESI, m / e)[M+1] + 231.3.
[0298] Intermediate 2-z8: tert-butyl (R)-4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)phenyl)piperidine-1-carboxylate [ka] Step 1: (R)-tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate A mixture of (R)-1-(2-(2-bromophenyl)pyrrolidin-1-yl)-2,2,2-trifluoroethanone (8 g, 24.8 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (11.5 g, 37.2 mmol), Pd(OAc) (560 mg, 2.48 mmol), tricyclohexylphosphine (1.4 g, 4.96 mmol), and KPO (15.8 g, 74.4 mmol, 3.0 equiv.) in toluene (100 mL) and HO (5 mL) was heated to 100 °C under N protection and stirred for 5 h. TLC showed the reaction was complete. The mixture was cooled to room temperature, diluted with EA (50 mL), washed with water (100 mL), brine (100 mL), dried over Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 5 / 1 to 2 / 1) to give (R)-tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate (9 g, crude) as a brown solid. MS (ESI, m / e) [M+1] + 425.2.
[0299] Step 2: (R)-tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)phenyl)piperidine-1-carboxylate A mixture of (R)-tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate (9 g, 21.2 mmol) and Pd / C (10%, 2 g) in CHOH (200 mL) was stirred at 20° C. under an H atmosphere (15 psi) for 12 h. LC / MS showed the reaction was complete. The mixture was filtered, and the filtrate was concentrated to give (R)-tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)phenyl)piperidine-1-carboxylate (7.5 g, crude) as an off-white solid. MS (ESI, m / e) [M+1] + 427.3.
[0300] Step 3: (R)-tert-butyl 4-(2-(pyrrolidin-2-yl)phenyl)piperidine-1-carboxylate To a solution of (R)-tert-butyl 4-(2-(1-(2,2,2-trifluoroacetyl)pyrrolidin-2-yl)phenyl)piperidine-1-carboxylate (7.5 g, 17.6 mmol) in CHOH (50 mL) was added a solution of NaOH (2.8 g, 70.4 mmol) in HO (30 mL). The mixture was then heated to 40 °C and stirred for 2 h. TLC showed the reaction was complete. The mixture was concentrated under reduced pressure to remove the organic solvent, and the remaining aqueous solution was extracted with EA (100 mL). The organic layer was washed with brine (100 mL), dried over NaSO, and concentrated to give (R)-tert-butyl 4-(2-(pyrrolidin-2-yl)phenyl)piperidine-1-carboxylate (6 g, crude). MS (ESI, m / e) [M+1] + 331.3.
[0301] Step 4: (R)-tert-butyl 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)phenyl)piperidine-1-carboxylate A mixture of (R)-tert-butyl 4-(2-(pyrrolidin-2-yl)phenyl)piperidine-1-carboxylate (2 g, 6.1 mmol), 1-bromo-4-iodobenzene (3.5 g, 12.2 mmol), Pd(dba) (559 mg, 0.61 mmol), BINAP (760 mg, 1.22 mmol), and t-BuOK (1.4 g, 12.2 mmol) in toluene (20 mL) was heated to 100 °C under N protection and stirred for 12 h. TLC showed the reaction was complete. The mixture was cooled to room temperature, diluted with EA (20 mL), washed with water (20 mL), brine (20 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: PE / EA=20 / 1 to 15 / 1) to give (R)-tert-butyl 4-(2-(1-(4-bromophenyl)pyrrolidin-2-yl)phenyl)piperidine-1-carboxylate (2 g). 1 H NMR (400MHz, CDCl3) δppm: 7.29 (1H, s), 7.22-7.26 (1H, m), 7.18-7.22 (2H, m), 7.01 -7.12(2H, m), 6.23-6.31(2H, m), 4.91(1H, d, J=6.8Hz), 4.31(2H, s), 3.65-3.75(1 H, m), 3.35-3.47(1H, m), 2.95-3.07(1H, m), 2.82(2H, s), 2.41-2.55(1H, m), 1.97- 2.10(2H, m), 1.79-1.93(3H, m), 1.61-1.74(2H, m), 1.51(9H, s).MS(ESI, m / e)[M+1] + 487.8.
[0302] Intermediate 2-z9: 1-(azetidin-3-yl)-2-(2-cyclopropylphenyl)pyrrolidine [ka] Step 1: tert-butyl 3-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)azetidine-1-carboxylate To a solution of 2-(2-cyclopropylphenyl)pyrrolidine (700 mg, 3.7 mmol) and tert-butyl 3-oxoazetidine-1-carboxylate (632 mg, 3.7 mmol) in DCM (10 mL) was added NaBH(OAc) (600 mg, 3 mmol). The mixture was stirred at room temperature for 14 hours. Then, saturated aqueous NH4Cl (30 mL) was added to the reaction mixture with stirring. The organic phase was separated, washed with brine (10 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to give 1 g of crude product. MS (ESI, m / e) [M+1] + 343.0.
[0303] Step 2: 1-(azetidin-3-yl)-2-(2-cyclopropylphenyl)pyrrolidine To a solution of tert-butyl 3-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)azetidine-1-carboxylate (680 mg, 2.0 mmol) in DCM (10 mL) was added TFA (2 mL). The mixture was stirred at room temperature for 4 hours. The solvent was removed to give 700 mg of 1-(azetidin-3-yl)-2-(2-cyclopropylphenyl)pyrrolidine. MS (ESI, m / e) [M+1] + 243.0.
[0304] Intermediate 2-z10: 6-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)-2-azaspiro[3.3]heptane Step 1: tert-Butyl 6-(methoxymethylene)-2-azaspiro[3.3]heptane-2-carboxylate To a solution of tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate (3 g, 0.014 mol) in toluene (50 mL) was added t-BuOK (2.0 g, 0.018 mol). The mixture was stirred at 25 °C for 20 minutes under a N2 atmosphere. Next, (methoxymethyl)triphenylphosphonium chloride (6.2 g, 0.018 mol) in toluene (20 mL) was added. The mixture was stirred at 70 °C for 4 hours. TLC showed that the reaction was complete. After removing the solvent, the residue was purified by column chromatography on silica gel (eluent: PE / EA = 20 / 1) to give tert-butyl 6-(methoxymethylene)-2-azaspiro[3.3]heptane-2-carboxylate (1 g). 1 H NMR (400MHz, CDCl3) δppm: 5.81 (s, 1H), 3.86-4.00 (s, 4H), 3.55 (s, 3H), 2.86 (s, 2H), 2.79 (s, 2H), 1.43 (s, 9H).
[0305] Step 2: tert-Butyl 6-formyl-2-azaspiro[3.3]heptane-2-carboxylate To a solution of tert-butyl 6-(methoxymethylene)-2-azaspiro[3.3]heptane-2-carboxylate (1 g, 4.18 mmol) in CHCN (36 mL) and HO (9 mL) was added TFA (1 mL), and the mixture was stirred at room temperature for 2 h. TLC showed the reaction was complete. The reaction mixture was adjusted to pH 8-9 with aqueous NaCO and extracted with EA (20 mL × 3). The combined organic layers were washed with brine, dried, filtered, and concentrated to give tert-butyl 6-formyl-2-azaspiro[3.3]heptane-2-carboxylate (0.9 g), which was used in the next step without further purification. 1 H NMR (400MHz, CDCl3)δppm:9.71(d,J=1.7Hz, 1H), 3.94(s,2H), 3.85-3.86(m,1H), 3 .80-3.84(m,1H), 3.82(s,1H), 2.98-3.20(m,1H), 2.30-2.46(m,4H), 1.41(s,9H).
[0306] Step 3: tert-butyl 6-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)-2-azaspiro[3.3]heptane-2-carboxylate To a solution of tert-butyl 6-formyl-2-azaspiro[3.3]heptane-2-carboxylate (0.9 g, 4.0 mmol) in DCE (30 mL) was added 2-(2-cyclopropylphenyl)pyrrolidine (0.68 g, 3.63 mmol) and HOAc (436 mg, 7.26 mmol). The mixture was stirred at room temperature for 30 min, after which NaBH(OAc) (1.54 g, 7.26 mmol) was added, followed by stirring for an additional 2 h. LC / MS showed the reaction was complete. The reaction was quenched with aqueous NaCO (10 mL) and then extracted with EA (3 × 50 mL). The organic layer was dried, filtered, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA=2 / 1) to give tert-butyl 6-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)-2-azaspiro[3.3]heptane-2-carboxylate (0.8 g). MS (ESI, m / e) [M+1] + 397.3.
[0307] Step 4: 6-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)-2-azaspiro[3.3]heptane To a solution of tert-butyl 6-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)-2-azaspiro[3.3]heptane-2-carboxylate (0.8 g, 2.0 mmol) in DCM (20 mL) was added TFA (10 mL) dropwise at 0 °C. The mixture was then stirred at room temperature for 2 h. TLC showed that the reaction was complete. The reaction mixture was adjusted to pH 8-9 using aqueous NaCO solution and then extracted with DCM. The organic layer was dried, filtered, and concentrated to give 6-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)-2-azaspiro[3.3]heptane (250 mg). 1H NMR (400MHz, CDCl3) δppm:7.57(d,J=7.4Hz, 1H), 7.15-7.23(m,1H), 7.13(dt,J=1.3, 7 .4Hz, 1H), 6.98(d,J=7.4Hz, 1H), 3.70-3.84(m,1H), 3.62(d,J=1.7Hz, 2H), 3.41(s,2H) ), 3.26(t,J=8.3Hz, 1H), 2.43-2.56(m,1H), 2.39(s,1H), 2.17-2.27(m,5H), 1.95-2.0 5(m,2H), 1.47-1.95(m,5H), 0.82-1.00(m,2H), 0.54-0.75(m,2H).MS(ESI, m / e)[M+1] + 297.3.
[0308] Intermediate 2-z11: 3-(2-cyclopropylphenyl)-2-azabicyclo[3.1.0]hexane [ka] Step 1: tert-butyl 2-(2-cyclopropylphenyl)-4-(tosyloxy)pyrrolidine-1-carboxylate To a solution of tert-butyl 2-(2-cyclopropylphenyl)-4-hydroxypyrrolidine-1-carboxylate (4.5 g, 14.8 mmol) in THF (50 mL) was added NaH (0.71 g, 17.8 mmol), and the mixture was stirred at 20 °C for 30 min. Then, TosCl (3.4 g, 17.8 mmol) was added to the mixture, and the mixture was further stirred at 20 °C for 12 h. TLC showed that the reaction was complete. The reaction mixture was quenched with water (100 mL) and extracted with EA (100 mL). The organic layer was washed with brine (100 mL), dried over NaSO, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 10 / 1 to 5 / 1) to give tert-butyl 2-(2-cyclopropylphenyl)-4-(tosyloxy)pyrrolidine-1-carboxylate (2.9 g). MS(ESI, m / e)[M+1] + 458.2.
[0309] Step 2: tert-butyl 2-(2-cyclopropylphenyl)-2,3-dihydro-1H-pyrrole-1-carboxylate To a solution of tert-butyl 2-(2-cyclopropylphenyl)-4-(tosyloxy)pyrrolidine-1-carboxylate (2.9 g, 6.3 mmol) in THF (50 mL) was added t-BuOK (1.4 g, 12.6 mmol) portionwise. After the addition, the mixture was stirred at 20 °C for 12 h. TLC showed that the reaction was complete. The mixture was quenched with saturated aqueous NH4Cl (50 mL) and extracted with EA (50 mL). The organic layer was washed with brine (50 mL), dried over Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 100 / 1) to give tert-butyl 2-(2-cyclopropylphenyl)-2,3-dihydro-1H-pyrrole-1-carboxylate (900 mg). MS (ESI, m / e) [M+1] + 286.4.
[0310] Step 3: tert-butyl 3-(2-cyclopropylphenyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate To a solution of tert-butyl 2-(2-cyclopropylphenyl)-2,3-dihydro-1H-pyrrole-1-carboxylate (900 mg, 3.2 mmol) in toluene (20 mL) at 0 °C, EtZn (1 M in toluene, 15.8 mL, 15.8 mmol) and ClCHI (5.56 g, 32 mmol) were added. The mixture was then stirred at 20 °C for 4 h. TLC showed that the reaction was complete. The reaction mixture was quenched with saturated aqueous NHCl (20 mL) and extracted with EA (30 mL × 2). The organic layer was washed with brine (20 mL), dried over NaSO, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 30 / 1) to give tert-butyl 3-(2-cyclopropylphenyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (500 mg). MS(ESI, m / e)[M+1] + 300.2.
[0311] Step 4: 3-(2-cyclopropylphenyl)-2-azabicyclo[3.1.0]hexane A solution of tert-butyl 3-(2-cyclopropylphenyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (500 mg, 1.7 mmol) in HCl in EA (4 M, 10 mL) was stirred at 20 °C for 2 h. TLC showed the reaction was complete. The mixture was quenched with saturated aqueous NaCO (20 mL) and extracted with EA (20 mL × 2). The organic layer was washed with brine (20 mL), dried over NaSO, and concentrated to give 3-(2-cyclopropylphenyl)-2-azabicyclo[3.1.0]hexane (293 mg). 1 H NMR (400MHz, CDCl3) δppm:7.63(dd,J=7.7, 1.3Hz, 1H), 7.18-7.23(m,1H), 7.11-7.16(m,1H), 6.98(d,J=7 .2Hz, 1H), 4.54(dd,J=10.0, 7.0Hz, 1H), 3.00(td,J=6.0, 2.6Hz, 1H), 2.37(dd,J=12.3, 7.0Hz, 1H), 1.91-2 .02(m,1H), 1.72-1.83(m,1H), 1.48-1.59(m,1H), 0.87-1.03(m,1H), 0.87-1.03(m,1H), 0.77-0.84(m,1H) , 0.60-0.73(m,2H), 0.60-0.73(m,2H), 0.42(dt,J=8.1, 5.9Hz, 1H), 0.37-0.47(m,1H).MS(ESI, m / e)[M+1] + 200.2.
[0312] Intermediate 2-z12: 1-(2-cyclopropylphenyl)octahydrocyclopenta[c]pyrrole [ka] Step 1: 3-(2-cyclopropylphenyl)hexahydrocyclopenta[c]pyrrol-1(2H)-one To a solution of 1-bromo-2-cyclopropylbenzene (8.5 g, 0.043 mol) in THF (20 mL) was added n-BuLi (21 mL, 0.052 mol, 2.5 M in hexane) at −78 °C under a N atmosphere. The mixture was then stirred at −78 °C for 1 h. To a solution of tetrahydrocyclopenta[c]pyrrole-1,3(2H,3aH)-dione (4 g, 0.029 mol) in THF (20 mL) was added n-BuLi (13 mL, 0.035 mol, 2.5 M in hexane) at −78 °C under a N atmosphere. The mixture was then stirred at 0 °C for 1 h. The solution formed from 1-bromo-2-cyclopropylbenzene was added dropwise to the solution formed from tetrahydrocyclopenta[c]pyrrole-1,3(2H,3aH)-dione at −78 °C. The resulting mixture was stirred at room temperature for 3 h. TLC showed that tetrahydrocyclopenta[c]pyrrole-1,3(2H,3aH)-dione was consumed. NaBH3CN (2.2 g, 0.035 mol) was added to the mixture, followed by 6N HCl acid (20 mL) at 0 °C and further stirring at room temperature for 1 h. Na2CO3 (50 mL) was added to the mixture to adjust the pH to 8-9. The mixture was then extracted with EA (50 mL × 3), and the organic layer was washed with brine (50 mL × 2). The combined organic layers were dried, filtered, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 10 / 1) to give 3-(2-cyclopropylphenyl)hexahydrocyclopenta[c]pyrrol-1(2H)-one (2.8 g). 1 H NMR (400MHz, CDCl3)δppm:7.19-7.23(m,1H), 7.11-7.16(m,2H), 6.95-7.01(m,1 H), 6.20(s,1H), 5.44(d,J=7.7Hz, 1H), 3.08-3.24(m,1H), 2.93-3.04(m,1H), 2.7 3-2.87(m,1H), 1.91-2.06(m,1H), 1.73-1.83(m,2H), 1.51-1.64(m,1H), 1.40-1. 49(m,2H), 1.33(s,1H), 1.10-1.20(m,1H), 0.52-0.73(m,2H).MS(ESI, m / e)[M+1] + 242.3.
[0313] Step 2: 1-(2-cyclopropylphenyl)octahydrocyclopenta[c]pyrrole To a solution of 3-(2-cyclopropylphenyl)hexahydrocyclopenta[c]pyrrol-1(2H)-one (1.0 g, 4.15 mmol, 1 equiv.) in THF (20 mL) was added BH3.DMS (4.2 mL, 41.5 mmol, 10 equiv., 10 M in DMS) dropwise at 0 °C. After the addition, the mixture was stirred at room temperature for 12 h. TLC showed that the reactants were completely consumed. At 0 °C, MeOH (2 mL) and 1 N HCl (20 mL) were carefully added to the reaction mixture. Then, the mixture was stirred at room temperature for 1 h. The reaction was quenched with aqueous Na2CO3 (50 mL) and adjusted to pH 9. The mixture was extracted with EA (50 mL × 3). The organic layer was washed with brine (50 mL × 2), dried, filtered, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA=5 / 1) to give the target product (300 mg). 1 H NMR (400MHz, CDCl3)δppm:7.54-7.59(m,1H), 7.12-7.19(m,2H), 6.95-7.01(m,1H), 4. 53(d,J=6.97Hz, 1H), 3.02-3.09(m,1H), 2.89-3.02(m,2H), 2.65(quin,J=7.86Hz, 1H) , 1.91-2.03(m,2H), 1.55-1.64(m,1H), 1.24-1.39(m,1H), 1.18-1.39(m,1H), 1.18-1. 20(m,1H), 1.11-1.21(m,1H), 0.87-0.99(m,3H), 0.61-0.78(m,2H).MS(ESI, m / e)[M+1] + 228.5.
[0314] Intermediate 2-z13: 2-((5-(2-cyclopropylphenyl)pyrrolidin-3-yl)oxy)-N,N-dimethylethan-1-amine [ka] Step 1: 2-((1-(tert-butylsulfonyl)-5-(2-cyclopropylphenyl)pyrrolidin-3-yl)oxy)-N,N-dimethylacetamide To a solution of 1-(tert-butylsulfonyl)-5-(2-cyclopropylphenyl)pyrrolidin-3-ol (10.5 g, 32.46 mmol) in DMF (250 mL) was added NaH (1.43 g, 35.71 mmol, 60%) portionwise at 10 °C. The mixture was stirred at 10 °C for 30 min. Then, 2-chloro-N,N-dimethylacetamide (4.14 g, 34.09 mmol) was added dropwise at 10 °C. The mixture was stirred at 10 °C for 2 h. TLC showed that the reactants were completely consumed. The reaction mixture was quenched with saturated aqueous NH Cl (50 mL) and extracted with EA (100 mL × 3). The combined organic phase was washed with brine (50 mL × 2), dried over anhydrous Na SO , filtered, and concentrated. The residue was purified by column chromatography (SiO2, PE / EA = 5 / 1 to 0 / 1) to give 2-((1-(tert-butylsulfonyl)-5-(2-cyclopropylphenyl)pyrrolidin-3-yl)oxy)-N,N-dimethylacetamide (8.48 g). MS (ESI, m / e) [M+1] + 410.1.
[0315] Step 2: 2-((5-(2-cyclopropylphenyl)pyrrolidin-3-yl)oxy)-N,N-dimethylacetamide A solution of 2-((1-(tert-butylsulfonyl)-5-(2-cyclopropylphenyl)pyrrolidin-3-yl)oxy)-N,N-dimethylacetamide (8.4 g, 20.56 mmol) in TFA (100 mL) was stirred at 75 °C for 12 h. LC / MS showed complete consumption of the reactants and the desired mass signals. The reaction mixture was concentrated under reduced pressure to approximately 20 mL and poured into saturated aqueous NaHCO (50 mL) to adjust the pH to approximately 8. The aqueous phase was extracted with EA (100 mL × 3). The combined organic phases were washed with brine (50 mL × 2), dried over anhydrous NaSO, filtered, and concentrated. 2-((5-(2-cyclopropylphenyl)pyrrolidin-3-yl)oxy)-N,N-dimethylacetamide (22 g, crude) was obtained. MS (ESI, m / e) [M+1] + 289.3.
[0316] Step 3: 2-((5-(2-cyclopropylphenyl)pyrrolidin-3-yl)oxy)-N,N-dimethylethanamine To a solution of 2-((5-(2-cyclopropylphenyl)pyrrolidin-3-yl)oxy)-N,N-dimethylacetamide (1.2 g, 4.16 mmol) in THF (50 mL) was added BH3.DMS (8.32 mL, 83.2 mmol, 10 N in DMS) dropwise at 20° C. The mixture was heated to 70° C. and stirred for 10 h. LC / MS showed that the reactants were completely consumed. The reaction mixture was quenched with MeOH (10 mL) and decomplexed with HCl / MeOH (4 N, 20 mL) at reflux for 2 h. LC / MS showed that the desired compound was produced. The reaction mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC (Xtimate C18 10 μg 250 mm H NMR (CDCl 1.0, δ 1.0- ... *Purification was performed by elution with 50 mm; mobile phase: [water (0.1% TFA)-ACN]. 2-((5-(2-cyclopropylphenyl)pyrrolidin-3-yl)oxy)-N,N-dimethylethanamine (1.4 g, TFA salt) was obtained. This salt was dissolved in CH3CN (100 mL), and K2CO3 (560.9 mg, 4.07 mmol, 1.5 equiv) was added to the solution in one portion, followed by stirring at 20 °C for 2 h. The mixture was filtered, and the filtrate was concentrated to give 2-((5-(2-cyclopropylphenyl)pyrrolidin-3-yl)oxy)-N,N-dimethylethanamine (385 mg). 1 H NMR (400MHz, CDCl3)δppm:7.46-7.57(m,1H), 7.10-7.20(m,2H), 6.93-7.02(m,1H), 4.9 1(t,J=8.0Hz, 1H), 4.10-4.20(m,1H), 3.50-3.58(m,2H), 3.34(dd,J=11.3, 5.1Hz, 1H), 3.05-3.18(m,1H), 2.54(t,J=5.8Hz, 2H), 2.35-2.46(m,1H), 2.19-2.33(m,6H), 1.92-2 .03(m,1H), 1.54-1.91(m,2H), 0.84-1.00(m,2H), 0.56-0.73(m,2H).MS(ESI, m / e)[M+1] + 275.1.
[0317] Intermediate 2-z14: (S)-2-(2-(2-ethoxyphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonane [ka] Step 1: (S)-2-(2-ethoxyphenyl)pyrrolidine To a mixture of (S)-2-(2-bromophenyl)pyrrolidine (1.5 g, 6.63 mmol) and EtONa (1.35 g, 19.90 mmol) in EtOH (15 mL) was added CuBr (475.81 mg, 3.32 mmol). The mixture was then stirred at 90 °C for 12 h. LC / MS showed the reaction was complete and a peak with the desired mass signal was present. The mixture was cooled to room temperature, adjusted to pH 11 using aqueous NaCO solution, and then extracted with EA (20 mL × 3). The combined organic layers were dried over NaSO, filtered, and concentrated. The residue was purified by preparative HPLC (TFA conditions). (S)-2-(2-ethoxyphenyl)pyrrolidine (0.7 g) was obtained. MS (ESI, m / e) [M+1] + 192.3.
[0318] Step 2: (S)-tert-butyl 2-(2-(2-ethoxyphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate A mixture of (S)-2-(2-ethoxyphenyl)pyrrolidine (0.5 g, 2.61 mmol), tert-butyl 2-oxo-7-azaspiro[3.5]nonane-7-carboxylate (568.71 mg, 2.38 mmol), and HOAc (428.13 mg, 7.13 mmol) in DCE (5 mL) was stirred at 20 °C for 2 h. NaBH(OAc) (1.01 g, 4.75 mmol) was added to the mixture, which was further stirred at 20 °C for 12 h. TLC showed that the reaction was complete. The mixture was adjusted to pH 11 using aqueous NaCO solution and then extracted with EA (20 mL × 3). The combined organic layers were dried over NaSO, filtered, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 20 / 1 to 10 / 1) to give (S)-tert-butyl 2-(2-(2-ethoxyphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate (0.6 g). MS (ESI, m / e) [M+1] + 415.4.
[0319] Step 3: (S)-2-(2-(2-ethoxyphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonane To a solution of (S)-tert-butyl 2-(2-(2-ethoxyphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate (0.6 g, 1.45 mmol) in DCM (10 mL) was added TFA (1.65 g, 14.47 mmol). The mixture was stirred at 20 °C for 1 h. TLC showed the formation of one new spot. The reaction mixture was adjusted to pH 8-9 using aqueous NaCO solution and then extracted with DCM (10 mL × 5). The combined organic layers were washed with brine, dried over NaSO, and concentrated. (S)-2-(2-(2-ethoxyphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonane (360 mg) was obtained. 1 H NMR (400MHz, CDCl3) δppm:7.49-7.58(m,1H), 7.13-7.21(m,1H), 6.93(t,J=7.4 Hz, 1H), 6.82(d,J=7.4Hz, 1H), 4.04(d,J=7.1Hz, 2H), 3.91(t,J=7.1Hz, 1H), 3. 07-3.21(m,2H), 2.72-2.90(m,4H), 2.40(q,J=8.4Hz, 1H), 2.14-2.26(m,1H), 1 .73-1.94(m,5H), 1.47-1.73(m,8H), 1.41(t,J=6.95Hz, 3H).MS(ESI, m / e)[M+1] + 315.3.
[0320] Intermediate 2-z15: 2-(2'-cyclopropyl-[1,1'-biphenyl]-2-yl)-7-azaspiro[3.5]nonane [ka] Step 1: tert-Butyl 2-(2-tosylhydrazono)-7-azaspiro[3.5]nonane-7-carboxylate A mixture of tert-butyl 2-oxo-7-azaspiro[3.5]nonane-7-carboxylate (10.00 g, 41.79 mmol) and 4-methylbenzenesulfonohydrazide (9.34 g, 50.14 mmol) in EtOH (100 mL) was stirred at 80 °C for 1 h. TLC showed the reaction was complete. The mixture was cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure to give tert-butyl 2-(2-tosylhydrazono)-7-azaspiro[3.5]nonane-7-carboxylate (8.0 g, crude). 1H NMR (400MHz, CDCl3) δppm:7.84(d,J=8.1Hz, 2H), 7.39(s,1H), 7.33(d,J=8.0Hz, 2H), 3.22 -3.39(m,5H), 2.64(s,2H), 2.49(s,2H), 2.44(s,3H), 1.54(t,J=5.5Hz, 4H), 1.45(s,10H).
[0321] Step 2: tert-butyl 2-(2-methoxyphenyl)-7-azaspiro[3.5]nonane-7-carboxylate A mixture of tert-butyl 2-(2-tosylhydrazono)-7-azaspiro[3.5]nonane-7-carboxylate (8.0 g, 19.63 mmol), (2-methoxyphenyl)boronic acid (8.95 g, 58.89 mmol), and CsCO (19.19 g, 58.89 mmol) in dioxane (100 mL) was stirred at 110 °C for 4 hours. TLC showed the reaction was complete. The mixture was filtered and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE). tert-butyl 2-(2-methoxyphenyl)-7-azaspiro[3.5]nonane-7-carboxylate (3.0 g) was obtained. MS (ESI, m / e) [M+1] + 332.3.
[0322] Step 3: tert-Butyl 2-(2-hydroxyphenyl)-7-azaspiro[3.5]nonane-7-carboxylate To a solution of tert-butyl 2-(2-methoxyphenyl)-7-azaspiro[3.5]nonane-7-carboxylate (3.0 g, 9.05 mmol) in DCM (30 mL) under N2 atmosphere was added BBr3 (9.07 g, 36.20 mmol) at -78 °C. After the addition, the mixture was stirred at 20 °C for 6 h. LC / MS showed that the reaction was complete. The mixture was quenched with aqueous Na2CO3 and extracted with DCM (20 mL x 3). The combined organic phases were washed with brine, dried over Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 20 / 1). tert-butyl 2-(2-hydroxyphenyl)-7-azaspiro[3.5]nonane-7-carboxylate (1.3 g) was obtained. MS (ESI, m / e) [M+1] + 318.4.
[0323] Step 4: tert-butyl 2-(2-(((trifluoromethyl)sulfonyl)oxy)phenyl)-7-azaspiro[3.5]nonane-7-carboxylate To a solution of tert-butyl 2-(2-hydroxyphenyl)-7-azaspiro[3.5]nonane-7-carboxylate (1.3 g, 4.10 mmol) and TEA (1.24 g, 6.14 mmol) in DCM (10 mL) was added TfO (1.73 g, 12.29 mmol) at 0 °C under a N atmosphere. The mixture was then stirred at 25 °C for 1 h. TLC showed that the reaction was complete. The mixture was quenched with HO (10 mL) and NHCl (10 mL) and extracted with DCM (10 mL × 3). The organic phase was washed with brine, dried over NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: PE / EA=40 / 1) to give ert-butyl 2-(2-(((trifluoromethyl)sulfonyl)oxy)phenyl)-7-azaspiro[3.5]nonane-7-carboxylate (1.84 g). MS (ESI, m / e) [M+1] + 450.2.
[0324] Step 5: tert-butyl 2-(2'-cyclopropyl-[1,1'-biphenyl]-2-yl)-7-azaspiro[3.5]nonane-7-carboxylate To a mixture of the compound tert-butyl 2-(2-(((trifluoromethyl)sulfonyl)oxy)phenyl)-7-azaspiro[3.5]nonane-7-carboxylate (1.4 g, 3.11 mmol), 2-(2-cyclopropylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.52 g, 6.23 mmol), and CsCO (3.04 g, 9.34 mmol) in dioxane (10 mL) was added Pd(dppf)Cl (1.14 g, 1.56 mmol) under a N atmosphere. The mixture was stirred at 90 °C for 12 hours. TLC showed that the reactants were completely consumed and one new spot was formed. The mixture was filtered and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA=50 / 1) to give tert-butyl 2-(2'-cyclopropyl-[1,1'-biphenyl]-2-yl)-7-azaspiro[3.5]nonane-7-carboxylate (0.6 mg). MS (ESI, m / e) [M+1] + 418.5.
[0325] Step 6: 2-(2'-cyclopropyl-[1,1'-biphenyl]-2-yl)-7-azaspiro[3.5]nonane To a mixture of tert-butyl 2-(2'-cyclopropyl-[1,1'-biphenyl]-2-yl)-7-azaspiro[3.5]nonane-7-carboxylate (0.6 g, 1.44 mmol) in DCM (5 mL) was added TFA (1.39 g, 14.37 mmol). The mixture was stirred at 25 °C for 2 h. LC / MS showed the reaction was complete. The reaction mixture was adjusted to pH 10 using aqueous NaCO solution and then extracted with DCM (10 mL × 3). The combined organic layers were washed with brine, dried over NaSO, and concentrated. 2-(2'-cyclopropyl-[1,1'-biphenyl]-2-yl)-7-azaspiro[3.5]nonane (340 mg) was obtained. 1H NMR (400MHz, CDCl3) δppm:7.34-7.46(m,2H), 7.22-7.32(m,3H), 7.13-7.22(m,2H), 7.06(d,J=7.5Hz, 1H), 6.83(d,J=7.7Hz, 1H), 3.46(m,J= 9.15Hz, 1H), 3.30(s,2H), 2.70-2.84(m,4H), 1.68-2.03(m,5H), 1.45-1.64(m,5H), 0.72-0.83(m,2H), 0.61-0.71(m,2H).MS(ESI, m / e)[M+1] + 318.1.
[0326] Intermediate 2-z16: 4-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)benzaldehyde [ka] Step 1: Methyl 4-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)benzoate To a solution of 2-(2-cyclopropylphenyl)pyrrolidine (1.5 g, 8.01 mmol), methyl 4-formylbenzoate (1.14 g, 7.29 mmol) in DCE (20 mL) was added CH3COOH (0.87 g, 14.58 mmol), and NaBH(OAc)3 (3.09 g, 14.58 mmol). The mixture was stirred at 25 °C for 4 h. TLC showed that the reactants were completely consumed. The reaction mixture was poured into HO (50 mL) and extracted with EA (20 mL × 3). The combined organic layers were washed with brine (25 mL × 2), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (eluent: PE / EA = 50 / 1 to 1 / 1) to give methyl 4-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)benzoate (1.8 g). MS (ESI, m / e) [M+1] + 336.5.
[0327] Step 2: (4-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)phenyl)methanol To a solution of methyl 4-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)benzoate (2 g, 6 mmol) in THF (30 mL) was added LiAlH (46 g, 17.28 mmol) slowly at 0 °C. The mixture was stirred at 0 °C for 30 min. TLC showed that the reactants were completely consumed. The residue was quenched with saturated aqueous NH Cl (50 mL) and extracted with EA (50 mL). The organic phase was washed with brine, dried over Na SO and concentrated to give (4-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)phenyl)methanol (1.5 g). MS (ESI, m / e) [M+1] + 308.3.
[0328] Step 3: 4-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)benzaldehyde To a solution of (4-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)phenyl)methanol (1.5 g, 4.89 mmol) in THF (20 mL) was added DMP (4.14 g, 9.78 mmol). The mixture was stirred at 25 °C for 4 h. LC / MS showed complete consumption of the reactants and one major peak with the desired mass signal. The reaction mixture was quenched by the addition of NaSO (25 ml) and NaHCO (15 ml) and extracted with EA (30 mL × 3). The combined organic layers were washed with brine (30 mL × 2), dried over NaSO, and concentrated to give 4-((2-(2-cyclopropylphenyl)pyrrolidin-1-yl)methyl)benzaldehyde (1.5 g). 1H NMR (400MHz, CDCl3) δppm:9.91(s,1H), 7.74(d,J=8.1Hz, 2H), 7.68(d,J=7.7Hz, 1H), 7.43(d,J=7.9Hz, 2H), 7.14-7.18(m,1H), 7.09(td,J=7.4, 1.2Hz, 1H), 6.94(d,J=7.5Hz, 1H), 3.96(t,J=8.2Hz, 1H), 3.86( d,J=13.8Hz, 1H), 2.98-3.14(m,2H), 2.18-2.32(m,1H), 2.14(q,J=8.8Hz, 1H), 1.98(d,J=7.7Hz, 1H), 1 .68-1.91(m,2H), 1.63(dd,J=9.7, 2.4Hz, 1H), 0.80-0.95(m,2H), 0.63-0.74(m,1H), 0.48-0.61(m,1H).
[0329] Intermediate 2-z17a and Intermediate 2-z17b: (S or R)-2-(3-chloro-2-cyclopropylphenyl)pyrrolidine; (R or S)-2-(3-chloro-2-cyclopropylphenyl)pyrrolidine [ka] Step 1: 1-Bromo-3-chloro-2-cyclopropylbenzene A mixture of 1-bromo-3-chloro-2-iodobenzene (7 g, 22.1 mmol), cyclopropylboronic acid (3.8 g, 44.2 mmol), Pd(dppf)Cl (1.6 g, 2.21 mmol), and KCO (2 g, 7.3 mmol, 1.0 equiv.) in dioxane (100 mL) was heated at 70 °C for 12 h under N protection. TLC showed the reaction was complete and a new spot had formed. The mixture was cooled to room temperature and diluted with EtOAc (150 mL) and HO (50 mL). The organic phase was separated, washed with water (150 mL), brine (150 mL), dried over NaSO, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE) to give 1-bromo-3-chloro-2-cyclopropylbenzene (3 g, crude), which was used directly in the next step.
[0330] Step 2: tert-butyl (4-(3-chloro-2-cyclopropylphenyl)-4-oxobutyl)carbamate To a solution of 1-bromo-3-chloro-2-cyclopropylbenzene (3 g, 13 mmol) in THF (30 mL) was added n-BuLi (2.5 M, 5.7 mL, 14.3 mmol) dropwise at −70° C. After stirring at −70° C. for 30 minutes, a solution of tert-butyl 2-oxopyrrolidine-1-carboxylate (2.64 g, 14.3 mmol, 1.1 equiv.) in THF (5 mL) was added dropwise to the mixture at −70° C. The mixture was further stirred at −70° C. for 2 hours. TLC showed that the reaction was complete. The mixture was quenched with water (50 mL) and extracted with EtOAc (50 mL). The organic layer was washed with brine (50 mL), dried over NaSO, and concentrated. The residue was purified by column chromatography on silica gel (eluent: PE / EA=5 / 1) to give tert-butyl (4-(3-chloro-2-cyclopropylphenyl)-4-oxobutyl)carbamate (1.3 g). 1 H NMR (400MHz, CDCl3) δppm:7.35(dd,J=7.6, 1.7Hz, 1H), 7.06-7.15(m,2H), 4.56(s,1H), 3.14(q,J=6.3 Hz, 2H), 2.89(t,J=7.2Hz, 2H), 1.78-1.95(m,3H), 1.37(s,9H), 0.92-1.03(m,2H), 0.35-0.45(m,2H).
[0331] Step 3: 4-amino-1-(3-chloro-2-cyclopropylphenyl)butan-1-one To a solution of tert-butyl (4-(3-chloro-2-cyclopropylphenyl)-4-oxobutyl)carbamate (1.3 g, 3.8 mmol) in DCM (20 mL) was added TFA (4.4 g, 38 mmol). The mixture was then stirred at 20° C. for 2 h. TLC showed the reaction was complete. The mixture was concentrated under reduced pressure to give 4-amino-1-(3-chloro-2-cyclopropylphenyl)butan-1-one (900 mg, crude). MS (ESI, m / e) [M+1] + 237.9.
[0332] Step 4: 2-(3-chloro-2-cyclopropylphenyl)pyrrolidine A solution of 4-amino-1-(3-chloro-2-cyclopropylphenyl)butan-1-one (900 mg, 3.8 mmol) and AcOH (0.5 mL) in EtOH (10 mL) was heated to 65 °C and stirred for 3 h. Then, the mixture was cooled to room temperature, and NaBHCN (360 mg, 5.7 mmol, 1.5 equiv.) was added to it. The mixture was further stirred at room temperature for 1 h. TLC showed that the reaction was complete. The reaction mixture was quenched and adjusted to pH 10 with saturated aqueous NaCO solution, then extracted with EtOAc (20 mL × 3). The organic layers were combined, dried over NaSO, and concentrated. The residue was purified by column chromatography on silica gel (eluent: EA / MeOH = 10 / 0 to 10 / 1) to give racemic 2-(3-chloro-2-cyclopropylphenyl)pyrrolidine.
[0333] The racemic product was purified by SFC (instrument: Thar SFC350 preparative SFC; column: Chiralpak AD, 250 * Purification by 50 mm i.d. 10 u; mobile phase: CO for A and MeOH (0.1% NH.HO) for B; gradient: B%=20%; flow rate: 200 g / min; wavelength: 220 nm; column temperature: 40 °C; system back pressure: 100 bar) gave two isomers: the faster isomer (715 mg, retention time: 2.4 min) is (S or R)-2-(3-chloro-2-cyclopropylphenyl)pyrrolidine; the slower isomer (737 mg, retention time: 2.7 min) is (R or S)-2-(3-chloro-2-cyclopropylphenyl)pyrrolidine.
[0334] Intermediate 3-a: 3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide [ka] To a solution of 4-fluoro-3-nitrobenzenesulfonamide (36.3 g, 0.165 mol) in THF (500 mL), (tetrahydro-2H-pyran-4-yl)methanamine (20.9 g, 0.182 mol) and TEA (20.0 g, 0.198 mol) were added at 0-5 °C, and the reaction was slowly warmed to room temperature and stirred for about 16 h. EA (1.5 L) was added to the reaction, and the mixture was washed with saturated NaHPO (100 mL) and saturated NaCl solution (100 mL), dried over anhydrous NaSO, filtered, and concentrated to give the product (49.1 g, 95.0% yield) as a yellow solid.
[0335] Intermediate 3-b: 4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)-3-nitrobenzenesulfonamide [ka] To a mixture of compound 4-fluoro-3-nitrobenzenesulfonamide (540 mg, 2.45 mmol) and Na2CO3 (155.97 mg, 1.47 mmol) in i-PrOH (1.5 mL) was added compound (4-fluorotetrahydro-2H-pyran-4-yl)methanol (489.89 mg, 3.68 mmol) at 20 ° C under N2, and the mixture was stirred at 60 ° C for 2 hours. The mixture was filtered and washed with water. Compound 4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)-3-nitrobenzenesulfonamide (758 mg) was obtained as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δppm:8.58(br t,J=6.0Hz, 1H), 8.46(d,J=6.0Hz, 1H), 7.81(dd,J=1.7, 9.3Hz, 1H), 7.40(br d,J=9.3Hz, 1H), 7.30(br s,2H), 3.81-3.70(m,4H), 3.56-3.45(m,2H), 1.89-1.69(m,4H). MS(ESI, m / e)[M+1] + 334.0.
[0336] Intermediate 3-c: 3-nitro-4-((1-(tetrahydro-2H-pyran-4-yl)azetidin-3-yl)amino)benzenesulfonamide [ka] Step 1: tert-butyl (1-(tetrahydro-2H-pyran-4-yl)azetidin-3-yl)carbamate [ka] To a solution of tetrahydro-4H-pyran-4-one (1.162 g, 11.6 mmol) in DCM (50 ml) was added tert-butyl azetidin-3-ylcarbamate (1 g, 5.8 mmol). The mixture was stirred at room temperature for 2 hours. Then, NaBH(OAc) (3.687 g, 17.4 mmol) was added to the mixture. The mixture was stirred at room temperature overnight. The mixture was diluted with DCM (200 ml), washed with brine (200 ml × 2), dried over NaSO, and concentrated. The residue was purified by chromatography on silica gel using an eluent of MeOH / DCM = 1 / 20 (v / v) to give the product (800 mg) as a yellow oil. MS (ESI, m / e) [M+1] + 257.1.
[0337] Step 2: 1-(tetrahydro-2H-pyran-4-yl)azetidin-3-amine dihydrochloride [ka] To a solution of 4N HCl (g) in dioxane (30 mL) was added tert-butyl (1-(tetrahydro-2H-pyran-4-yl)azetidin-3-yl)carbamate (300 mg, 1.17 mmol). The mixture was stirred at room temperature for 2 hours. The mixture was concentrated to give the crude product (250 mg).
[0338] Step 3: 3-nitro-4-((1-(tetrahydro-2H-pyran-4-yl)azetidin-3-yl)amino)benzenesulfonamide [ka] To a solution of 1-(tetrahydro-2H-pyran-4-yl)azetidin-3-amine dihydrochloride (206 mg, 0.899 mmol) and 4-fluoro-3-nitrobenzenesulfonamide (282 mg, 1.28 mmol) in THF (50 mL) was added triethylamine (540.4 mg, 5.35 mmol). The mixture was stirred at room temperature for 4 hours. The mixture was filtered to give the product (300 mg, 93.6%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δppm: 8.48(s,1H), 8.40(s,1H), 7.86(d,J=9.0Hz, 1H), 7.39(s,2H), 7.10(d,J=9.0Hz, 1H), 4. 46-4.21(m,1H), 3.97-3.56(m,4H), 3.47-3.14(m,4H), 2.46-2.19(m,1H), 1.63(d,J=10.4Hz, 2H), 1.20-1.19(m,2H).
[0339] Intermediate 3-d: 4-(((1-methylpiperidin-4-yl)methyl)amino)-3-nitrobenzenesulfonamide [ka] To a solution of 4-fluoro-3-nitrobenzenesulfonamide (1.15 g, 5.2 mmol) and (1-methylpiperidin-4-yl)methanamine (640 mg, 5 mmol) in THF (12 mL) was added TEA (1.01 g, 10 mmol). The mixture was stirred at room temperature for 3 hours, and some solid formed. The mixture was filtered. The solid (550 mg) was collected as a yellow solid. MS (ESI, m / e) [M+1] + 328.8.
[0340] Intermediate 3-e: 3-nitro-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)benzenesulfonamide [ka] To a solution of 7-oxa-2-azaspiro[3.5]nonane hydrochloride (556 mg, 3.4 mmol) and 4-fluoro-3-nitrobenzenesulfonamide (500 mg, 2.27 mmol) in THF (50 mL) was added triethylamine (688 mg, 6.81 mmol). The mixture was stirred at room temperature for 4 hours. The reaction mixture was concentrated and purified by chromatography on silica gel using an eluent of EA / PE = 1 / 1 (v / v) to give the product (600 mg, 80.7% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δppm:8.17(d,J=2.0Hz, 1H), 7.79(dd,J=9.0, 2.0Hz, 1H), 7.32(s,2H), 6.90 (d,J=9.0Hz, 1H), 3.79(s,4H), 3.526(t,J=5.0Hz, 4H), 1.733(t,J=5.0Hz, 4H).MS(ESI, m / e)[M+1] + 328.
[0341] Intermediate 3-f: 3-nitro-4-((1-(oxetan-3-yl)piperidin-4-yl)amino)benzenesulfonamide [ka] Step 1: tert-butyl (1-(oxetan-3-yl)piperidin-4-yl)carbamate [ka] To a solution of tert-butyl piperidin-4-ylcarbamate (1 g, 5 mmol) in DCM (50 ml) was added oxetan-3-one (1.08 g, 15 mmol) and HOAC (0.2 ml). The mixture was stirred at room temperature for 2 hours. Next, NaBH(OAc) (3.18 g, 15 mmol) was added to the mixture. The mixture was stirred at room temperature overnight. The mixture was diluted with DCM (200 ml), washed with saturated aqueous NaHCO (100 ml), brine (200 ml × 2), dried over NaSO, and concentrated. The reaction residue was purified by chromatography on silica (MeOH / DCM = 1 / 20) to give the product (1 g, 78%) as a yellow oil.1 H NMR (400MHz, DMSO-d6) δppm:6.79(d,J=6.3Hz, 1H), 4.59-4.24(m,4H), 3.32-3.26(m,1H), 3.2 5-3.07(m,1H), 2.72-2.50(m,3H), 1.84-1.55(m,4H), 1.47-1.13(m,11H).MS(ESI, m / e)[M+1] + 257.1.
[0342] Step 2: 1-(oxetan-3-yl)piperidin-4-amine bis(2,2,2-trifluoroacetate) [ka] To a solution of tert-butyl (1-(oxetan-3-yl)piperidin-4-yl)carbamate (1 g, 3.9 mmol) in DCM (30 mL) was added TFA (5 ml). The mixture was stirred at room temperature overnight. The mixture was concentrated to give the product (1.4 g, 93.4%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δppm: 11.02(s,1H), 8.23(s,3H), 4.82-4.63(m,4H), 4.43-4.21(m,1H), 3.59-3.20(m,3H), 3.04-2.76(m,2H), 2.24-1.97(m,2H), 1.91-1.63(m,2H).MS(ESI, m / e)[M+1] + 157.2.
[0343] Step 3: 3-nitro-4-((1-(oxetan-3-yl)piperidin-4-yl)amino)benzenesulfonamide [ka] To a solution of 1-(oxetan-3-yl)piperidin-4-amine bis(2,2,2-trifluoroacetate) (784 mg, 2.04 mmol) and 4-fluoro-3-nitrobenzenesulfonamide (471.6 mg, 2.142 mmol) in THF (50 mL) was added triethylamine (1.03 g, 10.2 mmol). The mixture was stirred at room temperature for 4 hours. The mixture was filtered to give the product (500 mg, 68.8%) as a yellow solid. MS (ESI, m / e) [M+1] + 357.0
[0344] Intermediate 3-g: 4-(((3-((tert-butyldimethylsilyl)oxy)oxetan-3-yl)methyl)amino)-3-nitrobenzenesulfonamide [ka] Step 1: (3-((tert-butyldimethylsilyl)oxy)oxetan-3-yl)methanamine [ka] To a solution of 3-(aminomethyl)oxetan-3-ol (500 mg, 4.85 mmol) in DCM (50 mL) was added tert-butylchlorodimethylsilane (694 mg, 4.6 mmol) and triethylamine (1.47 g, 14.55 mmol). The mixture was stirred at room temperature overnight. It was then washed with saturated aqueous NaHCO (500 mL), brine (50 mL × 2), dried over NaSO, and concentrated to give the crude product, which was used directly in the next step.
[0345] Step 2: 4-(((3-((tert-butyldimethylsilyl)oxy)oxetan-3-yl)methyl)amino)-3-nitrobenzenesulfonamide [ka] To a solution of (3-((tert-butyldimethylsilyl)oxy)oxetan-3-yl)methanamine (1.054 g, 4.85 mmol) in THF (50 mL) was added 4-fluoro-3-nitrobenzenesulfonamide (1.28 g, 5.82 mmol). The mixture was stirred at room temperature for 4 hours. The mixture was filtered to give the product (1.2 g, 59.3%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δppm:8.49(d,J=2.2Hz, 1H), 8.41(t,J=4.8Hz, 1H), 7.41-7.34(m,3H), 4.60(d,J =7.0Hz, 2H), 4.47(d,J=7.0Hz, 2H), 3.84(d,J=5.1Hz, 2H), 0.88(s,9H), 0.13(s,6H), MS(ESI, m / e)[M+1] + 418.1
[0346] Intermediate 3-h: 4-((4-((tert-butyldimethylsilyl)oxy)cyclohexyl)methoxy)-3-nitrobenzenesulfonamide [ka] Step 1: Ethyl 4-((tert-butyldimethylsilyl)oxy)cyclohexane-1-carboxylate [ka] To a solution of ethyl 4-hydroxycyclohexane-1-carboxylate (2 g, 11.61 mmol) in DMF (50 ml) was added tert-butylchlorodimethylsilane (1.575 g, 10.4 mmol) and imidazole (1.58 g, 23.22 mmol). The mixture was stirred at room temperature for 2 days. The mixture was concentrated. The residue was dissolved in DCM (200 ml), washed with brine, dried over Na2SO4, and concentrated. The residue was purified by chromatography on silica (eluent: EA / PE = 1 / 40) to give the product (2.32 g, 69.8%).
[0347] Step 2: (4-((tert-butyldimethylsilyl)oxy)cyclohexyl)methanol [ka] To a solution of ethyl 4-((tert-butyldimethylsilyl)oxy)cyclohexane-1-carboxylate (2.32 g, 8.1 mmol) in MTBE (50 mL) was added LAH (369 mg, 9.72 mmol). The mixture was stirred at reflux for 2 h. The mixture was quenched with MeOH (10 ml) at 0° C. The mixture was concentrated. The residue was purified by chromatography column on silica (eluent: EA / PE=1 / 2) to give the product (1.5 g, 75.8%) as a yellow oil. MS (ESI, m / e) [M+1] + 245.1
[0348] Step 3: 4-((4-((tert-butyldimethylsilyl)oxy)cyclohexyl)methoxy)-3-nitrobenzenesulfonamide [ka] To a solution of (4-((tert-butyldimethylsilyl)oxy)cyclohexyl)methanol (587 mg, 2.4 mmol) in THF (50 ml) was added NaH (576 mg, 14.4 mmol). The mixture was stirred at room temperature for 0.5 h. Next, 4-fluoro-3-nitrobenzenesulfonamide (370 mg, 1.68 mmol) was added to the mixture. The mixture was stirred at room temperature overnight. The mixture was poured into saturated aqueous NaHCO3 solution (200 mL), then adjusted to pH = 5-6 with HCl acid (1 M), and then extracted with ethyl acetate (200 mL × 3). The combined organic phases were washed with brine, dried over Na2SO4, and concentrated. The residue was purified by chromatography on silica (eluent: EA / PE = 1 / 2) to give the product as a yellow solid. MS (ESI, m / e) [M+1] + 445.1.
[0349] Intermediate 3-i: 4-((4-fluoro-1-(tetrahydrofuran-3-yl)piperidin-4-yl)methoxy)-3-nitrobenzenesulfonamide [ka] Step 1: tert-butyl 4-fluoro-4-((2-nitro-4-sulfamoylphenoxy)methyl)piperidine-1-carboxylate [ka] To a mixture of 4-fluoro-3-nitrobenzenesulfonamide (1 g, 4.54 mmol) and compound tert-butyl 4-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate (1.06 g, 4.54 mmol) in THF (20 mL) was added NaH (726.61 mg, 18.17 mmol, 60% purity) in one portion at 0 °C under N. The mixture was stirred at 15 °C for 14 h. TLC showed that the reaction was complete. 20 mL of saturated NH4Cl solution was added to the mixture, and the aqueous phase was extracted with ethyl acetate (20 mL × 3). The combined organic phase was washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by recrystallization in EtOAc (10 mL) to give tert-butyl 4-fluoro-4-((2-nitro-4-sulfamoylphenoxy)methyl)piperidine-1-carboxylate (1.17 g, 2.70 mmol, 59.4% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δppm:8.31(br s,1H), 8.06(br d,J=8.6Hz, 1H), 7.64-7.54(m,1H), 7.25(br s,2H), 4.48-4.33(m,2H), 3.84(br d,J=11.9Hz, 2H), 3.03(br s,2H), 1.97-1.84(m,2H), 1.82-1.61(m,2H), 1.41(d,J=2.9Hz, 9H).
[0350] Step 2: 4-((4-fluoropiperidin-4-yl)methoxy)-3-nitrobenzenesulfonamide [ka] To a mixture of tert-butyl 4-fluoro-4-((2-nitro-4-sulfamoylphenoxy)methyl)piperidine-1-carboxylate (1.17 g, 2.70 mmol) in EA under N was added HCl acid (4 M, 78.00 mL) in one portion at 15° C. The mixture was stirred at 15° C. for 12 h. TLC showed the reaction was complete. The mixture was concentrated under reduced pressure to give 4-((4-fluoropiperidin-4-yl)methoxy)-3-nitrobenzenesulfonamide (1 g, crude, HCl salt) as a yellow solid, which was used directly in the next step. 1 H NMR (400MHz, methanol-d4) δppm: 8.37 (d,J=2.3Hz, 1H), 8.12 (dd,J=2.4, 8.9Hz, 1H), 7.50( d,J=8.9Hz, 1H), 4.43(d,J=10.0Hz, 2H), 3.50-3.40(m,2H), 3.29-3.24(m,1H), 2.33(br dd,J=10.0, 12.8Hz, 2H), 2.23-2.10(m,2H).
[0351] Step 3: 4-((4-fluoro-1-(tetrahydrofuran-3-yl)piperidin-4-yl)methoxy)-3-nitrobenzenesulfonamide [ka] To a mixture of 4-((4-fluoropiperidin-4-yl)methoxy)-3-nitrobenzenesulfonamide (1 g, 2.70 mmol, HCl) and dihydrofuran-3(2H)-one (698.40 mg, 8.11 mmol) in MeOH (20 mL) was added NaBHCN (509.81 mg, 8.11 mmol) in one portion at 0 °C under N. The mixture was stirred at 15 °C for 12 h. LC-MS showed that the reaction was complete. The mixture was poured into saturated NaHCO (20 mL) solution, and the aqueous phase was extracted with ethyl acetate (20 mL × 3). The combined organic phases were washed with brine (30 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The mixture was dissolved in DCM and concentrated under reduced pressure to give a yellow solid. The crude product was purified by recrystallization from MTBE (15 mL) to give 4-((4-fluoro-1-(tetrahydrofuran-3-yl)piperidin-4-yl)methoxy)-3-nitrobenzenesulfonamide (0.666 g, 1.65 mmol, 61.05% yield, 96.19% purity) as a yellow solid. 1 H NMR (400MHz, methanol-d4) δppm: 8.34 (d,J=2.2Hz, 1H), 8.09 (dd,J=2.2, 8.8Hz, 1H), 7 .47(d,J=8.8Hz, 1H), 4.31(d,J=9.3Hz, 2H), 4.00-3.88(m,2H), 3.83-3.72(m,1H), 3.66(dd,J=7.0, 8.8Hz, 1H), 3.07(quin,J=7.2Hz, 1H), 2.90(d,J=11.0Hz, 1H), 2.7 1(d,J=11.8Hz, 1H), 2.46(q,J=11.8Hz, 2H), 2.20-1.80(m,6H).MS(ESI, m / e)[M+1] + 404.1.
[0352] Intermediate 3-j: 3-nitro-4-(((4-(oxetan-3-yl)morpholin-2-yl)methyl)amino)benzenesulfonamide [ka] Step 1: tert-butyl 2-(((2-nitro-4-sulfamoylphenyl)amino)methyl)morpholine-4-carboxylate [ka] To a solution of 4-fluoro-3-nitrobenzenesulfonamide (2.55 g, 11.56 mmol) in IPA (90 mL) at 55-60 °C was added Na2CO3 (735.09 mg, 6.94 mmol) and tert-butyl 2-(aminomethyl)morpholine-4-carboxylate (3 g, 13.87 mmol). The mixture was stirred at 55-65 °C for 4 h. TLC showed that 4-fluoro-3-nitrobenzenesulfonamide was completely consumed and one new spot was formed. The mixture was concentrated and extracted with EtOAc (30 mL × 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. tert-Butyl 2-(((2-nitro-4-sulfamoylphenyl)amino)methyl)morpholine-4-carboxylate (4.3 g, 10.33 mmol, 89.33% yield) was obtained as a yellow solid. The product was used directly in the next step. 1 H NMR (400MHz, CDCl3)δppm:8.78(d,J=2.2Hz, 1H), 8.61(br s,1H), 7.92(dd,J=2.1, 9.2Hz, 1H), 6.98(d,J=9.0Hz, 1H), 4.83(s,2H), 4.16-3.80(m ,3H), 3.74(t,J=3.4, 7.0, 10.5Hz, 1H), 3.65-3.47(m,2H), 3.46-3.37(m,1H), 3.01(br s,1H), 2.80(br s,1H), 1.48(s,9H).
[0353] Step 2: 4-((morpholin-2-ylmethyl)amino)-3-nitrobenzenesulfonamide [ka] A mixture of tert-butyl 2-(((2-nitro-4-sulfamoylphenyl)amino)methyl)morpholine-4-carboxylate (2.5 g, 6.00 mmol) in TFA (10 mL) and DCM (10 mL) was stirred at 25° C. for 1 h. TLC showed complete consumption of the reactants and the formation of one new spot. The reaction mixture was concentrated under reduced pressure to remove the solvent. 4-((morpholin-2-ylmethyl)amino)-3-nitrobenzenesulfonamide (2.5 g, crude) was obtained as a yellow oil, which was used directly in the next step. 1 H NMR (400MHz, DMSO-d6) δppm 8.57(br t,J=6.0Hz, 1H), 8.48(d,J=2.2Hz, 1H), 7.85(dd,J=2.1, 9.2Hz, 1H), 7.36(br s,1H), 7.30(d,J=9.2Hz, 1H), 4.08-3.89(m,2H), 3.77-3.61(m,2H), 3.61-3.51(m,1H), 3.34(br d,J=12.6Hz, 1H), 3.20(br d,J=12.6Hz, 1H), 3.01(br,1H), 2.90(m,1H).
[0354] Step 3: 3-nitro-4-(((4-(oxetan-3-yl)morpholin-2-yl)methyl)amino)benzenesulfonamide [ka] To a solution of 4-((morpholin-2-ylmethyl)amino)-3-nitrobenzenesulfonamide (600.00 mg, 1.90 mmol) and oxetan-3-one (410.05 mg, 5.69 mmol) in MeOH (60 mL) was added NaBHCN (357.58 mg, 5.69 mmol). The mixture was stirred at 15 °C for 14 h. LC-MS showed complete consumption of 4-((morpholin-2-ylmethyl)amino)-3-nitrobenzenesulfonamide and one major peak with the desired m / z. The reaction mixture was quenched by the addition of HO (10 mL), concentrated, and then extracted with EtOAc (10 mL × 3). The combined organic layers were washed with brine (10 mL), dried over NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was washed with EA (5 mL). 3-nitro-4-(((4-(oxetan-3-yl)morpholin-2-yl)methyl)amino)benzenesulfonamide (580 mg, 1.49 mmol, 78.76% yield) was obtained as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δppm:8.55(br t,J=5.5Hz, 1H), 8.47(d,J=2.0Hz, 1H), 7.84(dd,J=2.0, 9.0Hz, 1H), 7.34(s ,2H), 7.27(d,J=9.0Hz, 1H), 4.59-4.51(m,2H), 4.49-4.41(m,2H), 3.86(br d,J=11.0Hz, 1H), 3.75(br s,1H), 3.62-3.52(m,1H), 3.50-3.39(m,2H), 2.75(br d,J=11.0Hz, 1H), 2.57(br d,J=11.0Hz, 1H), 1.96(dt,J=2.9, 11.0Hz, 1H), 1.80(t,J=11.0Hz, 1H).MS(ESI, m / e)[M+1] + 373.1.
[0355] Intermediate 3-k: 4-(((4-cyclopropylmorpholin-2-yl)methyl)amino)-3-nitrobenzenesulfonamide [ka] To a solution of 4-((morpholin-2-ylmethyl)amino)-3-nitrobenzenesulfonamide (1 g, 3.16 mmol) in MeOH (30 mL) was added 4 Å molecular sieves (0.5 g, 9.48 mmol), AcOH (1.33 g, 22.13 mmol, 1.27 mL), (1-ethoxycyclopropoxy)trimethylsilane (2.76 g, 15.81 mmol, 3.18 mL), and NaBHCN (595.97 mg, 9.48 mmol). The mixture was stirred at 70 °C for 5 h. LC-MS showed complete consumption of 4-((morpholin-2-ylmethyl)amino)-3-nitrobenzenesulfonamide and one major peak with the desired m / z. The reaction mixture was concentrated, diluted with HO (20 mL), and extracted with EtOAc (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over NaSO, filtered, and concentrated under reduced pressure to give a residue, which was purified by column chromatography (eluent: PE / EA=10:1 to EA) to give 4-(((4-cyclopropylmorpholin-2-yl)methyl)amino)-3-nitrobenzenesulfonamide (300 mg, 25.82% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δppm:8.57(br t,J=5.4Hz, 1H), 8.47(d,J=2.2Hz, 1H), 7.84(dd,J=2.2, 9.1Hz, 1H), 7.35(s,2H), 7.28(d,J=9.3Hz, 1H), 3.83(br d,J=11.4Hz, 1H), 3.70-3.54(m,2H), 3.52-3.39(m,2H), 2.91(br d,J=10.5Hz, 1H), 2.73(br d,J=11.4Hz, 1H), 2.36-2.26(m,1H), 2.13(t,J=10.5Hz, 1H), 1.70-1.61(m,1H), 0.46-0.39(m,2H), 0.36-0.28(m,2H).MS(ESI, m / e)[M+1] + 357.1.
[0356] Intermediate 3-l: 3-nitro-4-(((1-(oxetan-3-yl)piperidin-4-yl)methyl)amino)benzenesulfonamide 2,2,2-trifluoroacetate [ka] Step 1: tert-butyl ((1-(oxetan-3-yl)piperidin-4-yl)methyl)carbamate [ka] To a solution of tert-butyl (piperidin-4-ylmethyl)carbamate (1 g, 4.67 mmol) in DCM (50 mL) was added oxetan-3-one (1.01 g, 14 mmol) and HOAc (0.2 mL). The mixture was stirred at room temperature for 2 hours. Then, NaBH(OAc) (2.967 g, 14 mmol) was added to the mixture. The mixture was stirred at room temperature overnight. The mixture was diluted with DCM (200 mL), washed with saturated aqueous NaHCO, brine (200 mL x 2), dried over NaSO, and concentrated. The residue was purified by chromatography on silica (eluent: MeOH / DCM = 1 / 20) to give the product (1.2 g, 95%) as a yellow oil. MS (ESI, m / e) [M+1] + 271.1.
[0357] Step 2: (1-(oxetan-3-yl)piperidin-4-yl)methanamine bis(2,2,2-trifluoroacetate) [ka] To a solution of tert-butyl ((1-(oxetan-3-yl)piperidin-4-yl)methyl)carbamate (1.2 g 4.44 mmol) in DCM (50 mL) was added TFA (15 mL). The mixture was stirred at room temperature overnight. The mixture was concentrated to give the product. The crude product was used directly in the next step.
[0358] Step 3: 3-nitro-4-(((1-(oxetan-3-yl)piperidin-4-yl)methyl)amino)benzenesulfonamide 2,2,2-trifluoroacetate [ka] To a solution of (1-(oxetan-3-yl)piperidin-4-yl)methanamine bis(2,2,2-trifluoroacetate) (1.77 g, 4.44 mmol) and 4-fluoro-3-nitrobenzenesulfonamide (1.026 g, 4.66 mmol) in THF (50 mL) was added triethylamine (2.24 g, 22.2 mmol). The mixture was stirred at room temperature overnight. The mixture was filtered to give the product (900 mg, 41.8%) as a yellow solid. MS (ESI, m / e) [M+1] + 371.1
[0359] Intermediate 3-m: (R)-4-(((1,4-dioxan-2-yl)methyl)amino)-3-nitrobenzenesulfonamide [ka] To a solution of (R)-(1,4-dioxan-2-yl)methanamine (450 mg, 2.93 mmol) in THF (50 mL) was added 4-fluoro-3-nitrobenzenesulfonamide (709.5 mg, 3.22 mmol) and triethylamine (1.48 g, 14.65 mmol). The mixture was stirred at room temperature for 4 hours. The reaction mixture was then filtered, and the precipitate was washed with petroleum to give the product (540 mg, 58%). MS (ESI, m / e) [M+1] + 318.0.
[0360] Intermediate 3-n: 4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide [ka] A solution of 4-fluoro-3-((trifluoromethyl)sulfonyl)benzenesulfonamide (469 mg, 1.53 mmol), (tetrahydro-2H-pyran-4-yl)methanamine (176 mg, 1.53 mmol), and EtN (232 mg, 2.3 mmol) was stirred at room temperature for 4 hours. After removal of the solvent, the resulting residue was dissolved in EA (100 mL), washed with brine (100 mL × 4), dried over anhydrous NaSO, filtered, and concentrated to give the crude product as a white solid (747 mg). MS (ESI, m / e) [M+1] 403.1.
[0361] Intermediate 3-o: 4-(((4-fluorotetrahydro-2H-pyran-4-yl)methyl)amino)-3-nitrobenzenesulfonamide [ka] Step 1: 1,6-Dioxaspiro[2.5]octane-2-carbonitrile To a solution of oxan-4-one (100 g, 1 mol) in tert-butanol (100 mL) was added 2-chloroacetonitrile (70 g, 0.93 mol). The resulting mixture was stirred at 25 °C for 30 min. After this, a solution of t-BuOK (120 g, 1.07 mol) in tert-butanol (1 L) was added dropwise with stirring over 40 min at 25 °C. The resulting mixture was stirred overnight at room temperature. After dilution with 200 mL of water and quenching with 40 mL of 10% hydrogen chloride, the resulting mixture was concentrated to one-third of its volume and then extracted with 3 × 400 mL of ether. The combined organic layers were washed with 500 mL of brine, dried over anhydrous sodium sulfate, and concentrated to give 84.5 g (crude) of 1,6-dioxaspiro[2.5]octane-2-carbonitrile as a yellow oil.
[0362] Step 2: 2-(4-fluorotetrahydro-2H-pyran-4-yl)-2-hydroxyacetonitrile To a solution of 1,6-dioxaspiro[2.5]octane-2-carbonitrile (169 g, 1.22 mol) in 1 L of dichloromethane was added 70% HF / Py (148 mL) dropwise at 0 °C. The resulting mixture was stirred at room temperature overnight. After dilution with 1000 mL of ethyl acetate, the reaction mixture was poured into NaHCO3 (saturated) and adjusted to pH ∼7 with solid NaHCO3 while stirring. The aqueous phase was extracted with 3 × 1000 mL of ethyl acetate, and the organic layers were combined and then washed with 850 mL of 1% hydrogen chloride and 1 × 1000 mL of brine. It was then dried over anhydrous sodium sulfate and concentrated to give 139 g (crude) of 2-(4-fluorooxan-4-yl)-2-hydroxyacetonitrile as a pale yellow oil.
[0363] Step 3: (4-Fluorotetrahydro-2H-pyran-4-yl)methanol To a solution of 2-(4-fluorooxan-4-yl)-2-hydroxyacetonitrile (109 g, 685.5 mmol) in i-propanol / HO (800 mL / 200 mL) was added NaBH (39.1 g, 1028.3 mmol) portionwise at 0 °C. The resulting mixture was stirred at 0 °C for 2 h, then quenched by the addition of 220 mL of acetone and stirred for an additional 1 h. The solid was filtered off and washed with 200 mL of ethyl acetate. The filtrate was concentrated and purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 3 / 1) to give 47.8 g of (4-fluorooxan-4-yl)methanol as a pale yellow oil.
[0364] Step 4: (4-Fluorotetrahydro-2H-pyran-4-yl)methyl methanesulfonate To a solution of (4-fluorooxan-4-yl)methanol (57.8 g, 431.3 mmol) and TEA (65.5 g, 647.0 mmol) in 500 mL of dichloromethane was added MsCl (73.2 g, 647.0 mmol) dropwise at 0 °C. The resulting mixture was stirred at room temperature for 2 h. After quenching with 500 mL of water, the resulting mixture was extracted with 2 × 500 mL of dichloromethane. The combined organic layers were dried over anhydrous sodium sulfate and concentrated to give 105.8 g (crude) of (4-fluorooxan-4-yl)methyl methanesulfonate as a yellow oil.
[0365] Step 5: 2-((4-fluorotetrahydro-2H-pyran-4-yl)methyl)isoindoline-1,3-dione To a solution of (4-fluorooxan-4-yl)methyl methanesulfonate (105.8 g, 499.1 mmol) in 1 L of DMF was added potassium 1,3-dioxo-2,3-dihydro-1H-isoindol-2-ide (138.5 g, 748.6 mmol). The resulting mixture was stirred at 140 °C overnight. After cooling to room temperature, the reaction mixture was poured into 3 L of water and then filtered. The filter cake was dried under reduced pressure to give 98 g (crude) of 2-((4-fluorotetrahydro-2H-pyran-4-yl)methyl)isoindoline-1,3-dione as an off-white solid.
[0366] Step 6: (4-Fluorotetrahydro-2H-pyran-4-yl)methanamine To a solution of 2-((4-fluorotetrahydro-2H-pyran-4-yl)methyl)isoindoline-1,3-dione (98 g, 372.6 mmol) in 1 L of EtOH was added NHNH.HO (111.8 g, 2.24 mol). The resulting mixture was stirred at 70 °C overnight. After cooling to room temperature, the reaction mixture was concentrated and then diluted with 1 L of DCM. After removing the solid by filtration, the filtrate was concentrated and purified by silica gel column chromatography (eluent: CHCl / MeOH = 100 / 1) to give 30.2 g of (4-fluorooxan-4-yl)methanamine as a pale yellow oil.
[0367] Step 7: 4-(((4-fluorotetrahydro-2H-pyran-4-yl)methyl)amino)-3-nitrobenzenesulfonamide To a solution of (4-fluorotetrahydro-2H-pyran-4-yl)methanamine (30 g, 225.6 mmol) and 4-fluoro-3-nitrobenzene-1-sulfonamide (41.4 g, 188.0 mmol) in 500 mL of i-PrOH was added Na2CO3 (12.0 g, 112.8 mmol). The resulting mixture was stirred at 60 °C for 2 hours, and a precipitate formed. After filtration, the filter cake was washed with 3 × 100 mL of water and then dried under infrared light to give 60.9 g of 4-[[(4-fluorooxan-4-yl)methyl]amino]-3-nitrobenzene-1-sulfonamide as a yellow solid.
[0368] Intermediate 3-p: 4-((((1r,4r)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrobenzenesulfonamide [ka] Step 1: 8-methyl-1,4-dioxaspiro[4.5]decan-8-ol To a stirred solution of CHMgBr (344.0 ml, 1.032 mol, 3 M in EtO) in dry toluene (2 L) was added dropwise a solution of 1,4-dioxaspiro[4.5]decan-8-one (70.0 g, 0.449 mol) in 350 ml of dry toluene. The resulting mixture was stirred at 5–10 °C for 2 h. The mixture was poured into saturated aqueous NHCl (3 L) and extracted with EtOAc (3 × 1 L). The combined organic phases were washed with brine (1.5 L), dried over NaSO, and concentrated to give 8-methyl-1,4-dioxaspiro[4.5]decan-8-ol (70.0 g, crude) as a white solid.
[0369] Step 2: 4-Hydroxy-4-methylcyclohexan-1-one To a stirred solution of 0.05 N HCl (1800 mL) was added 8-methyl-1,4-dioxaspiro[4.5]decan-8-ol (140.0 g, 0.814 mol). The mixture was stirred at 70 °C for 2.5 h. The resulting mixture was cooled to room temperature, and solid NaCl was added until saturated, followed by extraction with EtOAc (5 × 700 mL). The combined organic phases were dried over NaSO and concentrated to give 4-hydroxy-4-methylcyclohexan-1-one (105.0 g, crude) as a yellow oil.
[0370] Step 3: (S)-1-Methyl-4-(nitromethyl)cyclohex-3-en-1-ol To a stirred solution of 4-hydroxy-4-methylcyclohexan-1-one (105.0 g, 0.820 mol) in CH3NO2 (600.0 mL) was added N 1 ,N 1 -dimethylethane-1,2-diamine (7.216 g, 0.082 mol) was added. The mixture was stirred at 100° C. for 2 hours under a nitrogen atmosphere. After cooling to room temperature, the reaction mixture was concentrated and purified by silica gel column chromatography eluted with EA / PE=1 / 4 to give (S)-1-methyl-4-(nitromethyl)cyclohex-3-en-1-ol (96.0 g) as a yellow oil.
[0371] Step 4: (1r,4r)-1-methyl-4-(nitromethyl)cyclohexan-1-ol To a stirred solution of (S)-1-methyl-4-(nitromethyl)cyclohex-3-en-1-ol (96.0 g, 0.561 mol) in DCM (1.5 L) was added Crabtree's catalyst (6.8 g, 0.008 mmol). The mixture was stirred under an atmosphere of H (30 atm) at 50 °C overnight. After cooling to room temperature, the reaction mixture was filtered and concentrated to give (1r,4r)-1-methyl-4-(nitromethyl)cyclohexan-1-ol (100.0 g, crude) as a yellow oil.
[0372] Step 5: (1r,4r)-4-(aminomethyl)-1-methylcyclohexan-1-ol To a stirred solution of (1r,4r)-1-methyl-4-(nitromethyl)cyclohexan-1-ol (120.0 g, 0.694 mol) in MeOH (1.5 L) was added 10% wet Pd / C (30.0 g). The mixture was stirred under an atmosphere of H (30 atm) at 85 °C overnight. After cooling to room temperature, the reaction mixture was filtered and concentrated to give (1r,4r)-4-(aminomethyl)-1-methylcyclohexan-1-ol (95.0 g, crude) as a brown solid. 1 H NMR (300MHz, methanol-d4) δppm: 2.51(d,J=6.7Hz, 2H), 1.86-1.58(m,4H), 1.40-1.50(s,2H), 1.35-1.26(m,1H), 1.21(s,3H), 1.16-0.95(m,2H).
[0373] Step 6: 4-((((1r,4r)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrobenzenesulfonamide To a stirred solution of (1r,4r)-4-(aminomethyl)-1-methylcyclohexan-1-ol (100.0 g, 0.699 mol) in THF (1 L) was added 4-fluoro-3-nitrobenzenesulfonamide (107.6 g, 0.489 mol) and TEA (141.2 g, 1.389 mol). The mixture was stirred at room temperature overnight. The resulting mixture was diluted with water (500 mL) and extracted with EtOAc (3 × 800 mL). The combined organic phases were washed with brine (1 L), dried over anhydrous NaSO, and concentrated. The residue was purified three times by slurrying in EtOAc (800.0 mL) to give 4-((((1r,4r)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrobenzenesulfonamide (144.6 g) as a yellow solid. 1H NMR (300MHz, DMSO-d6) δppm:8.52(t,J=5.9Hz, 1H), 8.45(d,J=2.3Hz, 1H), 7.80(dd,J=9.2, 2.3Hz, 1H), 7.42-7.11(m,3H), 4.24(s,1H), 3 .31(t,J=6.3Hz, 2H), 1.66(d,J=11.5Hz, 3H), 1.53(d,J=12.7Hz, 2H), 1.31(td,J=12.4, 3.4Hz, 2H), 1.11-1.08(m,6H).MS(ESI, m / e)[M+1] + 343.9.
[0374] Intermediate 3-q1: (4-((((1s,4s)-4-hydroxy-4-(trifluoromethyl)cyclohexyl)methyl)amino)-3-nitrobenzenesulfonamide; [ka] Intermediate 3-q2: 4-((((1r,4r)-4-hydroxy-4-(trifluoromethyl)cyclohexyl)methyl)amino)-3-nitrobenzenesulfonamide [ka] Step 1: Ethyl 4-(trifluoromethyl)-4-((trimethylsilyl)oxy)cyclohexanecarboxylate To a solution of ethyl 4-oxocyclohexanecarboxylate (10 g, 58.75 mmol) in THF (100 mL) was added TMSCF (12.53 g, 88.13 mmol) and CsF (8.92 g, 58.75 mmol). The mixture was stirred at 20 °C for 6 h. TLC showed that the reactants were completely consumed. The reaction mixture was washed with saturated aqueous NaHCO (50 mL × 2) and extracted with ethyl acetate (50 mL × 3). The combined organic phases were washed with brine (50 mL × 2), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, eluent: PE / EA = 100 / 1 to 2 / 1). Ethyl 4-(trifluoromethyl)-4-((trimethylsilyl)oxy)cyclohexanecarboxylate (8.12 g) was obtained as a yellow oil. 1H NMR (400MHz, CDCl3)δppm:4.15(q,J=7.1Hz, 2H), 2.20-2.66(m,1H), 1.98-2.08(m,1H), 1.6 3-1.95(m,6H), 1.53(td,J=13.4, 4.2Hz, 1H), 1.27(t,J=7.1Hz, 3H), 0.17(d,J=4.5Hz, 9H).
[0375] Step 2: (4-(trifluoromethyl)-4-((trimethylsilyl)oxy)cyclohexyl)methanol To a solution of ethyl 4-(trifluoromethyl)-4-((trimethylsilyl)oxy)cyclohexanecarboxylate (8.10 g, 25.93 mmol) in THF (50 mL) was added LAH (1.97 g, 51.86 mmol) at 0 °C, and the mixture was stirred at 0 °C for 2 h. TLC showed that the reactants were completely consumed. The reaction mixture was quenched by the addition of water (15 mL) and then extracted with ethyl acetate (50 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product (6.2 g, crude) was used in the next step without further purification.
[0376] Step 3: (4-(trifluoromethyl)-4-((trimethylsilyl)oxy)cyclohexyl)methyl methanesulfonate To a solution of (4-(trifluoromethyl)-4-((trimethylsilyl)oxy)cyclohexyl)methanol (6.2 g, 22.93 mmol) and TEA (4.64 g, 45.86 mmol) in DCM (60 mL) was added MsCl (5.91 g, 51.60 mmol) at 0 °C, and the mixture was stirred at 0 °C for 2 h. TLC showed that the reactants were completely consumed. The reaction mixture was washed with saturated aqueous NaHCO (50 mL × 2) and extracted with DCM (50 mL × 2). The combined organic phases were washed with brine (50 mL × 2), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The crude product (8.52 g, crude) was used in the next step without further purification.
[0377] Step 4: ((4-(azidomethyl)-1-(trifluoromethyl)cyclohexyl)oxy)trimethylsilane To a solution of (4-(trifluoromethyl)-4-((trimethylsilyl)oxy)cyclohexyl)methyl methanesulfonate (8.51 g, 24.42 mmol) in DMF (150 mL) was added NaN (7.94 g, 122.11 mmol) at 20 °C, and the mixture was stirred at 50 °C for 12 h. TLC showed that the reactants were completely consumed. The mixture was diluted with water, extracted with MTBE (100 mL × 3), dried over anhydrous NaSO, and filtered. The combined organic layers were concentrated to give the crude product, which was used directly in the next step.
[0378] Step 5: (4-(trifluoromethyl)-4-((trimethylsilyl)oxy)cyclohexyl)methanamine To a mixture of ((4-(azidomethyl)-1-(trifluoromethyl)cyclohexyl)oxy)trimethylsilane (7.21 g, theoretical yield) in CHOH (50 mL) was added Pd / C (2.5 g), and the mixture was stirred under H (30 psi) at 30° C. for 16 h. TLC showed complete consumption of the reactants. The mixture was filtered and concentrated under reduced pressure. (4-(trifluoromethyl)-4-((trimethylsilyl)oxy)cyclohexyl)methanamine (4.67 g, crude) was obtained as a yellow oil. The crude product was used in the next step without further purification.
[0379] Step 6: 4-(((4-hydroxy-4-(trifluoromethyl)cyclohexyl)methyl)amino)-3-nitrobenzenesulfonamide To a solution of 4-fluoro-3-nitrobenzenesulfonamide (2.50 g, 11.35 mmol) and (4-(trifluoromethyl)-4-((trimethylsilyl)oxy)cyclohexyl)methanamine (4.59 g, 17.04 mmol) in DMF (75 mL) was added DIPEA (2.94 g, 22.74 mmol), and the mixture was stirred at 55 °C for 2 h. TLC showed that the reactants were completely consumed. The reaction mixture was washed with water (200 mL) and extracted with EA (100 mL × 3). The combined organic phases were washed with brine (50 mL × 2), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The residue was washed with PE / EA = 5 / 1 (30 mL) and filtered. The filter cake was purified by preparative HPLC (neutral). 4-((((1s,4s)-4-hydroxy-4-(trifluoromethyl)cyclohexyl)methyl)amino)-3-nitrobenzenesulfonamide (intermediate 3-q1, retention time: 2.5 minutes) (1.04 g) was obtained as a yellow solid. 1H NMR (400MHz, methanol-d4) δppm:8.65(d,J=1.9Hz, 1H), 8.49(t,J=4.7Hz, 1H), 7.91(dd,J=9.1, 1.63Hz, 1H), 7.17(d,J =9.3Hz, 1H), 3.46(t,J=6.3Hz, 2H), 2.06(d,J=4.1Hz, 1H), 1.84-2.00(m,4H), 1.52-1.70(m,4H).MS(ESI, m / e)[M-1] - 396.0; 4-((((1r,4r)-4-hydroxy-4-(trifluoromethyl)cyclohexyl)methyl)amino)-3-nitrobenzenesulfonamide (intermediate 3-q2, retention time: 2.6 minutes) (842 mg) was obtained as a yellow solid. 1 H NMR (400MHz, methanol-d4) δppm:8.65(d,J=1.9Hz, 1H), 8.54(t,J=5.2Hz, 1H), 7.90(dd,J=9.1, 1.6Hz, 1H), 7.17(d,J=9.3H) z, 1H), 3.33-3.41(m,2H), 1.24(s,1H), 1.87(d,J=12.5Hz, 2H), 1.71-1.82(m,3H), 1.42-1.69(m,4H).MS(ESI, m / e)[M-1] - 396.0.
[0380] Intermediate 3-r: 4-(((3-oxabicyclo[3.1.0]hexan-6-yl)methyl)amino)-3-nitrobenzenesulfonamide [ka] Step 1: Ethyl 3-oxabicyclo[3.1.0]hexane-6-carboxylate To a solution of 2,5-dihydrofuran (10 g, 142.67 mmol) and ethyl 2-diazoacetate (32.56 g, 285.35 mmol) in DCM (250 mL) was added Rh(AcO) (63.06 mg, 2.85 mmol). The mixture was stirred at 20 °C for 12 h. TLC showed complete consumption of the reactants. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative MPLC to give ethyl 3-oxabicyclo[3.1.0]hexane-6-carboxylate (10.0 g). 1 H NMR (400MHz, CDCl3) δppm: 4.08-4.16(m,2H), 3.92(d,J=8.6Hz, 2H), 3.74(d,J=8.4Hz, 2H), 2.13-2.17(m,2H), 1.59(t,J=3.1Hz, 1H), 1.23-1.28(m,3H).
[0381] Step 2: 3-oxabicyclo[3.1.0]hexan-6-ylmethanol To a solution of ethyl 3-oxabicyclo[3.1.0]hexane-6-carboxylate (10 g, 64.03 mmol) in THF (50 mL) was added LiAlH (2.43 g, 64.03 mmol) at 0 °C. The mixture was stirred at 0 °C for 4 h. TLC showed that the reactants were completely consumed. The reaction mixture was poured into HO (30 mL), extracted with EA (30 mL × 3), dried over NaSO, filtered, and concentrated. 3-oxabicyclo[3.1.0]hexane-6-ylmethanol (7.0 g, crude) was obtained, which was used in the next step without further purification.
[0382] Step 3: 3-oxabicyclo[3.1.0]hexan-6-ylmethyl methanesulfonate To a solution of 3-oxabicyclo[3.1.0]hexan-6-ylmethanol (7.0 g, 61.33 mmol) in DCM (100 mL) was added MsCl (21.08 g, 183.98 mmol) and TEA (24.82 g, 245.31 mmol). The mixture was stirred at 25 °C for 5 h. TLC showed complete consumption of the reactants. The reaction mixture was quenched with aqueous NH4Cl (30 mL), extracted with EA (30 mL × 3), dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography (SiO2, PE / EA = 100 / 1 to 30 / 1). 3-oxabicyclo[3.1.0]hexan-6-ylmethyl methanesulfonate (3.5 g) was obtained. 1 H NMR (400MHz, CDCl3) δppm: 4.15(d,J=7.5Hz, 2H), 3.90(d,J=8.4Hz, 2H), 3.71(d,J=8.4Hz, 2H), 3.03(s,3H), 1.69-1.72(m,2H), 1.21-1.29(m,1H).
[0383] Step 4: 6-(azidomethyl)-3-oxabicyclo[3.1.0]hexane To a solution of 3-oxabicyclo[3.1.0]hexan-6-ylmethyl methanesulfonate (2 g, 10.4 mmol) in DMF (20 mL) was added NaN (676.37 mg, 10.4 mmol). The mixture was stirred at 50 °C for 12 h. TLC showed that the reactants were completely consumed. The reaction mixture was poured into H O (30 mL), extracted with EA (30 mL × 3), dried over Na SO , filtered, and concentrated. The crude product was used directly in the next step.
[0384] Step 5: 3-oxabicyclo[3.1.0]hexan-6-ylmethanamine To a solution of 6-(azidomethyl)-3-oxabicyclo[3.1.0]hexane (1.4 g, 10.06 mmol) in DMF (15 mL) was added Pd / C (0.7 g, 1.006 mmol). The mixture was stirred at 25° C. under H atmosphere (15 Psi) for 2 h. LC / MS showed complete consumption of the reactants and one major peak with the desired mass signal. The reaction mixture was filtered and used directly in the next step. MS (ESI, m / e) [M+1] + 114.0.
[0385] Step 6: 4-(((3-oxabicyclo[3.1.0]hexan-6-yl)methyl)amino)-3-nitrobenzenesulfonamide To a solution of 4-fluoro-3-nitrobenzenesulfonamide (1.5 g, 6.8 mmol) and 3-oxabicyclo[3.1.0]hexan-6-ylmethanamine (1 g, 8.84 mmol) in DMF (15 mL) was added DIEA (1.76 g, 13.6 mmol). The mixture was stirred at 60 °C for 2 h. LC / MS showed complete consumption of 4-fluoro-3-nitrobenzenesulfonamide and one major peak with the desired mass signal. The reaction mixture was cooled to room temperature and poured into HO (50 mL) with stirring. The precipitate was filtered, and the cake was washed with MTBE (10 mL) and dried under reduced pressure. 4-((3-oxabicyclo[3.1.0]hexan-6-ylmethyl)amino)-3-nitrobenzenesulfonamide (758 mg) was obtained. 1 H NMR (400MHz, DMSO-d6) δppm: 8.59(br,1H), 8.47(s,1H), 7.84(d,J=8.8Hz, 1H), 7.37(s,2H), 7.28(d,J=9.2Hz , 1H), 3.72(d,J=8.2Hz, 2H), 3.55(d,J=7.9Hz, 2H), 3.36(s,2H), 1.71(s,2H), 1.05(s,1H).MS(ESI, m / e)[M+1] + 314.0.
[0386] Example A1: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-4'-(2-phenylpyrrolidin-1-yl)-[1,1'-biphenyl]-4-carboxamide [ka] Step 1: 1-(4-bromophenyl)-2-phenylpyrrolidine [ka] To a degassed solution of 2-phenylpyrrolidine (588 mg, 4 mmol), 1-bromo-4-iodobenzene (1.132 g, 16 mmol), BINAP (497 mg, 0.8 mmol), and K-OtBu (1.2 g, 12 mmol) in toluene (25 mL) was added Pd(dba) (366 mg, 0.4 mmol). Nitrogen was bubbled through the mixture for 5 minutes, then heated to 90 °C and stirred overnight. After cooling to room temperature, the reaction mixture was washed successively with water and brine. The organic layer was dried over anhydrous NaSO, filtered, concentrated, and purified by column chromatography using 5%-20% EA / PE as the eluent to give 1-(4-bromophenyl)-2-phenylpyrrolidine (750 mg, 62%) as a colorless oil. MS (ESI, m / e) [M+1] + 302.0, 304.1.
[0387] Step 2: tert-butyl-3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-phenylpyrrolidin-1-yl)-[1,1'-biphenyl]-4-carboxylate [ka] Under a nitrogen atmosphere, a mixture of 1-(4-bromophenyl)-2-phenylpyrrolidine (525 mg, 1.74 mmol), tert-butyl 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (985 mg, 2.26 mmol), Pd(dppf)Cl (128 mg, 0.174 mmol), and KCO (480 mg, 3.48 mmol) in 1,4-dioxane / HO (50 mL / 10 mL) was heated to 90 °C with stirring overnight. After cooling to room temperature, the reaction mixture was washed successively with water and brine. The organic layer was dried over anhydrous Na2SO4, then filtered, concentrated, and purified by column chromatography using 10%-50% EA / PE as eluent to give tert-butyl-3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-phenylpyrrolidin-1-yl)-[1,1'-biphenyl]-4-carboxylate (530 mg, 57.4%) as a white foam. MS (ESI, m / e) [M+1] + 532.3.
[0388] Step 3: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-phenylpyrrolidin-1-yl)-[1,1'-biphenyl]-4-carboxylic acid [ka] To a solution of tert-butyl-3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-phenylpyrrolidin-1-yl)-[1,1'-biphenyl]-4-carboxylate (531 mg, 1 mmol) in dichloromethane (25 mL) was added trifluoroacetic acid (5 mL). The reaction was stirred at room temperature overnight. The solvent was then removed under reduced pressure, and the resulting residue was purified by column chromatography on silica gel using 5% methanol / dichloromethane to give 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-phenylpyrrolidin-1-yl)-[1,1'-biphenyl]-4-carboxylic acid (400 mg, 84.2%) as a white foam. MS (ESI, m / e) [M+1] + 476.2.
[0389] Step 4: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-4'-(2-phenylpyrrolidin-1-yl)-[1,1'-biphenyl]-4-carboxamide [ka] To a solution of 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-phenylpyrrolidin-1-yl)-[1,1'-biphenyl]-4-carboxylic acid (95 mg, 0.2 mmol) in dichloromethane (25 mL) was added HATU (114 mg, 0.3 mmol) and trimethylamine (0.2 mL). The mixture was stirred at room temperature for 0.5 h. Then, 3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide (126 mg, 0.4 mmol) was added. After stirring overnight at room temperature, the reaction mixture was washed with water (10 mL), and the organic layer was dried over anhydrous NaSO and then concentrated under reduced pressure. The residue was further purified by preparative HPLC to give the desired compound. 1H NMR (400MHz, DMSO-d6) δppm: 12.16(s,1H), 11.68(s,1H), 8.57(s,1H), 8.54(s,1H), 8.03(s,1H), 7.80(d,J =8.6Hz, 1H), 7.59-7.46(m,3H), 7.33-7.25(m,5H), 7.20-7.14(m,3H), 7.08(d,J=8.1Hz, 1H), 6.89(s,1H), 6.42(d,J=8.5Hz, 2H), 6.37(s,1H), 4.78(d,J=7.4Hz, 1H), 3.84(d,J=8.4Hz, 2H), 3.68(s,1H), 3.31-3.20( m,3H), 2.37-2.34(m,1H), 1.94-1.80(m,4H), 1.60(d,J=12.0Hz, 2H), 1.38-1.14(m,4H).MS(ESI, m / e)[M+1] + 773.3
[0390] Example A2: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-(4-chlorophenyl)pyrrolidin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-[1,1'-biphenyl]-4-carboxamide [ka] Following a similar procedure as in Example A1, the desired compound was synthesized starting from 2-(4-chlorophenyl)pyrrolidine and 1-bromo-4-iodobenzene. 1H NMR (400MHz, DMSO-d6) δppm: 12.16(s,1H), 11.70(s,1H), 8.60(s,1H), 8.56(s,1H), 8.05(d,J=2.2Hz, 1H), 7.82(d ,J=8.4Hz, 1H), 7.59(s,1H), 7.57-7.48(m,2H), 7.34-7.28(m,5H), 7.18(d,J=8.3Hz, 2H), 7.12(d,J=9.3Hz, 1H), 6. 89(s,1H), 6.41(d,J=8.6Hz, 2H), 6.38(s,1H), 4.78(d,J=7.1Hz, 1H), 3.84(d,J=8.4Hz, 2H), 3.67(t,J=7.1Hz, 1H) , 3.30-3.18(m,4H), 2.37(m,1H), 2.00-1.69(m,4H), 1.60(d,J=12.4Hz, 2H), 1.34-1.13(m,3H).MS(ESI, m / e)[M+1] + 807.1
[0391] Example A3: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-(3-chlorophenyl)pyrrolidin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-[1,1'-biphenyl]-4-carboxamide [ka] Following a similar procedure as in Example A1, the desired compound was synthesized starting from 2-(3-chlorophenyl)pyrrolidine and 1-bromo-4-iodobenzene. 1H NMR (400MHz, DMSO-d6) δppm: 12.17(s,1H), 11.70(s,1H), 8.59(s,1H), 8.57(s,1H), 8.05(s,1H), 7.83( d,J=9.0Hz, 1H), 7.60(s,1H), 7.55-7.51(m,2H), 7.36-7.21(m,6H), 7.13(d,J=8.4Hz, 2H), 6.91(s,1H), 6.43(d,J=8.4Hz, 2H), 6.39(s,1H), 4.80(d,J=7.7Hz, 1H), 3.85(d,J=9.9Hz, 2H), 3.70(s,1H), 3.31-3.1 8(m,4H), 2.36-2.31(m,1H), 1.94-1.79(m,4H), 1.60(d,J=12.5Hz, 2H), 1.25(m,3H).MS(ESI, m / e)[M+1] + 807.1
[0392] Example A4: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-(2-chlorophenyl)pyrrolidin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-[1,1'-biphenyl]-4-carboxamide [ka] Following a similar procedure as in Example A1, the desired compound was synthesized starting from 2-(2-chlorophenyl)pyrrolidine and 1-bromo-4-iodobenzene. 1H NMR (400MHz, DMSO-d6) δppm: 12.17(s,1H), 11.70(s,1H), 8.61(s,1H), 8.57(s,1H), 8.05(s,1H), 7.8 3(d,J=9.4Hz, 1H), 7.60-7.41(m,4H), 7.35-7.30(m,3H),7.25-7.12(m,3H), 7.00(d,J=7.7Hz, 1H), 6. 90(s,1H), 6.48-6.27(m,3H), 4.97(d,J=7.4Hz, 1H), 3.85(d,J=11.3Hz, 2H), 3.74(s,1H), 3.31-3.19( m,4H), 2.43-2.35(m,1H), 1.99-1.83(m,4H), 1.60(d,J=12.5Hz, 2H), 1.23(s,3H).MS(ESI, m / e)[M+1] + 807.1.
[0393] Example A4a: (S)-3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-(2-chlorophenyl)pyrrolidin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-[1,1'-biphenyl]-4-carboxamide; Example A4b: (R)-3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-(2-chlorophenyl)pyrrolidin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-[1,1'-biphenyl]-4-carboxamide [ka] The two enantiomers, A4a (faster isomer) and A4b (slower isomer), were separated by chiral preparative HPLC. The chiral separation conditions are shown below. The faster enantiomer eluted at a retention time of 1.1 minutes and yielded 252 mg of product. The slower enantiomer eluted at a retention time of 1.8 minutes and yielded 238 mg of product. The absolute configuration of the fast enantiomer was confirmed to be S by co-crystallization of Bcl2 with A4a. See the section "Protein Purification and Co-Crystallization of Bcl2 with A4a."
[0394] [Table 2]
[0395] Example A5: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-3'-chloro-4'-(2-(2-chlorophenyl)pyrrolidin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-[1,1'-biphenyl]-4-carboxamide [ka] The desired compound was synthesized according to a similar procedure as in Example A1, starting from 2-(2-chlorophenyl)pyrrolidine and 4-bromo-2-chloro-1-iodobenzene. 1H NMR (400MHz, DMSO-d6) δppm: 12.32(s,1H), 11.70(s,1H), 8.61(t,J=5.7Hz, 1H), 8.55(d,J=2.0Hz, 1H), 8.03( d,J=2.4Hz, 1H), 7.82(d,J=7.6Hz, 1H), 7.62-7.46(m,4H), 7.44-7.34(m,2H), 7.33-7.22(m,2H), 7.22-7.15(m ,2H), 7.12(d,J=9.4Hz, 1H), 6.99(s,1H), 6.71(d,J=8.8Hz, 1H), 6.37(s,1H), 5.20(t,J=7.6Hz, 1H), 4.16(m,1 H), 3.84(d,J=8.4Hz, 2H), 3.45-3.11(m,5H), 2.10-1.80(m,3H), 1.63(m,2H), 1.24(m,4H).MS(ESI, m / e)[M+1] + 841.1.
[0396] Example A6: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-4'-(2-phenylpyrrolidin-1-yl)-3'-(trifluoromethyl)-[1,1'-biphenyl]-4-carboxamide [ka] Step 1: 1-(4-bromo-2-(trifluoromethyl)phenyl)-2-phenylpyrrolidine [ka] A mixture of 2-phenylpyrrolidine (1.46 g, 10 mmol), 4-bromo-1-fluoro-2-(trifluoromethyl)benzene (4.8 g, 20 mmol), and N,N-diisopropylethylamine (2.5 g, 20 mmol) in dimethyl sulfoxide (50 mL) was heated to 150 °C in a sealed tube with stirring overnight. The mixture was cooled and poured into water (100 mL). The mixture was then extracted with EA (50 mL × 3), and the organics were washed with water, brine, and dried over anhydrous NaSO. The solvent was removed under reduced pressure, and the residue was purified by petroleum column chromatography to give 1-(4-bromo-2-(trifluoromethyl)phenyl)-2-phenylpyrrolidine (180 mg, 4.9%) as a brown oil.
[0397] The desired compound was then synthesized from 1-(4-bromo-2-(trifluoromethyl)phenyl)-2-phenylpyrrolidine according to the following procedure similar to that in Example A1. 1 H NMR (400MHz, DMSO-d6) δppm: 12.32(s,1H), 11.66(s,1H), 8.56-8.53(m,2H), 8.01(s,1H), 7.78(s,1H), 7.66 (s,1H), 7.61-7.42(m,4H), 7.39(d,J=8.0Hz, 1H), 7.30(d,J=7.2Hz, 2H), 7.23(t,J=7.2Hz, 2H), 7.1-7.00(m, 4H), 6.35(s,1H), 4.87(d,J=9.4Hz, 1H), 4.02-3.64(m,3H), 3.26-3.22(m,4H), 2.43-2.31(m,1H), 2.00-1.98 (m,1H), 1.93-1.81(m,2H), 1.72-1.67(m,1H), 1.60(d,J=12.0Hz, 2H), 1.29-1.19(m,3H).MS(ESI, m / e)[M+1] + 841.1.
[0398] Example A7: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-4'-(2-(3-(trifluoromethyl)phenyl)pyrrolidin-1-yl)-[1,1'-biphenyl]-4-carboxamide [ka] The desired compound was synthesized following a similar procedure as in Example A1, starting from 2-(3-(trifluoromethyl)phenyl)pyrrolidine and 1-bromo-4-iodobenzene. 1 H NMR (400MHz, DMSO-d6) δppm: 12.17(s,1H), 11.70(s,1H), 8.61(s,1H), 8.56(s,1H), 8.05(d,J=2.0 Hz, 1H), 7.82(d,J=9.2Hz, 1H), 7.64-7.42(m,7H), 7.33(dd,J=14.2, 8.5Hz, 3H), 7.13(d,J=9.2Hz, 1 H), 6.90(s,1H), 6.56-6.31(m,3H), 4.90(d,J=7.4Hz, 1H), 3.84(d,J=8.5Hz, 2H), 3.73(t,J=7.1Hz, 1H), 3.31-3.22(m,5H), 2.05-1.77(m,5H), 1.60(d,J=12.1Hz, 2H), 1.28(s,2H).MS(ESI, m / e)[M+1] + 841.1.
[0399] Example A8: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-[1,1'-biphenyl]-4-carboxamide [ka] The desired compound was synthesized from 2-(2-cyclopropylphenyl)pyrrolidine and 1-bromo-4-iodobenzene according to the following procedure similar to that in Example A1.1 H NMR (400MHz, CDCl3) δppm: 10.31(s,1H), 9.14(s,1H), 8.93(d,J=2.0Hz, 1H), 8.5 4(t,J=5.2Hz, 1H), 8.24(d,J=2.0Hz, 1H), 8.19(d,J=7.6Hz, 1H), 8.09(d,J=8.6H z, 1H), 7.71(d,J=2.0Hz, 1H), 7.45-7.41(m,1H), 7.29(s,1H), 7.20(d,J=8.6Hz, 2H), 7.12(t,J=7.6Hz, 1H), 7.04-6.98(m,2H), 6.93(d,J=8.6Hz, 2H), 6.81(s,1H) ), 6.53(s,1H), 6.36(d,J=8.6Hz, 2H), 5.20(d,J=8.0Hz, 1H), 4.03(dd,J=11.0, 3 .6Hz, 2H), 3.70(t,J=7.1Hz, 1H), 3.50-3.41(m,3H), 3.27(t,J=6.0Hz, 2H), 2.47 -2.37(m,1H), 2.04-1.90(m,7H), 1.76-1.71(m,2H), 1.63(s,4H), 1.50-1.36(m, 2H), 1.04-0.94(m,2H), 0.84-0.80(m,1H), 0.72-0.68(m,1H).MS(ESI, m / e)[M+1] + 813.1.
[0400] Example A8a and Example A8b: (R or S)-3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-[1,1'-biphenyl]-4-carboxamide or (S or R)-3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-(2-cyclopropylphenyl)pyrrolidin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-[1,1'-biphenyl]-4-carboxamide [ka] The two enantiomers, A8a (faster isomer) and A8b (slower isomer), were separated by chiral preparative HPLC. The chiral separation conditions are shown below. The faster enantiomer eluted at a retention time of 3.9 minutes, yielding 231 mg of product. The slower enantiomer eluted at a retention time of 4.7 minutes, yielding 219 mg of product.
[0401] [Table 3]
[0402] Example A9: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-4'-(2-(4-(trifluoromethyl)phenyl)pyrrolidin-1-yl)-[1,1'-biphenyl]-4-carboxamide [ka] Following a similar procedure as in Example A1, the desired compound was synthesized starting from 2-(4-(trifluoromethyl)phenyl)pyrrolidine and 1-bromo-4-iodobenzene. 1H NMR (400MHz, DMSO-d6) δppm: 12.17(s,1H), 11.70(s,1H), 8.60(s,1H), 8.56(s,1H), 8.04(s,1H), 7.82(d,J=8.2Hz, 1H), 7.64(d,J =8.0Hz, 2H), 7.58(s,1H), 7.53(d,J=8.2Hz, 1H), 7.50(s,1H), 7.39(d,J=8.0Hz, 2H), 7.33(d,J=8.2Hz, 1H), 7.30(d,J=8.5Hz, 2H), 7.12(d,J=8.2Hz, 1H), 6.89(s,1H), 6.43(d,J=8.5Hz, 2H), 6.38(s,1H), 4.89(d,J=7.7Hz, 1H), 3.84(d,J=8.3Hz, 2H), 3.71(t,J=7 .4Hz, 1H), 3.43-3.19(m,5H), 2.46-2.35(m,1H), 2.05-1.76(m,4H), 1.60(d,J=12.4Hz, 2H), 1.29-1.20(m,2H).MS(ESI, m / e)[M+1] + 841.1.
[0403] Example A10: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-(3-cyclopropylphenyl)pyrrolidin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-[1,1'-biphenyl]-4-carboxamide [ka] 2-(3-Cyclopropylphenyl)pyrrolidine was prepared by the same procedure as that of 2-(2-cyclopropylphenyl)pyrrolidine. The desired compound was then synthesized from 2-(3-cyclopropylphenyl)pyrrolidine and 1-bromo-4-iodobenzene according to the following procedure similar to that in Example A1. 1H NMR (400MHz, DMSO-d6) δppm: 11.55(s,1H), 8.39(s,1H), 8.34(t,J=5.6Hz, 1H), 7.95(s,1H), 7.64(d,J=8.0Hz, 1H), 7.57(d,J=8.0Hz, 1H), 7 .41(s,1H), 7.34(s,1H), 7.30(d,J=8.4Hz, 2H), 7.25(d,J=8.0Hz, 1H), 7.13(t,J=7.5Hz, 1H), 6.95(s,1H), 6.93(s,1H), 6.89(d,J=8.0Hz, 1 H), 6.85-6.77(m,2H), 6.42(d,J=8.4Hz, 2H), 6.29(s,1H), 4.72(d,J=8.0Hz, 1H), 3.83(d,J=8.0Hz, 2H), 3.67(s,1H), 3.25-3.23(m,3H), 2. 41-2.27(m,1H), 1.93-1.78(m,6H), 1.60(d,J=8.0Hz, 2H), 1.29-1.17(m,3H), 0.89(d,J=8.0Hz, 2H), 0.64-0.57(m,2H).MS(ESI, m / e)[M+1] + 813.1.
[0404] Example A11: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-4'-(2-(o-tolyl)pyrrolidin-1-yl)-[1,1'-biphenyl]-4-carboxamide [ka] Following a similar procedure as in Example A1, the desired compound was synthesized starting from 2-(o-tolyl)pyrrolidine and 1-bromo-4-iodobenzene. 1H NMR (400MHz, DMSO-d6) δppm: 11.54(s,1H), 8.39(s,1H), 8.34(t,J=5.5Hz, 1 H), 7.95(d,J=2.1Hz, 1H), 7.65(d,J=9.1Hz, 1H), 7.56(d,J=8.0Hz, 1H), 7.41 (s,1H), 7.35(d,J=2.1Hz, 1H), 7.29(d,J=8.5Hz, 2H), 7.23(d,J=8.0Hz, 1H), 7.18(d,J=8.0Hz, 1H), 7.09(t,J=7.3Hz, 1H), 7.02(t,J=7.3Hz, 1H), 6.89(s, 1H), 6.87(d,J=8.0Hz, 1H), 6.83(d,J=9.1Hz, 1H), 6.35(d,J=8.5Hz, 2H), 6.3 0(d,J=2.1Hz, 1H), 4.86(d,J=8.0Hz, 1H), 3.83(d,J=8.0Hz, 2H), 3.75-3.71( m,1H), 3.25-3.23(m,3H), 3.17(s,1H), 2.38(s,3H), 2.04-1.80(m,3H), 1.74 -1.71(m,1H), 1.60(d,J=12.0Hz, 2H), 1.28-1.20(m,4H).MS(ESI, m / e)[M+1] + 787.1.
[0405] Example A12: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-(2-isopropylphenyl)pyrrolidin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-[1,1'-biphenyl]-4-carboxamide [ka] The desired compound was synthesized according to the following procedure similar to that in Example A1, starting from 2-(2-isopropylphenyl)pyrrolidine and 1-bromo-4-iodobenzene. 1H NMR (400MHz, DMSO-d6) δppm: 12.16(s,1H), 11.70(s,1H), 8.61(s,1H), 8.56(s,1H), 8.04(s,1H), 7.82(d,J=8.5H z, 1H), 7.50-7.58(m,3H), 7.29-7.35(m,4H), 7.24-7.06(m,2H), 6.98(t,J=7.3Hz, 1H), 6.91(s,1H), 6.82(d,J=7 .6Hz, 1H), 6.35-6.37(m,3H), 4.99(d,J=7.9Hz, 1H), 3.84(d,J=8.5Hz, 2H), 3.70(t,J=7.9Hz, 1H), 3.18-3.38(m, 5H), 3.01(s,1H), 2.04-1.82(m,4H), 1.70(s,1H), 1.60(d,J=12.2Hz, 2H), 1.27-1.23(m,8H).MS(ESI, m / e)[M+1] + 815.2.
[0406] Example A13: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-([1,1'-biphenyl]-2-yl)pyrrolidin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-[1,1'-biphenyl]-4-carboxamide [ka] The desired compound was synthesized according to the following procedure similar to that in Example A1, starting from 2-([1,1'-biphenyl]-2-yl)pyrrolidine and 1-bromo-4-iodobenzene. 1H NMR (400MHz, DMSO-d6) δppm: 12.16(s,1H), 11.62(s,1H), 8.48(s,2H), 8.00(s,1H), 7.73(s,1H) , 7.62-7.35(m,8H), 7.35-7.13(m,7H), 7.10(s,1H), 6.90(s,1H), 6.33(d,J=8.4Hz, 3H), 4.61(d ,J=7.8Hz, 1H), 3.84(d,J=9.9Hz, 2H), 3.70(s,1H), 3.26(m,4H), 2.98(s,1H), 2.19-2.07(m,1H) , 1.97-2.02(m,2H), 1.78-1.89(m,3H), 1.60(d,J=12.7Hz, 2H), 1.28(s,1H).MS(ESI, m / e)[M+1] + 849.1.
[0407] Example A14: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4'-(2-(4-cyclopropylphenyl)pyrrolidin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-[1,1'-biphenyl]-4-carboxamide [ka] Following a similar procedure as in Example A1, the desired compound was synthesized starting from 2-(4-cyclopropylphenyl)pyrrolidine and 1-bromo-4-iodobenzene. 1H NMR (400MHz, DMSO-d6) δppm: 12.16(s,1H), 11.72(s,1H), 8.63(t,J=5.7Hz, 1H), 8.57(d,J=1.8Hz, 1H), 8.05(d,J=2.2Hz, 1H) , 7.83(d,J=9.1Hz, 1H), 7.60(d,J=2.2Hz, 1H), 7.55-7.50(m,2H), 7.35-7.25(m,3H), 7.14(d,J=9.3Hz, 1H),7.05-6.95(m,4H) ), 6.89(s,1H), 6.45-6.35(m,3H), 4.72(d,J=8.0Hz, 2H), 3.90-3.80(m,2H), 3.70-3.60(m,2H), 3.40-3.15(m,3H), 2.35-2.2 6(m,2H), 2.02-1.68(m,4H), 1.65-1.55(m,2H), 1.30-1.15(m,2H), 0.92-0.86(m,2H), 0.62-0.55(m,2H).MS(ESI, m / e)[M+1] + 813.2.
[0408] Example A15: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-4'-(2-phenylazepan-1-yl)-[1,1'-biphenyl]-4-carboxamide [ka] Following the same procedures as in the examples, the desired compound was synthesized starting from 2-phenylazepane and 1-bromo-4-iodobenzene. 1H NMR (400MHz, DMSO-d6) δppm: 12.15(s,1H), 11.72(s,1H), 8.68-8.63(m,1H), 8.58-8.52(m,1H), 8.06(d,J=2.0Hz, 1H ), 7.84(d,J=8.2Hz, 1H), 7.61(d,J=2.1Hz, 1H), 7.53(t,J=5.7Hz, 3H), 7.40-7.23(m,6H), 7.20-7.13(m,5H), 6.87(s ,1H), 6.57(d,J=8.6Hz, 2H), 6.39(s,1H), 4.65-4.55(m,1H), 3.88-3.75(m,2H), 3.58-3.43(m,1H), 3.30-3.20(m,3H) ), 2.42-2.30(m,1H),1.95-1.87(m,2H), 1.82-1.67(m,3H), 1.65-1.52(m,4H).1.29-1.23(m,2H).MS(ESI, m / e)[M+1] + 801.2.
[0409] Example A16: 3-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-4'-(2-phenylpiperidin-1-yl)-[1,1'-biphenyl]-4-carboxamide [ka] Following a similar procedure as in E...
Claims
1. Formula (I) [Formula 1] (In the formula, L 1 and L 2 are each independently a direct bond, and L 4 is -C(O)NR g SO 2 -, where R g is hydrogen and C 1~6 is alkyl; L 3 is a direct bond, -(CR a R b ) t -, - (CR a R b ) t-1 - (CR c =CR d )-(CR a R b ) v-1 -, - (CR a R b ) t-1 -(C≡C)-(CR a R b ) v-1 -, -O-, -S-, -S(O)-, -SO 2 -, -C(O)-, C(O)O-, -OC(O)-, -NR a --, --C(O)NR a --, --NR a C(O)-, -NR a C(O)O-, -NR a C(O)NR b -, -SO 2 N.R. a --, --NR a SO 2 --, --NR a S (O) 2 N.R. b --, --NR a S(O)NR b --, --C(O)NR a SO 2 --, --C(O)NR a SO- or -C(=NR a ) N.R. b-, where t and v are independently at each occurrence a number from 1 to 7, and -(CR a R b ) t -, - (CR a R b ) t-1 - (CR c =CR d )-(CR a R b ) v-1 -, - (CR a R b ) t-1 -(C≡C)-(CR a R b ) v-1 -One or two CRs in a R b The moiety is unsubstituted or is O, S, SO, SO 2 , C(O) and NR a substituted with one or more moieties selected from Each ring A is a ring having 1 to 4 substituents R 2 cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclyl, or heteroaryl optionally substituted with R 2 is independently at each occurrence hydrogen, halogen, or -C optionally substituted with halogen 1~8 selected from the group consisting of alkyl; Each ring B is a ring having 1 to 4 substituents R 1 is heterocyclyl or heteroaryl optionally substituted with R 1 is independently for each occurrence hydrogen, halogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO 2 , -OR 1a , -SO 2 R 1a , -COR 1a , -CO 2 R 1a , -CONR 1a R 1b, -C(=NR 1a ) N.R. 1b R 1c , -NR 1a R 1b , -NR 1a C.O.R. 1b , -NR 1a C.O.N.R. 1b R 1c , -NR 1a CO 2 R 1b , -NR 1a SONR 1b R 1c , -NR 1a SO 2 N.R. 1b R 1c Or -NR 1a SO 2 R 1b wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl each independently represent 1 to 4 substituents R 1d and optionally substituted with R 1a , R 1b and R 1c are each independently hydrogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Each of alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is selected from halogen, hydroxy or -C 1~8 optionally substituted with alkyloxy; R 1d represents independently at each occurrence a halogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, -NO 2 , -OR Ba , -SO 2 R Ba , -COR Ba , -CO 2 R Ba , -CONR Ba R Bb , -C(=NR Ba ) N.R. Bb R Bc , -NR Ba R Bb , -NR Ba C.O.R. Bb , -NR Ba C.O.N.R. Bb R Bc , -NR Ba CO 2 R Bb , -NR Ba SONR Bb R Bc , -NR Ba SO 2 N.R. Bb R Bc Or -NR Ba SO 2 R Bb wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl each independently represent 1 to 4 substituents R Bd optionally substituted with; R Ba , R Bb and R Bc are each independently hydrogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Each of alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is selected from halogen, hydroxy, —NH 2 Or -N(C 1~6 Alkyl) 2 , -C 1~8optionally substituted with alkyloxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R Bd is independently for each occurrence hydrogen, halogen, oxo, -CN, -NO 2 , -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Each of alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is selected from halogen, hydroxy, -C 1~8 optionally substituted with alkyloxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R 3 is hydrogen, halogen, C 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, 1~8 Alkyl, C 2~8 Alkenyl, C 2~8 Each of the alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl may be one to four substituents R 3a optionally substituted with; R 3a represents independently at each occurrence a halogen, a cyano, -NO 2 , -OR 3b , -SR 3b , -NR 3b R 3c , -COR 3b , -SO 2 R 3b , -C(=O)OR 3b , -C(=O)NR 3b R 3c , -C(=NR 3b ) N.R. 3c R 3d , -N(R 3b ) C(=O)R 3c , -N(R 3b) C(=O)OR 3c , -N(R 3b )C(O)NR 3c R 3d , -N(R 3b ) S(O)NR 3c R 3d , -N(R 3b ) S (O) 2 N.R. 3c R 3d , -NR 3b SO 2 R 3c , -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 selected from alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; R 3b , R 3c and R 3d are independently hydrogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Each of alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is selected from halogen, hydroxy or -C 1~8 optionally substituted with alkyloxy; R 4 Yes, NO 2 and m is an integer from 1 to 4; R 5 Is, -L 5 - CyC, Here, L 5 is a direct bond, -(CR a R b ) t -, - (CR a R b ) t-1 - (CR c =CR d )-(CR a R b ) v-1 -, - (CR a R b ) t-1 -(C≡C)-(CR a R b ) v-1 -, -O-, -S-, -S(O)-, -SO 2 -, -C(O)-, C(O)O-, -OC(O)-, -NR a --, --C(O)NR a --, --NR a C(O)-, -NR a C(O)O-, -NR a C(O)NR b -, -SO 2 N.R. a --, --NR a SO 2 --, --NR a S (O) 2 N.R. b --, --NR a S(O)NR b --, --C(O)NR a SO 2 --, --C(O)NR a SO- or -C(=NR a ) N.R. b -, where t and v are independently at each occurrence a number from 1 to 7, and -(CR a R b ) t -, - (CR a R b ) t-1 - (CR c =CR d )-(CR a R b ) v-1 -, - (CR a R b ) t-1 -(C≡C)-(CR a R b ) v-1 -One or two CRs in a R b The moiety is unsubstituted or is O, S, SO, SO 2 , C(O) and NR a substituted with one or more moieties selected from CyC each contains one or two substituents R 5acycloalkyl, heterocyclyl, aryl, or heteroaryl optionally substituted with R 5a is independently selected for each occurrence from hydrogen, halogen, cyano, oxo, -NO 2 , -OR 5b , -SR 5b , -NR 5b R 5c , -COR 5b , -SO 2 R 5b , -C(=O)OR 5b , -C(=O)NR 5b R 5c , -C(=NR 5b ) N.R. 5c R 5d , -N(R 5b ) C(=O)R 5c , -N(R 5b ) C(=O)OR 5c , -N(R 5b )C(O)NR 5c R 5d , -N(R 5b ) S(O)NR 5c R 5d , -N(R 5b ) S (O) 2 N.R. 5c R 5d , -NR 5b SO 2 R 5c , -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, -cycloalkyl, heterocyclyl, aryl or heteroaryl, 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Each of alkynyl, -cycloalkyl, heterocyclyl, aryl or heteroaryl may have one or two substituents R 5e optionally substituted with; Here, R 5b , R 5c and R 5d are each independently hydrogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, 1~8 Alkyl, -C 2~8 Alkenyl, C 2~8 Each of alkynyl, -cycloalkyl, heterocyclyl, aryl or heteroaryl may have one or two substituents R 5e optionally substituted with; R 5e is independently selected for each occurrence from hydrogen, halogen, cyano, oxo, -NO 2 , -OR 5f , -SR 5f , -NR 5f R 5g , -COR 5f , -SO 2 R 5f , -C(=O)OR 5f , -C(=O)NR 5f R 5g , -C(=NR 5f ) N.R. 5g R 5h , -N(R 5f ) C(=O)R 5g , -N(R 5f ) C(=O)OR 5g , -N(R 5f )C(O)NR 5g R 5h , -N(R 5f ) S(O)NR 5g R 5h , -N(R 5f ) S (O) 2 N.R. 5g R 5h , -NR 5f SO 2 R 5g , -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 selected from alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; R 5f , R 5g and R 5h are each independently hydrogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; or Two adjacent R on the phenyl ring 5 together with the phenyl ring form a benzo ring, the ring being free of halogen, oxo, cyano, -NO 2 , -OR 5i , -SR 5i , -NR 5i R 5j , -COR 5i , -SO 2 R 5i , -C(=O)OR 5i , -C(=O)NR 5i R 5j , -C(=NR 5i ) N.R. 5j R 5k , -N(R 5i ) C(=O)R 5j , -N(R 5i ) C(=O)OR 5j , -N(R 5i )C(O)NR 5j R 5k , -N(R 5i ) S(O)NR 5j R 5k , -N(R 5i ) S (O) 2 N.R. 5j R 5k , -NR 5i SO 2 R 5k , -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 optionally substituted with alkynyl, -cycloalkyl, heterocyclyl, aryl or heteroaryl; R 5i , R 5j and R 5k are independently hydrogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8Each of alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is selected from halogen, hydroxy or -C 1~8 optionally substituted with alkyloxy; R a , R b , R c and R d represents independently for each occurrence hydrogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl are each independently -CN, halogen, -NO 2 , -NR e R f , oxo, -OR e Or -SR e is replaced by; Here, R e and R f are each independently hydrogen, C 1~8 Alkyl, C 1~8 Alkoxy-C 1~8 Alkyl-, C 2~8 Alkenyl, C 2~8 alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl or a pharma- ceutically acceptable salt or stereoisomer thereof.
2. R a , R b , R c and R d is independently at each occurrence hydrogen or C 1~6 2. The compound according to claim 1, wherein alkyl is hydrogen or methyl.
3. L 3 is a direct bond, -(CR a R b ) t -, -O-, -S-, -S(O)-, -SO 2 -, -C(O)-, C(O)O-, -OC(O)- or -NR a -, where R a , R b and t are defined as in formula (I), and preferably R a and R b are independently hydrogen or C 1~6 2. The compound of claim 1, wherein t is alkyl and t is 1 or 2.
4. L 3 is -O-, -CH 2 --, --NR a The compound according to claim 3, wherein the alkyl group is -, a direct bond or -C(O)-.
5. L 3 The compound according to claim 3, wherein is -O-.
6. R 3 is one or two substituents R 3a 2. The compound of claim 1, wherein the heteroaryl is optionally substituted with
7. R 3 is halogen, -C 1~8 Alkyl or -NR 3b R 3c one or two substituents R selected from 3a Heteroaryl optionally substituted with, where R 3b and R 3c are independently hydrogen or -C 1~8 The compound of claim 6, which is alkyl.
8. R 3 is halogen, -C 1~8 Alkyl or -NR 3b R 3c one or two substituents R selected from 3a is a 5-7 membered nitrogen-containing monocyclic heteroaryl optionally substituted with 3b and R 3c are independently hydrogen or -C 1~8The compound of claim 6, which is alkyl.
9. R 3 are halogen, -C 1~8 Alkyl or -NR 3b R 3c one or two substituents R selected from 3a tetrazolyl, trizolyl, pyrazolyl, pyrrolyl, pyridinyl, pyrimidinyl, optionally substituted with 3b and R 3c are independently hydrogen or -C 1~8 The compound of claim 6, which is alkyl.
10. R 3 The compound of claim 6, wherein is an 8-12 membered bicyclic heteroaryl containing 1, or 2, or 3 nitrogen atoms.
11. R 3 are halogen, -C 1~8 Alkyl or -NR 3b R 3c one or two substituents R selected from 3a indolyl, pyrrolopyridinyl or pyrazolopyridinyl optionally substituted with 3b and R 3c are independently hydrogen or -C 1~8 The compound of claim 10 which is alkyl.
12. R 3 The compound according to claim 11, wherein is indol-4-yl, pyrrolo[2,3-b]pyridin-5-yl, or pyrazolo[4,3-b]pyridin-1-yl.
13. R 3 is halogen, -C 1~8 Alkyl or -NR 3b R 3c one or two substituents R selected from 3a 11-14 membered tricyclic heteroaryl containing 1, or 2, or 3, or 4, or 5 nitrogen atoms optionally substituted with 3b and R 3c are independently hydrogen or -C 1~8 The compound of claim 6, which is alkyl.
14. L 3 is —O—, and R 3 The compound of claim 1, wherein is pyrrolo[2,3-b]pyridin-5-yl.
15. L 4 is -C(O)NR a SO 2 -, where R a is hydrogen and C 1~6 2. The compound of claim 1, wherein R is an alkyl group; preferably R is hydrogen.
16. Each ring A is a ring having 1 to 4 substituents R 2 2. The compound of claim 1, wherein the aryl is cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl, optionally substituted with.
17. R 2 is hydrogen, halogen (e.g., F, Cl, or Br), or C optionally substituted with halogen (e.g., F, Cl, or Br). 1~6 17. The compound of claim 16, which is alkyl (e.g., methyl).
18. The compound of claim 16, wherein ring A is a phenyl ring which is 1,2-phenylene, 1,3-phenylene or 1,4-phenylene.
19. Ring A is C 3~8 17. The compound of claim 16, wherein the cycloalkyl ring is cycloalkyl.
20. 20. The compound of claim 19, wherein A is selected from cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.
21. The compound according to claim 20, wherein ring A is 1,2-cyclobutylene, 1,3-cyclobutylene, 1,2-cyclopentylene, 1,3-cyclopentylene, 1,2-cyclohexylene, 1,3-cyclohexylene, 1,4-cyclohexylene, 1,2-cycloheptylene, 1,3-cycloheptylene, or 1,4-cycloheptylene.
22. Ring A is C 3~8 The compound according to claim 16, which is a cycloalkenyl, preferably cyclohexenyl, more preferably cyclohex-3-enyl or cyclohex-2-enyl.
23. 17. The compound of claim 16, wherein Ring A is a monocyclic 5- or 6-membered heteroaryl or an 8- to 12-membered bicyclic heteroaryl ring containing 1, or 2, or 3, or 4 heteroatoms selected from nitrogen, oxygen, and sulfur.
24. Ring A is a) a monocyclic 4- to 9-membered heterocyclyl group containing as ring members 1 or 2 heteroatoms selected from nitrogen, or oxygen, or sulfur; b) a 5- to 12-membered spiroheterocyclyl containing as ring members one or two heteroatoms selected from nitrogen, sulfur and oxygen; c) a 5- to 12-membered fused heterocyclyl containing, as ring members, one or two heteroatoms selected from nitrogen, sulfur, and oxygen; and d) a 5- to 12-membered bridged heterocyclyl containing, as ring members, one or two heteroatoms selected from nitrogen, sulfur and oxygen; 17. The compound of claim 16, wherein the heterocyclyl is selected from:
25. Ring A is selected from the group consisting of piperidine, pyrrolidine and azetidine; 7-azaspiro[3.5]nonane, 2-azaspiro[3.5]nonane, 8-azabicyclo[3.2.1]octane; tetrahydrothienopyridines (e.g., 4,5,6,7-tetrahydrothieno[2,3-c]pyridine), tetrahydropyrrolopyrazines (e.g., 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine), tetrahydropyrrolopyrazines (e.g., 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine), hexahydroindolizines (e.g., 1,2,3,5 or Ring A is a 5-12 membered spiroheterocyclyl containing one or two heteroatoms selected from nitrogen, sulfur and oxygen as ring members; preferably Ring A is a 4 / 4, 3 / 5, 4 / 5, 4 / 6, 5 / 5 or 5 / 6 membered monospiroheterocyclyl containing one or two nitrogen or oxygen as ring members; more preferably Ring A is [Case 2] (7-azaspiro[3.5]nonane-2,7-diyl), [C3] (2-azaspiro[3.5]nonane-2,7-diyl), [C4] (3-azaspiro[5.5]undecane-3,9-diyl), [C5] (2-azaspiro[3.3]heptane-2,6-diyl), [C6] (8-azaspiro[4.5]decane-2,8-diyl), or [C7] (2-azaspiro[4.5]decane-2,8-diyl), * 1 is L 1 and ** 2 is L 2The compound of claim 24, wherein the position is bonded to
26. Ring A is [C8] (7-azaspiro[3.5]nonane-2,7-diyl), [C9] (2-azaspiro[3.5]nonane-2,7-diyl), [C10] (8-azabicyclo[3.2.1]octane-3,8-diyl), [C11] (3-azaspiro[5.5]undecane-3,9-diyl), [C12] (2-azaspiro[3.3]heptane-2,6-diyl), [C13] (8-azaspiro[4.5]decane-2,8-diyl), [C14] (2-azaspiro[4.5]decane-2,8-diyl), [C15] wherein: * 1 is L 1 and ** 2 is L 2 The compound of claim 20, wherein the position is bonded to
27. Ring A is [C16] where: * 1 is L 1 and ** 2 is L 2 The compound of claim 20, wherein the position is bonded to
28. Each ring B is a ring having 1 to 4 substituents R 1is heterocyclyl optionally substituted with R 1 is halogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, aryl, heteroaryl, oxo, -CN or -OR 1a wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, aryl or heteroaryl each independently represent 1 to 4 substituents R 1d and optionally substituted with R 1a is hydrogen or -C 1~8 alkyl, 1~8 Alkyl is halogen, hydroxy or -C 1~8 optionally substituted with alkyloxy; R 1d represents independently at each occurrence a halogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -CN, -OR Ba , -SO 2 R Ba , -CONR Ba R Bb , -NR Ba R Bb , -NR Ba C.O.R. Bb Or -NR Ba SO 2 R Bb wherein said -C 1~8 Alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl each independently represent 1 to 4 substituents R Bd optionally substituted with; R Ba and R Bb are each independently hydrogen, -C 1~8 alkyl, cycloalkyl or aryl, 1~8Each of alkyl, cycloalkyl, and aryl is selected from halogen, hydroxy, —C 1~8 optionally substituted with alkyloxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R Bd is independently for each occurrence hydrogen, halogen, -CN, -C 1~8 Alkyl, -C 2~8 alkynyl, cycloalkyl or aryl, 1~8 Alkyl, -C 2~8 Each of alkynyl or aryl is selected from halogen, hydroxy, -C 1~8 2. The compound of claim 1, optionally substituted with alkyloxy, cycloalkyl, heterocyclyl, aryl or heteroaryl.
29. Each ring B is a ring having 1 to 4 substituents R 1 2. The compound of claim 1, wherein the heterocyclyl is a monocyclic 4-9 membered heterocyclyl, a 5-20 membered spiro heterocyclyl, a 5-20 membered fused heterocyclyl, or a 5-20 membered bridged heterocyclyl, optionally substituted with
30. The monocyclic heterocyclyl may have NH, O, S, SO or SO as ring members. 2 The compound of claim 29, which is a monocyclic 4- to 9-membered heterocyclyl containing one or more heteroatoms selected from the group consisting of heteroatoms.
31. The compound according to claim 29, wherein the monocyclic heterocyclyl is a monocyclic 4- to 9-membered heterocyclyl containing one nitrogen atom as a ring member.
32. 31. The compound of claim 30, wherein said monocyclic 4-9 membered heterocyclyl containing one nitrogen atom as a ring member is C-bonded or N-bonded.
33. The compound of claim 30, wherein the monocyclic 4- to 9-membered heterocyclyl containing one nitrogen atom as a ring member is saturated.
34. 34. The compound of claim 33, wherein said saturated heterocyclyl is an N-linked saturated heterocyclyl.
35. 35. The compound of claim 34, wherein said saturated heterocyclyl is aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl or azocan-1-yl.
36. 34. The compound of claim 33, wherein said saturated heterocyclyl is a C-linked saturated heterocyclyl.
37. 34. The compound of claim 33, wherein the saturated heterocyclyl is aziridin-2-yl, azetidin-2-yl, azetidin-3-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, azepan-2-yl, azepan-3-yl, azepan-4-yl, azocan-2-yl, azocan-3-yl, azocan-4-yl, or azocan-5-yl.
38. The compound of claim 30, wherein the monocyclic 4- to 9-membered heterocyclyl containing one nitrogen atom as a ring member is unsaturated.
39. The compound of claim 38, wherein the monocyclic 4- to 9-membered heterocyclyl containing one nitrogen atom as a ring member contains one carbon-carbon double bond.
40. 39. A compound according to claim 38, wherein the monocyclic 4- to 9-membered heterocyclyl containing one nitrogen atom as a ring member is a dihydropyrrole, such as 2,3-dihydro-1H-pyrrole and 2,5-dihydro-1H-pyrrole or a tetrahydropyridine group.
41. The monocyclic heterocyclyl has one nitrogen atom and NH, O, S, SO or SO as ring members. 2 The compound of claim 29 which is a monocyclic 4- to 9-membered heterocyclyl containing one additional heteroatom selected from the group consisting of heteroatoms.
42. As ring members, one nitrogen atom and NH, O, S, SO or SO 2 42. The compound of claim 41, wherein said monocyclic 4-9 membered heterocyclyl containing one further heteroatom selected from the group consisting of heteroatoms is C-bonded or N-bonded.
43. 42. The compound of claim 41, wherein said monocyclic heterocyclyl is saturated.
44. 42. The compound of claim 41, wherein said saturated monocyclic heterocyclyl is N-linked or C-linked.
45. Ring B is a ring having 1 to 4 substituents R 1 30. The compound of claim 29, which is pyrrolidin-1-yl substituted with:
46. R 1 is a phenyl group.
47. Ring B is aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, azepan-1-yl or azocan-1-yl, preferably substituted at the 2-position with a phenyl group and one, two or three substituents R 1 and said phenyl group at 2-position is R as defined in formula (I). 1d 30. The compound of claim 29, optionally substituted with
48. R 1 is halogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, aryl, heteroaryl, oxo, -CN or -OR 1a wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, aryl or heteroaryl may be one to four substituents R 1dwhere R 1a is hydrogen or C 1~8 alkyl, preferably methyl, and R 1d is halogen or -OR Ba where R Ba is hydrogen or -C 1~8 48. The compound of claim 47, which is alkyl.
49. R 1 is heteroaryl, preferably furanyl, more preferably furan-3-yl.
50. R 1d is halogen, -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -CN, -OR Ba , -SO 2 R Ba , -CONR Ba R Bb , -NO 2 , -NR Ba R Bb , -NR Ba C.O.R. Bb Or -NR Ba SO 2 R Bb wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl each independently represent one to four substituents R as defined in formula (I). Bd , preferably one or two substituents R Bd 48. The compound of claim 47, optionally substituted with:
51. R 1d is halogen, phenyl or cycloalkyl (e.g., C 3~8 1 to 4 substituents R Bd -C optionally further substituted with 1~8 49. The compound of claim 48, which is alkyl.
52. R 1d is R Bd -C is selected from methyl, ethyl, isopropyl, propyl, tert-butyl and isobutyl, optionally substituted with 1~8 52. The compound of claim 51, which is alkyl.
53. R 1d is halogen, cyano, C 2~8 C optionally substituted with alkynyl (preferably ethynyl) or halogen 1~8 Alkyl (preferably CF 3 ) 1 to 4 substituents R Bd 51. The compound of claim 50, wherein said aryl is cycloalkyl optionally further substituted with.
54. R 1d is R Bd C selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted with 3~8 51. The compound of claim 50 which is cycloalkyl.
55. R 1d is prop-1-en-2-yl-C 2~8 51. The compound of claim 50 which is alkenyl.
56. R 1d is ethynyl -C 2~8 51. The compound of claim 50 which is alkynyl.
57. R 1d -OR as Ba In the definition of Ba is hydrogen, C 1~8 alkyl (selected from methyl, ethyl, propyl and isopropyl), C 3~8 cycloalkyl (preferably cyclopropyl or cyclohexyl), aryl (preferably phenyl), where C 1~8 Alkyl, C 3~8Cycloalkyl and aryl are each independently halogen, heterocyclyl (preferably a monocyclic 4- to 9-membered heterocyclyl, more preferably morpholino), hydroxy or -C 1~8 51. The compound of claim 50, which is substituted with alkoxyl, preferably methoxyl.
58. R 1d is phenyl.
59. R 1d is a heterocycle which is a monocyclic 4- to 9-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen, or oxygen, or sulfur as ring members, preferably a monocyclic 4- to 6-membered heterocyclyl containing one oxygen atom as a ring member or a monocyclic 6-membered heterocyclyl containing one or two nitrogen atoms as ring members.
60. R 1d 51. The compound of claim 50, wherein is heteroaryl, preferably thiophenyl or furanyl.
61. 30. The compound of claim 29, wherein Ring B is pyrrolidin-1-yl substituted with a naphthyl group, preferably substituted at the 2-position with naphthyl.
62. 30. The compound of claim 29, wherein Ring B is pyrrolidin-1-yl substituted with a heteroaryl group, preferably substituted at the 2-position with a heteroaryl group.
63. 63. The compound of claim 62, wherein the heteroaryl is a 5- to 6-membered heteroaryl containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur.
64. 63. The compound of claim 62, wherein said heteroaryl is pyridinyl, furanyl, thiophenyl, or pyrazole.
65. The heteroaryl is halogen or C 3~863. The compound of claim 62, optionally substituted with cycloalkyl, preferably cyclopropyl.
66. Ring B is -C 1~8 Alkyl, -C 2~8 Alkenyl or -C 2~8 alkynyl substituted, preferably at the 2-position -C 1~8 Alkyl, -C 2~8 Alkenyl or -C 2~8 pyrrolidin-1-yl substituted with alkynyl, 1~8 Alkyl, -C 2~8 Alkenyl or -C 2~8 Each alkynyl is unsubstituted or substituted with a phenyl group, said phenyl group being selected from the group consisting of a halogen and a C 3~8 30. The compound of claim 29, optionally substituted with cycloalkyl, preferably cyclopropyl.
67. 67. The compound of claim 66, wherein Ring B is pyrrolidin-1-yl substituted with methyl, ethenyl or ethynyl, each of which is optionally substituted with a phenyl group, each of which is optionally substituted as described above.
68. Ring B is a ring having 1 to 4 substituents R 1 67. The compound of claim 66, which is pyrrolidin-1-yl optionally substituted with
69.
17. teeth, [C18] [C19] [C20] [C21] [C22] [C23] [C24] [C25] [C26] 30. The compound of claim 1 or 29, selected from the group consisting of:
70. Ring B is a 2-substituted pyrrolidin-1-yl group; L 1 is a direct bond, L 2 is a direct bond, Ring A is a 1,4-phenylene ring or a 5-12 membered spiroheterocyclyl containing one or two heteroatoms selected from nitrogen, sulfur and oxygen as ring members; preferably Ring A is a 4 / 4, 3 / 5, 4 / 5, 4 / 6, 5 / 5 or 5 / 6 membered monospiroheterocyclyl containing one or two nitrogen or oxygen as ring members; more preferably Ring A is [C27] (7-azaspiro[3.5]nonane-2,7-diyl), [C28] (2-azaspiro[3.5]nonane-2,7-diyl), [C29] (3-azaspiro[5.5]undecane-3,9-diyl), [C30] (2-azaspiro[3.3]heptane-2,6-diyl), [C31] (8-azaspiro[4.5]decane-2,8-diyl), or [C32] (2-azaspiro[4.5]decane-2,8-diyl), * 1 is L 1 and ** 2 is L 2 The compound of claim 1 , wherein the position is bonded to
71. Ring B is a 2-(substituted phenyl)pyrrolidin-1-yl group; L 1is a direct bond, ring A is a 1,4-phenylene ring or 7-azaspiro[3.5]nonane-2,7-diyl, 2-azaspiro[3.5]nonane-2,7-diyl, 3-azaspiro[5.5]undecane-3,9-diyl, 2-azaspiro[3.3]heptane-2,6-diyl, 8-azaspiro[4.5]decane-2,8-diyl or 2-azaspiro[4.5]decane-2,8-diyl, and L 2 The compound of claim 1 , wherein:
72. Ring B is a 2-(2-substituted phenyl)pyrrolidin-1-yl or 2-(3-substituted phenyl)pyrrolidin-1-yl group; L 1 is a direct bond, ring A is a 1,4-phenylene ring or 7-azaspiro[3.5]nonane-2,7-diyl, 2-azaspiro[3.5]nonane-2,7-diyl, 3-azaspiro[5.5]undecane-3,9-diyl, 2-azaspiro[3.3]heptane-2,6-diyl, 8-azaspiro[4.5]decane-2,8-diyl or 2-azaspiro[4.5]decane-2,8-diyl, and L 2 is a direct bond, wherein the phenyl group at the 2-position of said pyrrolidin-1-yl is substituted with one to four substituents R 1d 2. The compound of claim 1 , substituted with:
73. Ring B is a 2-(2-substituted phenyl)pyrrolidin-1-yl or 2-(3-substituted phenyl)pyrrolidin-1-yl group; L 1 is a direct bond, ring A is a 1,4-cyclohexylene ring or 1,4-cyclohex-3-enyl, or 1,4-cyclohex-2-enyl, or 1,4-cyclohex-1-enyl, or 7-azaspiro[3.5]nonane-2,7-diyl, 2-azaspiro[3.5]nonane-2,7-diyl, 3-azaspiro[5.5]undecane-3,9-diyl, 2-azaspiro[3.3]heptane-2,6-diyl, 8-azaspiro[4.5]decane-2,8-diyl, or 2-azaspiro[4.5]decane-2,8-diyl, and L 2is a direct bond, wherein the phenyl group at the 2-position of said pyrrolidin-1-yl is substituted with one to four substituents R 1d 2. The compound of claim 1 , substituted with:
74. The compound of claim 1 , wherein m is 1.
75. L 5 is a direct bond, -(CR a R b ) t -or-NR a -, where t is a number from 1 to 7, and -(CR a R b ) t -One or two CRs in a R b The moiety is unsubstituted or is selected from the group consisting of O and NR a wherein R a and R b The compound according to claim 1, wherein:
76. L 5 is a direct bond, -(CR a R b ) 1~4 -, -O-(CR a R b ) 1~3 -, -NH-(CR a R b ) 1~3 or -NH-, where R a and R b The compound of claim 73, wherein:
77. L 5 is a direct bond, -(CH 2 ) 1~4 -, -O-(CH 2 ) 1~3 -, -NH-(CR a R b )-(CH 2 ) 2 - or -NH-, where R a is hydrogen, and R bis optionally substituted with phenyl-S- 1~8 74. The compound of claim 73, which is alkyl.
78. CyC each contains one or two substituents R 5a is cycloalkyl or heterocyclyl optionally substituted with; R 5a are independently hydrogen, halogen, cyano, oxo, -OR 5b , -NR 5b R 5c , -COR 5b , -SO 2 R 5b , -C 1~8 Alkyl, -C 2~8 alkynyl, -cycloalkyl or heterocyclyl, 1~8 Each of alkyl and heterocyclyl is selected from hydrogen, halogen, cyano, -OR 5f , -C 1~8 one or two substituents R selected from alkyl, -cycloalkyl or heterocyclyl; 5e optionally substituted with; Here, R 5b and R 5c are each independently hydrogen, -C 1~8 alkyl or heterocyclyl, 1~8 Alkyl is hydrogen, -NR 5f R 5g or - one or two substituents R which are cycloalkyl; 5e optionally substituted with; R 5f and R 5g are each independently hydrogen or -C 1~8 is alkyl; or Two adjacent R 5 2. The compound of claim 1, wherein together with the phenyl ring, forms a benzo ring, which is optionally substituted with heteroaryl.
79. CyC each contains one or two substituents R 5a Monocyclic C optionally substituted with 3~8Cycloalkyl or bridged cycloalkyl [C33] 79. The compound of claim 78, wherein the cycloalkyl is selected from:
80. CyC each contains one or two substituents R 5a 80. The compound of claim 79, wherein said cyclopentyl or cyclohexyl is optionally substituted with.
81. CyC each contains one or two R 5a optionally substituted with a) monocyclic 4- to 9-membered heterocyclyl groups containing one nitrogen, oxygen, or sulfur heteroatom as a ring member; b) a monocyclic 4- to 9-membered heterocyclyl group containing as ring members two heteroatoms selected from oxygen, sulfur and nitrogen; and c) a 5- to 20-membered spiroheterocyclyl containing, as ring members, one or two heteroatoms selected from nitrogen, sulfur and oxygen; 79. The compound of claim 78, wherein the heterocyclyl is selected from:
82. 81. The compound of claim 80, wherein CyC is a monocyclic 4-6 membered heterocyclyl group containing one nitrogen, oxygen, or sulfur heteroatom as a ring member.
83. 83. The compound of claim 82, wherein Cyc is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, and piperidinyl.
84. 83. The compound of claim 82, wherein CyC is selected from oxetan-2-yl, oxetan-3-yl, tetrahydrofuran-4-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, azetidin-3-yl, azetidin-2-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-4-yl, piperidin-2-yl, and piperidin-3-yl.
85. 83. The compound of claim 82, wherein CyC is a monocyclic 6-membered heterocyclyl group containing, as ring members, two heteroatoms selected from oxygen and nitrogen.
86. 86. The compound of claim 85, wherein CyC is dioxanyl, morpholino, morpholinyl, or piperidinyl.
87. 85. The compound of claim 84, wherein CyC is 1,3-dioxan-2-yl, 1,3-dioxan-4-yl, 1,4-dioxan-2-yl, morpholin-1-yl, morpholin-2-yl, or morpholin-3-yl.
88. 81. The compound of claim 80, wherein CyC is a 4 / 4, 3 / 5, 4 / 5, 4 / 6, 5 / 5 or 5 / 6 membered monospiroheterocyclyl containing one or two nitrogen or oxygen ring members.
89. CyC is [C34] (7-oxa-2-azaspiro[3.5]nonan-2-yl), or [C35] The compound of claim 88, which is (2-oxaspiro[3.5]nonan-7-yl).
90. R 5a are independently hydrogen, halogen, cyano, oxo, -OR 5b , -NR 5b R 5c , -COR 5b , -SO 2 R 5b , -C 1~8 Alkyl, -C 2~8 Alkynyl, monocyclic C 3~8 cycloalkyl or monocyclic 4- to 9-membered heterocyclyl groups containing, as ring members, one or two heteroatoms selected from nitrogen, oxygen, or sulfur heteroatoms, 1~8Each of the alkyl and monocyclic 4- to 9-membered heterocyclyl groups may have one or two substituents R 5e 82. The compound of claim 81, optionally substituted with:
91. R 5a Cycloalkyl as the group is C 3~6 91. The compound of claim 90, which is cycloalkyl; more preferably cyclopropyl.
92. R 5a The compound according to claim 90, wherein the heterocyclyl as is a 4-6 membered heterocyclyl group containing, as ring members, one or two heteroatoms selected from nitrogen, or oxygen, or sulfur heteroatoms.
93. R 5a 91. The compound of claim 90, wherein the heterocyclyl as is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl or morpholinyl.
94. R 5a The compound according to claim 90, wherein heterocyclyl as is oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydro-2H-pyran-4-yl or morpholin-4-yl.
95. R 5e The compound according to claim 90, wherein the heterocyclyl as is a monocyclic 4-9 membered heterocyclyl group containing, as ring members, one or two heteroatoms selected from nitrogen, or oxygen, or sulfur heteroatoms.
96. R 5e The compound according to claim 90, wherein the heterocyclyl as is tetrahydro-pyran-4-yl.
97. R 5a is -NR 5b R 5c where R 5b is hydrogen, and R 5c is heterocyclyl.
98. R 5a is -NR 5b R 5c where R 5b is hydrogen, and R 5c is tetrahydro-pyran-4-yl.
99. R 5a is -NR 5b R 5c where R 5b and R 5c are each independently a hydrogen or a cycloalkyl-substituted —C 1~6 Alkyl, preferably monocyclic C 3~8 -C substituted with cycloalkyl 1~6 91. The compound of claim 90, which is alkyl.
100. R 5a is -OR 5b Or -SO 2 R 5b where R 5b is hydrogen or C 1~8 91. The compound according to claim 90, which is alkyl, preferably methyl.
101. R 5a is -COR 5b where R 5b is hydrogen or -NR 5f R 5g C optionally substituted with 1~8 alkyl, where R 5f and R 5g are each independently hydrogen or C 1~8 91. The compound according to claim 90, which is alkyl, preferably methyl.
102. Two adjacent R 5 The compound of claim 1 , wherein together with the phenyl ring forms an indazolyl substituted with tetrahydropyranyl.
103. m is 1 and -L 5 -CyC is [C36] [C37] 2. The compound of claim 1 selected from the group consisting of:
104. <h2 style=";text-align:left;direction:ltr">A1、A2、A3、A4、A4a、A4b、A5、A6、A7、A8、A8a、A8b、A9、A10、A11、A12、A13、A14 、A15、A16、A17、A18、A19、A20、A21、A22、A23、A24、A25、A26、A27、A28、A29、A 30、A31、A32、A33、A35、A46、A47、A54、A55、A56、A57、A61、A62、A63、A64、A65 、A67、A68、A69、A70、A73、A74、A75、A76、A77、A79、A80、A81、A82、A83、A84、A8 5、B1、B2、B3、B4、B5、B6、B8、B12、B17、 B18、B21、C1、C2、C3、C4、C5、C6、C7、C8 、C9、C10、C11、C12、C13、C14、C15、C16 、C17、C18、C19、C21、C22、C24a、C24b、 C26a、C26b、C28、C31、C36、C37、C39、C 40、C41、C-42、C45、C46、C47、C48、C51 、C52、C53、C54、C55、C57、C60、C62、C6 3、C66、C67、C69、C81、C86、C87、C88a、C 88b、C89、C90、C99、C118、C125、C126、 C127、C128、C129、C131、C132、C133、C 134、C135、C136、C137、C138、C139、C1 40、C141、C142、C143、C144、C145、C14 6、C152、C161、C162、C163、C164、C165 、C166、C167、C168、C169、C170、C171、 C172、C173、C174、C175、C176、C177、C 178、C179、C180、C181、C182、C183、C18 4、C185、C186、C187、C-189、C190、C19 1、C192、C193、C194、C195、D1a、D1b、D 2a、D2b、D2a-S、D2b-S、D2a-R、D2b-R、D3a、D3b、D4a、D4b、D5、D6、D13-1a、D13 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 64, 65, 67, 69, 68, 69, 69, 69, 69, 69, 69, 65 ... 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169 ...F32、F33、F36、G1、G1C、G2、G2C、G3、G4、G5、G6、G7、G8、G8-S、G8-a、G8-b、G9、G9-a、G9-b、G9-S、G10a、G10b、G10b-S、G10b-a、G10b-b、G11、G12、G13、G16、G18、G20、G24b、G24b-S、G24b-a、G24b-b、G26、G27、G30、G30-S、G30-a、G30-b、G30-R、G31、G32、G35-S、G35-a、G35-b、G36、G37、G39、G63、G64、G70、G72、G73、G75-a、G75-b、G75、G76、G76-S、G77、G77-S、G80a、G80b、G81a、G81b、G84、G85-S、G85-R、G86、G87、G88-S、G89-S、G90-S、G90-a、G90-b、G91-R、G92-R、G92-S、G93-R、G93-S、G94-R、G94-S、G95-R、G95-S、G96-R、G96-S、G97-R、G97-S、G98、G100a、G100b、G103、G104、G105、G106、G107-a、G107-b、G43a、G43b、G108a、G108b、G109、G110a、G110b、G110b-a、G110b-b、G111、G112、G113、G114、G115、G116、G117、H3a、H3、I7、I8、I9、I10、A37、A66、A72、A78、A86、A87、A68-S、A68-R、A88、A89、A90、A91、A93、A94、A95、A96、A97、A98、A99、A100、A101、A102、A103、A104、A105、A106、A107、A108、A109、A110、A111、A112、A113、A114、A115、A116、A117a、A117b、A118a、A118b、A119、A120、A121、A122、A123、A124、A125、A126、A127、A128、A129、A130、A131、A132、A133、A134、A135、A136、A137、A138、A139、A140、A141、A142、A143、A144、A145a、A145b、A145c、A145d、A146、A147a、A147b、A148、A149、A150、A151、A152、A153、A154、A155、A156, A157, A158, B13, B14, B15, B16, B19a, B19b, B20a, B20b, B21, B22, B23, B24, B25, B26, B27, B28, B29, B30, B31, B32, B33, B34, B35, B36, B37, B38, B39, B40, D107a, D107b, F23, F22, F21, F24, F25, F26, F27, F28, F29, F34, F35, F37, F38, F39 a, F39b, F40, F41, F42, F43, F44, F45, F46, F47, F48, F49, F50, F51, F52, F53, F54, F55, F56, F57, F58, F59, F60, F61, F62, F63, F64, F65, F66, F67, F68, F69, F70, F71, F72a, F72b, F73, F74a, F74b, F75, F76, F77, F78, F79, F80, F81, F82, F83, F84, F85, F86, F87, F88, F89, F90, F91a, F91b, F92, F93, F94, F95, F96, F97, F98, F99, F100, F101a, F101b, F102, F103, F104, F 105, F106, F107, F108, F109, F110, F111, F112, F113, F114, F115, F116, F117, F118, F119, F120, F121, F122, F123, F124a , F124b, F125, F126, F127, F128, F129, F130, F131a, F131b, F132a, F132b, G99, G101a, G101b, G102, G118, G119, G120, G121, G122, G123, G124, G125, G126, G127, G128, G129, G130, G131, G132a, G132b, G133, G134 or G135.
105. A method for treating a disease of dysregulated apoptosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 112, or a pharma- ceutically acceptable salt or stereoisomer thereof.
106. The method of claim 105, wherein the disease of dysregulated apoptosis is a neurodegenerative disease, a proliferative disease, or a prothrombotic disease.
107. A pharmaceutical composition comprising a compound according to any one of claims 1 to 105, or a pharma- ceutically acceptable salt or stereoisomer thereof, and a pharma- ceutically acceptable carrier.
108.
38. A compound selected from:
109. Formula (II) [C39] (In the formula, Each ring A is a ring having 1 to 4 substituents R 2 a phenyl ring which is 1,4-phenylene optionally substituted with; or a 5- to 12-membered spiroheterocyclyl containing as ring members one or two heteroatoms selected from nitrogen, sulfur and oxygen; R 2 is independently at each occurrence hydrogen, halogen, or -C optionally substituted with halogen 1~8 selected from the group consisting of alkyl; Ring B is a monocyclic 4- to 9-membered heterocyclyl containing one nitrogen atom as a ring member, or one nitrogen atom and NH, O, S, SO, or SO as ring members. 2 a monocyclic 4-9 membered heterocyclyl containing one additional heteroatom selected from the group consisting of heteroatoms, said ring being N-linked; R 1 , R 5 and m is defined in formula (I). or a pharma- ceutically acceptable salt or stereoisomer thereof.
110. The compound according to claim 109, wherein ring A is 1,4-phenylene.
111. The compound according to claim 109, wherein Ring A is a 5-12 membered spiroheterocyclyl containing one or two heteroatoms selected from nitrogen, sulfur and oxygen as ring members; preferably Ring A is a 4 / 4 membered, 3 / 5 membered, 4 / 5 membered, 4 / 6 membered, 5 / 5 membered or 5 / 6 membered monospiroheterocyclyl containing one or two nitrogen or oxygen as ring members.
112. Ring A is [C40] (7-azaspiro[3.5]nonane-2,7-diyl), [C41] (2-azaspiro[3.5]nonane-2,7-diyl), [C42] (3-azaspiro[5.5]undecane-3,9-diyl), [C43] 2-azaspiro[3.3]heptane-2,6-diyl, * 1 refers to the position attached to the pyrrolidinyl ring, and ** 112. The compound of claim 111, wherein 2 refers to the position attached to the phenyl ring.
113. Ring B is aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, azepan-1-yl or azocan-1-yl, preferably substituted at the 2-position with a phenyl group and one, two or three substituents R 1 and said phenyl group at the 2-position (i.e. the ortho-position) is R as defined in formula (I). 1d 110. The compound of claim 109, optionally substituted with:
114. The following formula (III) [C44] 110. The compound of claim 109, having the formula:
115. Ring A is [C45] , [C46] (7-azaspiro[3.5]nonane-2,7-diyl), [C47] (2-azaspiro[3.5]nonane-2,7-diyl), [C48] (3-azaspiro[5.5]undecane-3,9-diyl), [C49] 2-azaspiro[3.3]heptane-2,6-diyl, * 1 refers to the position attached to the pyrrolidinyl ring, and ** 115. The compound of claim 114, wherein 2 refers to the position attached to the phenyl ring.
116. The following subgeneric formula (III-A), (III-B), (III-C), (III-D) or (III-E): [50] (Wherein, the variable R 1d , R 2 , R 5 and m is defined in formula (I). The compound of claim 115, represented by:
117. R 2 The compound according to any one of claims 109 to 116, wherein is hydrogen.
118. R 1d is defined in formula (I), preferably R 1d are independently halogen, —C when substituted on the phenyl group at the 2-position of ring B (including aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, piperidin-1-yl, azepan-1-yl or azocan-1-yl, preferably the pyrrolidin-1-yl group). 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -CN, -OR Ba , -SO 2 R Ba , -CONR Ba R Bb , -NO 2 , -NR Ba R Bb , -NR Ba C.O.R. Bb Or -NR Ba SO 2 R Bb wherein said -C 1~8 Alkyl, -C 2~8 Alkenyl, -C 2~8 Alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl each independently represent one to four substituents R as defined in formula (I). Bd , preferably one or two substituents R Bd In another embodiment, one R 1d is at the 2-position of the phenyl ring at the 2-position of ring B.
119. R 1d is methyl, ethyl, isopropyl, propyl or methoxymethyl or two methyls at positions on the phenyl ring; or propenyl; or cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; or ethoxy or isopropoxy; or amino or dimethylamino.
120. The 2-(2-substituted phenyl)pyrrolidin-1-yl moiety as ring B is [C51] [C52] 120. The compound according to any one of claims 109 to 119, selected from the group consisting of:
121. m is 1; and L 5is a direct bond, -(CR a R b ) t -or-NR a -, where t is a number from 1 to 7, and -(CR a R b ) t -One or two CRs in a R b The moiety is unsubstituted or is selected from the group consisting of O and NR a wherein R a and R b The compound according to any one of claims 109 to 120, wherein:
122. L 5 is a direct bond, -(CR a R b ) 1~4 -, -O-(CR a R b ) 1~3 -, -NH-(CR a R b ) 1~3 or -NH-, where R a and R b is defined as in formula (I), whereby -L 5 The -CyC moiety is CyC, -(CR a R b ) 1~4 -CyC, -O-(CR a R b ) 1~3 -CyC, -NH-(CR a R b ) 1~3 -CyC or -NH-CyC, more preferably L 5 is a direct bond, -(CH 2 ) 1~4 -, -O-(CH 2 ) 1~3 -, -NH-(CR a R b )-(CH 2 ) 2 - or -NH-, where R a is hydrogen, and R bis optionally substituted with phenyl-S- 1~8 alkyl, whereby said -L 5 The -CyC moiety is CyC, -(CH 2 ) 1~4 -CyC, -O-(CH 2 ) 1~3 -CyC, -NH-(CR a R b )-(CH 2 ) 2 -CyC or -NH-CyC, more preferably L 5 is a direct bond, -CH 2 --, --O-CH 2 --NH-CH 2 - or -NH-, whereby said -L 5 The -CyC portion is CyC, -CH 2 -CyC, -O-CH 2 -CyC, -NH-CH 2 The compound according to any one of claims 109 to 121, which is -CyC or -NH-CyC.
123. CyC each contains one or two substituents R 5a is cycloalkyl or heterocyclyl optionally substituted with; R 5a are independently hydrogen, halogen, cyano, oxo, -OR 5b , -NR 5b R 5c , -COR 5b , -SO 2 R 5b , -C 1~8 Alkyl, -C 2~8 alkynyl, -cycloalkyl or heterocyclyl, 1~8 Each of alkyl and heterocyclyl is selected from hydrogen, halogen, cyano, -OR 5f , -C 1~8 one or two substituents R selected from alkyl, -cycloalkyl or heterocyclyl; 5e optionally substituted with; Here, R 5b and R 5care each independently hydrogen, -C 1~8 alkyl or heterocyclyl, 1~8 Alkyl is hydrogen, -NR 5f R 5g or - one or two substituents R which are cycloalkyl; 5e optionally substituted with; R 5f and R 5g are each independently hydrogen or -C 1~8 is alkyl; or Two adjacent R 5 The compound of any one of claims 109-122, wherein together with the phenyl ring, forms a benzo ring, which is optionally substituted with heteroaryl.
124. CyC each contains one or two substituents R 5a Monocyclic C optionally substituted with 3~8 Cycloalkyl or bridged cycloalkyl [C53] and preferably each CyC is selected from one or two substituents R 5a 124. The compound of claim 123, wherein the aryl group is cyclopentyl or cyclohexyl optionally substituted with.
125. CyC each contains one or two R 5a optionally substituted with a) monocyclic 4- to 9-membered heterocyclyl groups containing one nitrogen, oxygen, or sulfur heteroatom as a ring member; b) a monocyclic 4- to 9-membered heterocyclyl group containing as ring members two heteroatoms selected from oxygen, sulfur and nitrogen; and c) a 5- to 20-membered spiroheterocyclyl containing, as ring members, one or two heteroatoms selected from nitrogen, sulfur and oxygen; 124. The compound of claim 123, wherein the heterocyclyl is selected from:
126. 126. The compound of claim 125, wherein CyC is a monocyclic 4-6 membered heterocyclyl group containing one nitrogen, oxygen or sulfur heteroatom as a ring member, more preferably Cyc is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, even more preferably CyC is selected from oxetan-2-yl, oxetan-3-yl, tetrahydrofuran-4-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, azetidin-3-yl, azetidin-2-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-4-yl, piperidin-2-yl and piperidin-3-yl.
127. 126. The compound of claim 125, wherein CyC is a monocyclic 6-membered heterocyclyl group containing as ring members two heteroatoms selected from oxygen and nitrogen, more preferably CyC is dioxanyl, morpholino, morpholinyl or piperidinyl, even more preferably 1,3-dioxan-2-yl, 1,3-dioxan-4-yl, 1,4-dioxan-2-yl, morpholin-1-yl, morpholin-2-yl or morpholin-3-yl.
128. R 5a are independently hydrogen, halogen, cyano, oxo, -OR 5b , -NR 5b R 5c , -COR 5b , -SO 2 R 5b , -C 1~8 Alkyl, -C 2~8 Alkynyl, monocyclic C 3~8 cycloalkyl or monocyclic 4- to 9-membered heterocyclyl groups containing, as ring members, one or two heteroatoms selected from nitrogen, oxygen, or sulfur heteroatoms, 1~8 Each of the alkyl and monocyclic 4- to 9-membered heterocyclyl groups may have one or two substituents R 5e Optionally substituted with; preferably, R 5aCycloalkyl as the group is C 3~6 Cycloalkyl; more preferably cyclopropyl; preferably R 5a Heterocyclyl as R is a 4-6 membered heterocyclyl group containing, as ring members, one or two heteroatoms selected from nitrogen, or oxygen, or sulfur heteroatoms; more preferably R 5a Heterocyclyl as is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl or morpholinyl; even more preferably, R 5a The compound according to any one of claims 123 to 125, wherein heterocyclyl as is oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydro-2H-pyran-4-yl or morpholin-4-yl.
129. R 5e The compound according to any one of claims 123 to 125, wherein the heterocyclyl as is a monocyclic 4-9 membered heterocyclyl group containing, as ring members, one or two heteroatoms selected from nitrogen, or oxygen, or sulfur heteroatoms.
130. R 5e The compound according to claim 129, wherein the heterocyclyl as is tetrahydro-pyran-4-yl.
131. R 5a is -NR 5b R 5c where R 5b is hydrogen, and R 5c is heterocyclyl.
132. R 5a is -NR 5b R 5c where R 5b is hydrogen, and R 5c is tetrahydro-pyran-4-yl.
133. R 5a is -NR 5b R 5c where R 5b and R 5c are each independently a hydrogen or a cycloalkyl-substituted —C 1~6 Alkyl, preferably monocyclic C 3~8 -C substituted with cycloalkyl 1~6 126. The compound of any one of claims 123 to 125, which is alkyl.
134. R 5a is -OR 5b Or -SO 2 R 5b where R 5b is hydrogen or C 1~8 126. The compound according to any one of claims 123 to 125, which is alkyl, preferably methyl.
135. R 5a is -COR 5b where R 5b is hydrogen or -NR 5f R 5g C optionally substituted with 1~8 alkyl, where R 5f and R 5g are each independently hydrogen or C 1~8 126. The compound according to any one of claims 123 to 125, which is alkyl, preferably methyl.
136. Two adjacent R 5 together with the phenyl ring forms an indazolyl substituted with tetrahydropyranyl.
137. m is 1 and R 5 teeth, [C54] [C55] -L selected from the group consisting of 5 -CyC.
138. m is 1 and R 5 teeth, [C56] The compound of claim 137,
139. Formula (IV) [C57] (Wherein, the variable R 1 , R 1d , R 5 and m is defined in formula (I). A compound of formula (I) having the formula:
Citation Information
Patent Citations
Apoptosis-inducing agents for the treatment of cancer, as well as immune and autoimmune diseases.
JP2012528178A
Apoptosis-inducing agents for the treatment of cancer, as well as immune and autoimmune diseases.
JP2013527202A
Cited By
Load measuring system, damage probability estimating system, lifespan predicting system, load measuring method, damage probability monitoring method and program
EP4715200A1
